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Abstract 
Tuberculosis, caused by the intracellular bacterium Mycobacterium tuberculosis (Mtb), is the 
second leading cause of death from infectious disease. BCG, the only licensed vaccine to date, 
only provides variable protection against pulmonary disease. Although there is a broad 
understanding of protective factors in the immune response to Mtb infection, including TNFα, 
IFNγ and the Th1 axis, these are incompletely understood, hindering development of novel 
vaccine regimes. Factors that are detrimental to control of Mtb infection, such as the 
immunosuppressive cytokine IL-10, are also induced upon Mtb infection and BCG vaccination. 
Blockade of the IL-10 receptor during BCG vaccination enhances protection in both resistant 
and susceptible mouse models of Mtb.  
 
Work in this thesis further investigated IL-10 mediated suppression of BCG-induced protection 
in Mtb susceptible mice and assessed how BCG vaccination in the context of IL-10 receptor 
blockade affected the onset of adaptive immunity. Vaccination in this context impacted the 
early immune response to Mtb challenge with accelerated and enhanced IL-17 and GM-CSF 
production. Furthermore, GM-CSF was required for optimal control of bacterial load upon Mtb 
challenge following BCG vaccination. GM-CSF was also required throughout primary Mtb 
infection as GM-CSF neutralisation was detrimental to control of bacterial load in both Mtb 
resistant and Mtb susceptible mouse models.  
 
Previous work showed IFNγ and IL-17 production by an “innate-like lymphoid” population 
upon Mtb challenge, following vaccination. This thesis further studied the response and role of 
ILCs in the early innate response to both the lab-adapted Mtb strain H37Rv and the clinical 
isolate HN878. ILCs were identified as a source of GM-CSF upon HN878 infection and were 
protective in the innate response to HN878 infection.  
 
 4 
Overall this thesis demonstrates the importance of GM-CSF in the primary and recall responses 
to Mtb infection and identifies ILCs as an early, innate source of GM-CSF.  
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1.1. Tuberculosis – a global problem 
Tuberculosis (TB) is caused by infection with the acid-fast bacilli Mycobacterium tuberculosis 
(Mtb), which was first identified by Robert Koch in 1882 (Koch, 1882). Despite the knowledge 
of the causative pathogen for over 100 years, TB remains a considerable global health problem, 
being the second leading cause of death by infectious disease (WHO, 2014b). In 2013 there was 
an estimated 9 million new TB cases and 1.5 million deaths in 2013 (WHO, 2014b). 
Furthermore it is estimated that approximately one third of the world’s population is infected 
with Mtb (Dye et al., 1999). Such a high burden of disease exists despite initiatives such as the 
Stop TB Strategy by the World Health Organisation (WHO), which aims to half the incidence 
of TB by 2015 compared to 1990 (which has been achieved) with the ultimate goal of achieving 
a TB-free world by 2050 (WHO, 2006; WHO, 2014b).  
 
1.1.1 Clinical manifestations of Mtb infection 
Mtb is transmitted predominately via aerosol droplets and most commonly leads to a pulmonary 
disease, although it can affect many organs (Lawn and Zumla, 2011). Following infection with 
Mtb there are several potential clinical outcomes (Figure 1.1). A minority of individuals will 
rapidly develop active disease where there is bacterial replication and clinical symptoms 
including weight loss, fever and in pulmonary disease haemoptysis (reviewed in O'Garra et al., 
2013). Active tuberculosis is most commonly defined by the presence of symptoms and the 
demonstration of the bacteria through sputum (or tissue) microscopy and culture of the bacillus 
(Chegou et al., 2011). Due to the technical difficulties involved in acquiring sputum, the 
possibility that bacterial loads are below the detection limit, and the time taken to culture Mtb, 
other tests have been developed to identify the presence of bacteria such as GeneXpert. This is a 
PCR based test which is also able to identify whether the infecting Mtb strain has rifampicin 
resistance (Boehme et al., 2010).  
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The majority of those infected with Mtb will develop a latent infection, displaying evidence of 
infection through demonstration of an adaptive immune response (through a positive Tuberculin 
Skin Test (TST) or Interferon Gamma Release Assay (IGRA)) in the absence of clinical 
symptoms (Barry et al., 2009; Young et al., 2009). However, this definition of latent infection 
could, encompass a wide range of clinical phenotypes (Barry et al., 2009; Young et al., 2009). 
This definition could include those who have mounted an effective adaptive immune response 
and have no viable bacteria, those who are controlling infection with non-replicating bacteria or 
those with a subclinical disease where there is active bacterial replication but the absence of 
clinical symptoms (Young et al., 2009). Furthermore, it should be noted that a positive TST test 
and/or IGRA does not distinguish between active and latent tuberculosis and thus diagnostic 
tools with this capability are required (Young et al., 2009).  
 
In addition to the heterogeneity of clinical phenotypes encompassed by a positive TST or IGRA 
test, definition of latent tuberculosis by the TST test is flawed as it relies on a delayed 
hypersensitivity response to Purified Protein Derivative (PPD), which is prepared from heat 
killed Mtb cultures (Reichman, 1979). This mixture contains multiple Mtb antigens but also 
antigens from other mycobacterial strains including the vaccine BCG and various 
environmental mycobacteria, which leads to false positive results for example, in BCG 
vaccinated individuals (Richeldi, 2006). More recently IGRAs were developed which measure 
IFNγ release in response to Mtb specific antigens present in the Region of Difference 1 (RD1) 
locus, which is absent in BCG (Mahairas et al., 1996) and most other environmental 
mycobacteria, thus avoiding the false positive results observed with the TST (Richeldi, 2006).  
  
Individuals can remain latently infected for long periods of time or even over their entire 
lifetime (reviewed in O'Garra et al., 2013). However, some individuals reactivate, progressing 
from a latent disease state to active disease. An immunocompetent individual has an 
approximately 5-10% lifetime risk of reactivating to active disease, with the highest risk 
following infection and in early adulthood (reviewed in O'Garra et al., 2013). The risk of 
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reactivation is dramatically increased when an individual is immunocompromised, for example 
through infection with Human Immunodeficiency Virus (HIV) (Cooper, 2009; Schutz et al., 
2010) or by iatrogenic means such as through anti-TNFα treatment for Rheumatoid Arthritis of 
Crohn’s disease (Cooper, 2009; Keane et al., 2001). 
 
It has also been postulated that some people may be able to clear Mtb infection utilising only the 
innate immune system, without the requirement to mount an adaptive immune response 
(reviewed in Barry et al., 2009; Young et al., 2009). Evidence for such a phenomenon is 
provided by the observation that a proportion of individuals in repeated, close contact with 
active tuberculosis patients, such as healthcare workers or household contacts, fail to convert to 
TST positivity (Alcais et al., 2005; Joshi et al., 2006; Morrison et al., 2008; Young et al., 2009). 
In such individuals innate immune mechanisms including macrophages, neutrophils and innate 
lymphocytes such as Natural Killer (NK) cells (discussed in more detail later) are suggested to 
be capable of clearing the infection before the development of an adaptive immune response 
(Verrall et al., 2014). However, it must also be considered that the lack of TST positivity may 
be due to other causes such as HIV infection where there is induced deficiency in the adaptive 
response (reviewed in Barry et al., 2009).  
 
1.1.2 HIV-TB Co-infection 
Co-infection with Mtb and HIV is common, occurring in approximately 13% of all TB cases 
reported in 2013 (WHO, 2014b), although the burden of HIV/TB co-infection is highest in sub-
Saharan Africa constituting 79% of all global cases (Lawn et al., 2013). TB is a major cause of 
mortality in HIV infected individuals, accounting for approximately a quarter of such deaths 
(Lawn et al., 2013). HIV infection increases not only the risk of reactivation (discussed earlier) 
but also the risk of developing primary disease following infection (Corbett et al., 2003; Schutz 
et al., 2010). Thus co-infection with Mtb and HIV represents a major barrier to the global 
control of TB (WHO, 2014b). 
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One initiative employed to reduce mortality in HIV-TB co-infection is the initiation of Anti-
Retroviral Therapy (ART) (Lawn and Zumla, 2011). ART allows immune recovery and is 
reported to reduced incidence rates of TB by 67% in patients co-infected with HIV (Lawn and 
Zumla, 2011). However, a complication of ART in co-infected patients can be the development 
of Immune Reconstitution Inflammatory Syndrome (IRIS) (Walker et al., 2015b). TB-IRIS 
results in excessive inflammation accompanied by considerable morbidity and mortality. It can 
occur in patients already being treated for Mtb infection prior to the initiation of ART 
(paradoxical TB-IRIS) or in those where Mtb infection was not diagnosed prior to the initiation 
of ART (unmasking TB-IRIS) (Walker et al., 2015b). Despite the risk of this complication, 
initiation of ART therapy is still recommended and can largely be continued if TB-IRIS 
develops (Schutz et al., 2010). 
 
1.2.3 Drug resistance in tuberculosis  
The emergence of Multi-Drug Resistant (MDR) (resistant to isoniazid and rifampicin) and 
Extensively Drug Resistant (XDR) (resistant to isoniazid, rifampicin, fluoroquinolones and any 
of the second line injectable drugs including capreomycin and kanamycin) tuberculosis strains 
represents another major threat to the global efforts to control TB (Abubakar et al., 2013). The 
emergence of such drug resistant strains heightens the need for novel drugs in the treatment of 
tuberculosis (Abubakar et al., 2013). The shortest drug treatment regime for drug susceptible 
TB consists of 2 months of rifampicin, isoniazid, pyrazinamide and ethambutol followed by 4 
months of rifampicin and isoniazid (Dorman and Chaisson, 2007). The length of treatment and 
the side effects of these drugs often result in non-compliance, and this coupled with 
malabsorption and poor prescribing by clinicians all contribute to the development of resistant 
strains (Dorman and Chaisson, 2007). Globally in 2013 MDR-TB caused 3.5% of new TB 
cases. However, the global distribution of drug resistant TB in unequal. In Eastern Europe and 
central Asia in 2013 up to 35% of newly diagnosed TB cases were drug resistant and India, 
China and the Russian Federation account for more than 50% of MDR-TB cases (WHO, 
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2014a). MDR-TB is a serious risk to global health and strategies need to be put in place to 
combat its development and transmission as well as strategies to aid rapid diagnosis and 
effective treatment (WHO, 2014a). 
 
As the second leading cause of death from infectious disease, tuberculosis represents a major 
global health risk (WHO, 2014b). Difficulties in diagnosis and treatment of the disease along 
with the development of drug resistant strains and HIV-TB co-infection are all barriers to global 
control of the disease. Another barrier to control of the disease is the lack of an effective 
vaccine (discussed in more detail below). If the aim of a TB free world by 2050 is to be met, 
better diagnostics, treatments and an effective vaccine are all required. A better understanding 
of Mtb infection and the host immune response is essential to achieve this target.   
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1.2. Models of Mtb infection 
 
Several animal models have been utilised to study Mtb infection, including mouse, rabbit, 
guinea pig, zebrafish and non-human primate (NHP), and these have aided our understanding of 
the immune response to Mtb (Capuano et al., 2003; North and Jung, 2004), although the mouse, 
rabbit, guinea pig and NHP are not natural hosts for Mtb infection (Flynn, 2006). The NHP 
model of TB is argued to most reflect human disease. Similarly to humans, when NHPs are 
infected with Mtb a range of clinical outcomes are observed (Capuano et al., 2003). A 
proportion of animals develop active disease, a proportion develops a latent disease, and a 
proportion of latently infected animals will reactivate, developing active disease (Capuano et al., 
2003). Furthermore, the heterogeneity in disease states described in humans is reflected in the 
NHP model, as some animals develop a subclinical disease, where there is an absence of clinical 
symptoms but culture positive Bronchoalveolar Lavage (BAL) (Lin et al., 2009). In addition, 
the structure of granulomas (a complex aggregate of immune cells characteristic of Mtb, 
discussed in detail below) in NHPs is similar to those described in humans (Flynn et al., 2015).  
 
The guinea pig model of TB was used by Koch in his identification of Mtb (Koch, 1882). The 
guinea pig is susceptible to infection with low does of Mtb and develops granulomas that 
resemble those observed in humans, however it does not develop latent infection (Gupta and 
Katoch, 2005; North and Jung, 2004). The rabbit also develops granulomas that resemble those 
seen in the humans, and infection with clinical isolates of Mtb has been demonstrated to cause a 
progressive infection (Flynn, 2006; Subbian et al., 2012). In addition a model of latent TB 
infection has been described in rabbits (Flynn, 2006; Subbian et al., 2012).  
 
The zebrafish model employs infection with M. marinum (Ramakrishnan, 2013). The zebrafish 
is a natural host for M. marinum, which contrasts to the other models studied for TB, as they are 
not natural hosts for Mtb or M. bovis (Flynn, 2006). The transparency of the zebrafish in early 
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life enables experiments to track cells and assess early granuloma formation, although it should 
be noted that at this stage in development no adaptive immune system is present 
(Ramakrishnan, 2013).  
 
The most commonly used model of TB is the mouse model. Several factors of the immune 
response to Mtb known to be protective in humans including IL-12, IFNγ and TNFα (all 
discussed below) are also crucial to the immune response in mice, suggesting there is at least 
some overlap in responses (Cooper, 2009; Fortin et al., 2007; North and Jung, 2004). There are 
several benefits for using the mouse to study TB. Firstly, mice are relatively inexpensive and 
easier to maintain in BSL-3 conditions than some other models (Flynn et al., 2015). 
Furthermore, a wide range of reagents are available for study of the mouse immune response 
(North and Jung, 2004). Finally many inbred and genetically engineered mouse strains exist 
facilitating study of specific components of the immune response (Flynn et al., 2015); Apt and 
Kramnik, 2009). However, it is argued that the mouse does not reflect human disease and 
therefore is not an appropriate model to study (Apt and Kramnik, 2009). This argument is based 
on several observations. Firstly, that all mice eventually succumb to the disease, and do not 
develop latent infection (Flynn, 2006). Secondly, that the structure of the granuloma does not 
mirror that observed in the human (Apt and Kramnik, 2009). The granulomas in the most 
commonly used strains of mice do not develop central necrosis (Rhoades et al., 1997), in 
contrast to humans (Tsai et al., 2006; Ulrichs et al., 2004; Via et al., 2008). Furthermore the 
granulomas within these commonly studied mouse strains are not hypoxic, in contrast to 
humans (Tsai et al., 2006; Via et al., 2008). However, granuloma structure in human Tb patients 
as well as the NHP model of Mtb infection has been shown to be heterogeneous, with some 
lesions not developing a necrotic core (Barry et al., 2009). In addition, many of the observations 
used to suggest the mouse is not an adequate model of Mtb are based on mouse strains that are 
resistant to Mtb (Apt and Kramnik, 2009; Rhoades et al., 1997; Tsai et al., 2006). There are 
several other in-bred mouse strains that display higher susceptibility to Mtb infection, with 
different patterns of bacterial growth and pathology, which will be discussed below. 
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1.2.1. Resistant and susceptible mouse strains 
Following aerosol infection with Mtb, different inbred strains of mice display different patterns 
of bacterial growth and survival. C57BL/6 and BALB/c mice are “resistant” mouse strains 
where uncontrolled bacterial growth occurs rapidly for approximately the first 3-4 weeks of 
infection. Following this bacterial growth is controlled and bacterial load plateaus until the 
mouse succumbs to infection and dies approximately 300 days post infection (Medina and 
North, 1998; North and Jung, 2004). In contrast, infection of “susceptible” mouse strains 
including DBA/2, CBA, C3H and I/St strains leads to higher bacterial loads, as these strains fail 
to control bacterial growth and no plateau is reached (North and Jung, 2004; Turner et al., 
2001). These mice succumb to infection earlier, at approximately 100-150 days post infection 
(Eruslanov et al., 2005; Eruslanov et al., 2004; Medina and North, 1998; North and Jung, 2004). 
The immune response to infection in these susceptible mouse strains is also described to differ 
to resistant mouse strains, with many susceptible strains showing increased accumulation of 
granulocytes (Eruslanov et al., 2005; Keller et al., 2006; Marzo et al., 2014). In addition, the 
kinetics of the immune response are delayed in susceptible mouse strains (Chackerian et al., 
2002b; Turner et al., 2001). Furthermore, the lung pathology in susceptible mouse strains also 
differs, with descriptions of necrotic and hypoxic granulomas forming in C3HeB/FeJ mice (Apt 
and Kramnik, 2009; Harper et al., 2012; Kramnik et al., 2000). Thus it is suggested that 
susceptible mouse strains may provide a model of TB that more resembles active human 
disease. 
 
The basis for susceptibility of the different mouse strains is not completely understood. 
However, use of genetic approaches has identified loci that confer susceptibility to tuberculosis 
(North and Jung, 2004). For example, through analysis of C3HeB/FeJ x B6 F2 mice, the 
susceptibility to tuberculosis 1 (sst1) loci was identified (Kramnik et al., 2000). This locus was 
found to play a role in necrosis of granulomas (Kramnik et al., 2000). A subsequent study 
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showed that resistant mice expressing this susceptibility locus display necrotising granulomas 
and decreased survive (Pichugin et al., 2009). Furthermore C3H mice expressing the sst1 locus 
from resistant mice display lower bacterial loads and their granulomas lack necrosis (Pan et al., 
2005). A gene within this locus, Intracellular pathogen resistance 1 (Ipr1), was found to 
contribute to control of intracellular growth of Mtb and promote apoptotic cell death of infected 
macrophages (Pan et al., 2005). Such analysis of susceptible mouse strains may enable 
identification of factors that contribute to human susceptibility to TB.  
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1.3 Immune response to Mtb 
 
Animal models of TB have enabled investigation of events following infection with Mtb. They 
have also enabled the identification of immune factors that are protective and some that are 
detrimental to control of Mtb infection. This section will discuss the development of the 
immune response to infection as well as individual aspects of the immune response that are 
thought to be important in protection or contribute to host pathology and disease.  
 
1.3.1 Development of the immune response to Mtb 
Following infection with Mtb the immune response is slow to develop, with the onset of 
adaptive immunity not occurring until 3-4 weeks post infection in a resistant mouse model 
(reviewed in Cooper, 2009) and until 5-6 weeks post infection in humans (Urdahl, 2014; 
Wallgren, 1948). The immune response that develops is adequate to control disease but largely 
incapable of eradicating infection, with many individuals developing latent infection (reviewed 
in O'Garra et al., 2013). It is suggested that Mtb manipulates the host immune response to create 
a niche to facilitate bacterial growth and also to create a lesion that enables release of bacteria 
and transmission to other hosts (reviewed in  
 et al., 2015).  
 
1.3.1.1 Infection of innate cells and formation of the early granuloma 
Following aerosol inhalation of the Mtb bacillus, it is thought that the first cell to become 
infected is the alveolar macrophage (Srivastava et al., 2014). Other innate cells rapidly 
accumulate and are infected with Mtb, including dendritic cells (DCs), neutrophils and 
monocytes (Wolf et al., 2007). This aggregation of innate immune cells forms the early 
granuloma. Work in the zebrafish model suggests that this early granuloma is a permissive 
niche for mycobacterial growth (Davis and Ramakrishnan, 2009). In this model M. marinum 
promoted necrotic cell death to facilitate recruitment and infection of macrophages (Davis and 
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Ramakrishnan, 2009). In addition, Mtb has developed multiple mechanisms to avoid 
intracellular killing mechanisms including inhibition of phago-lysosome fusion and disruption 
of normal acidification of the phagosome, thus enabling growth within macrophages (Russell et 
al., 2010). Thus the environment within this early granuloma is suggested to allow unchecked 
bacterial growth and progressive infection of recruited innate cells (Ramakrishnan, 2012).  
 
1.3.1.2 Priming of an adaptive response in the lymph node 
The adaptive immune response is crucial to control of Mtb infection (discussed in detail below), 
with mice deficient in lymphocytes displaying increased susceptibility to Mtb infection (Orme 
and Collins, 1983), and HIV infection increasing the risk of active TB in humans (Geldmacher 
et al., 2012; Schutz et al., 2010). The onset of an adaptive immune response against Mtb is slow 
compared to other infections, even in previously BCG vaccinated hosts (Cooper, 2009; Urdahl 
et al., 2011). This delay in adaptive immunity prolongs the period of uncontrolled bacterial 
growth described above and is detrimental to the host. Indeed, a delay in the onset of an 
adaptive immune response has been associated with susceptibility to Mtb infection, with the 
time taken for infected DCs to traffic to the draining lymph node and initiate T cell responses 
being longer in the susceptible C3H mouse strain compared to the resistant C57BL/6 mice 
(Chackerian et al., 2002b).  
 
A threshold of antigen availability is required in the lymph node for initiation of T cell priming, 
which is not reported to occur until approximately 11 days post infection in a resistant mouse 
model (Reiley et al., 2008; Wolf et al., 2008). This threshold of antigen availability is met 
through DCs and inflammatory monocytes trafficking bacteria from the lung to the lymph node 
(Samstein et al., 2013; Wolf et al., 2007). DC trafficking to the draining lymph node has been 
reported to be dependent upon the chemokines CCL19 and CCL21 (Wolf et al., 2007) and also 
IL-12p40 (Khader et al., 2006). Trafficking of DCs that have phagocytosed apoptotic 
neutrophils is suggested to facilitate priming of an adaptive response (Blomgran et al., 2012; 
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Blomgran and Ernst, 2011). Mtb is suggested to delay the onset of adaptive immunity through 
inhibition of apoptosis (Blomgran et al., 2012). Indeed, increasing the apoptosis of neutrophils 
through infection with an Mtb strain that promotes apoptosis accelerated the priming of an 
adaptive response (Blomgran et al., 2012). 
 
The adaptive immune response is an antigen specific response and requires T cell activation by 
professional antigen presenting cells (APCs) such as DCs. APCs present antigen in the context 
of Major Histocompatibility Complex (MHC) class I or MHC class II molecules to CD8+ or 
CD4+ T cells respectively, both of which are activated in the response to Mtb (Behar, 2013; 
Flynn and Chan, 2001). Mtb infected DCs were shown to be inefficient at presenting antigen to 
naïve T cells (Wolf et al., 2007). However, recently it has been shown that infected DCs are 
capable of transferring antigen to DCs in the draining lymph node, facilitating antigen 
presentation (Srivastava and Ernst, 2014). 
 
Depending on the context in which naïve CD4+ T cells are activated they display different 
phenotypes, capable of producing specific cytokines. In response to mycobacterial infection 
CD4+ T cells are polarised mostly toward a Th1 phenotype, where they express IFNγ, but also a 
Th17 phenotype, where they express IL-17 (discussed in more detail below) (Cruz et al., 2006). 
Mtb specific suppressive regulatory T cells (Treg) also expand in the lymph node upon infection 
and contribute to the delay in priming of adaptive response (Scott-Browne et al., 2007; Shafiani 
et al., 2010).  
 
1.3.1.3 The adaptive immune response arrests growth of bacteria and contributes to the 
formation of the granuloma 
Following their activation T cells are recruited to the lung and arrive at approximately 20 days 
post infection in resistant mouse models (reviewed in Cooper, 2009). The initiation of an 
adaptive immune response in the lung leads to activation of phagocytes (at least partly through 
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IFNγ) to restrict mycobacterial growth via mechanisms such as reactive nitrogen intermediates 
(RNIs) (reviewed in Nathan and Shiloh, 2000; O'Garra et al., 2013) (discussed in more detail 
below). Initiation of the adaptive response in the lung correlates with control of bacterial growth 
in resistant mouse strains reflecting the requirement for an adaptive response to control 
infection, despite its inability to eradicate infection (North and Jung, 2004). Initiation of the 
adaptive immune response leads to the formation of the mature granuloma (Figure 1.2).  
 
The localisation of T cells within the infected lung is also important. Mice deficient for CXCR5, 
the chemokine receptor for CXCL13, are more susceptible to Mtb infection through poor 
localisation of T cells within lung parenchyma (Slight et al., 2013). Furthermore distinct T cell 
populations residing either within the vasculature or the lung parenchyma have recently been 
identified (Sakai et al., 2014). These populations are described to have different capacities to 
protect against Mtb infection when adoptively transferred into T cell deficient hosts (Sakai et 
al., 2014). Thus it is not only the arrival of an adaptive response, but its appropriate localisation 
that enables control of infection.  
 
1.3.2 The Granuloma 
The granuloma is a complex aggregate of immune cells that forms in response to persistent 
stimuli and granulomas are a hallmark of Mtb infection. In humans the classic granuloma 
(shown in Figure 1.2) has a caseous necrotic core surrounding by highly activated infected 
macrophages, neutrophils and DCs (Ramakrishnan, 2012; Ulrichs et al., 2004). Macrophages 
within the granuloma undergo specialisation into multinucleated giant cells, epitheloid cells and 
foamy macrophages (Russell et al., 2009). This central core of innate cells is surrounded by a 
lymphocytic cuff of T and B cells and also fibroblasts which produce a fibrotic capsule 
(Ramakrishnan, 2012). As discussed above, the resistant mouse model of TB does not form 
granulomas that possess all of these features (Rhoades et al., 1997; Tsai et al., 2006), although 
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some susceptible mouse strains, rabbits, guinea pigs and NHPs more closely resemble human 
granulomas (Apt and Kramnik, 2009; Flynn, 2006). 
 
1.3.2.1 Heterogeneity in granuloma structure  
Use of imaging tools such as Computer Tomography (CT) and Positron Emission Tomography 
(PET) has allowed visualisation of granuloma in the NHP model and human patients (Barry et 
al., 2009; Lin et al., 2014). Such studies have underlined the considerable heterogeneity within 
lesions from a single animal or patient and have demonstrated that not all lesions are necrotic 
(like that shown in Figure 1.2) (Barry et al., 2009; Lin et al., 2014). Some granulomas that are 
non-necrotizing and contain mainly macrophages are most commonly found in patients with 
active TB, and others are fibrotic, composed mainly of fibroblasts (Barry et al., 2009). 
Considerable overlap in the structure of lesions in latent and active patients and NHP has been 
observed (Gideon and Flynn, 2011; Lin et al., 2009).  
 
1.3.2.3 Function of granuloma 
The function of the granuloma is classically regarded to be a site for control of mycobacterial 
growth, which contains bacteria and prevents dissemination (Flynn et al., 2011). However, more 
recently it has been proposed to provide a niche for bacterial replication and aid dissemination. 
In the zebrafish model of M. marinum infection, macrophages were shown to be recruited to 
nascent granulomas where they became infected and provided a niche for bacterial growth and 
promoted dissemination (Davis and Ramakrishnan, 2009; Ramakrishnan, 2012).  
 
Studies using the NHP model have shown that granulomas have distinct outcomes. Some 
reached sterilization whilst others were permissive to continued bacterial growth (Lin et al., 
2014). This data suggests that the function of the granuloma cannot be labelled as either 
protective or permissive, but that the environment at the level of individual granulomas dictates 
this function. In silico modelling has suggested that the balance between pro- and anti-
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inflammatory cytokines is important in determining the outcome of granulomas (Cilfone et al., 
2015). In addition, assessment of the T cell responses in individual granulomas from NHPs has 
shown that there is inverse correlation between T cells producing pro-inflammatory cytokine 
(such as TNFα, IL-17 or IFNγ) and the bacterial load within the granuloma (Gideon et al., 
2015). Thus, although granulomas can form a permissive niche for bacterial growth, data also 
suggests that they can eliminate bacteria indicating that they can be protective or contribute to 
pathology. 
 
1.3.3 Multifaceted Role of Neutrophils in Mtb infection 
Neutrophils are short-lived phagocytes that possess several killing mechanisms to combat 
infection such as the generation of reactive oxygen species (ROS), production of enzymes 
including lysozyme and proteases, production of antimicrobial peptides and molecules that 
sequester iron (Dallenga et al., 2015). The role of neutrophils during Mtb infection has been 
controversial with conflicting reports implicating them in protection through Mtb killing or 
pathogenesis through excessive inflammation (Lowe et al., 2012). These conflicting reports may 
reflect a dual role for neutrophils in the response to Mtb infection. Initially they are protective 
and contribute to control of infection but as inflammation and infection progresses they become 
detrimental facilitating pathogenesis.  
 
1.3.3.1 Neutrophils are recruited and infected upon mycobacterial infection 
Neutrophils are recruited early upon infection with several mycobacterial species (Lowe et al., 
2012). In mice neutrophils are observed at the site of BCG infection as early as 4h post infection 
(Abadie et al., 2005). However, in contrast, in the zebrafish model of M. marinum infection, 
neutrophil recruitment was only obsevered following the death of infected macrophages within 
the nascent granuloma (Yang et al., 2012). Despite this finding it is thought that neutrophils are 
rapidly recruited to disease sites (Lowe et al., 2012). Once recruited, neutrophils are then 
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infected with Mtb. A study using a fluorescent Mtb strain showed that neutrophils can be 
infected with Mtb and that they were a prominent infected population following infection (Wolf 
et al., 2007). Furthermore in humans neutrophils were found to be the most infected phagocyte 
in human sputum (Eum et al., 2010).  
 
1.3.3.2 Neutrophils can be protective in Mtb infection 
A protective role for neutrophils in mycobacterial infection has been reported. Several studies 
show that neutrophil depletion prior to, or early in infection is detrimental to the outcome of 
Mtb infection (Lowe et al., 2012). Similarly LPS treatment in order to recruit neutrophils of rats 
prior to Mtb infection led to lower bacterial loads later in infection (Sugawara et al., 2004). In 
the zebrafish model of M. marinum neutrophils were found be important in the early control of 
infection and granuloma formation, as defects in their recruitment (through mutation in the 
chemokine receptor CXCR4) led to impaired granuloma formation and higher bacterial loads 
(Yang et al., 2012). In the same study a subset of neutrophils were also found to be capable of 
killing bacteria in a ROS dependent manner (Yang et al., 2012). Although neutrophils possess 
several mechanisms by which they could kill Mtb, whether restriction of mycobacterial growth 
by neutrophils takes place in vivo, in humans and in the mouse model, is unclear (Lowe et al., 
2012). 
 
Neutrophils are also suggested to benefit the immune response to Mtb infection through 
influencing the priming of an adaptive immune response (Blomgran et al., 2012; Blomgran and 
Ernst, 2011). Depletion of neutrophils at 9 days post infection increased the frequency of 
infected DCs, however, a decrease in DC trafficking to the draining lymph node and the 
initiation of an adaptive response was simultaneously observed (Blomgran and Ernst, 2011). 
This study suggested that phagocytosis of infected neutrophils is important in facilitating 
trafficking of DCs to the draining lymph node and initiating the adaptive immune response 
(Blomgran and Ernst, 2011). In this context DCs were suggested to acquire bacteria at least 
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partly from apoptotic neutrophils (Blomgran et al., 2012). Indeed augmenting apoptosis using a 
mutant Mtb strain accelerated the T cell response in a neutrophil dependent manner (Blomgran 
et al., 2012).  
 
1.3.3.3 Accumulation of neutrophils is detrimental to the outcome of Mtb infection 
Although protective roles for neutrophils have been described, increased neutrophil numbers 
have been found to correlate with poor outcome. Increased bacterial loads and delayed 
clearance of bacteria from sputum in human TB patients has been observed (Lowe et al., 2013; 
Martineau et al., 2011). Furthermore, the level of neutrophilia in the blood in HIV positive 
patients correlates with bacterial load in the sputum (Kerkhoff et al., 2013). Increased number of 
neutrophils expressing Granzyme B in NHP and human granulomas also correlated with 
increased bacterial load (Mattila et al., 2015). This data correlating increased numbers of 
neutrophils with higher bacterial loads and poor outcome of infection, and a report correlating a 
neutrophil driven signature with severity of disease (Berry et al., 2010), is suggestive of a 
negative role for neutrophils in Mtb infection. 
 
In various mouse studies increased susceptibility to infection has been correlated with increased 
neutrophil influx. Increased recruitment of granulocytes has been observed in the susceptible 
DBA, C3H/FeBJ and I/St mice and suggested to contribute to susceptibility (Eruslanov et al., 
2005; Keller et al., 2006; Marzo et al., 2014). In the I/St mice neutrophils were suggested to 
harbour large amounts of bacteria and provide a permissible environment for bacterial 
replication (Eruslanov et al., 2005). In addition, the increased susceptibility of mice deficient for 
Caspase Recruitment Domain-Containing Protein 9 (CARD9) or the micro-RNA mir-223 
correlated with increased neutrophilia leading to excessive inflammation (Dorhoi et al., 2010; 
Dorhoi et al., 2013). IFNγ signalling has been described to negatively regulate neutrophil 
accumulation and survival (Desvignes et al., 2012; Nandi and Behar, 2011). Thus neutrophilia 
during infection may represent a response with inadequate IFNγ production.  
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One way in which neutrophils are suggested to play a detrimental role in Mtb infection is 
through production of immunosuppressive cytokines. Indeed, neutrophils have been identified 
as a source of the immunosuppressive cytokine IL-10 upon infection (Dorhoi et al., 2010; 
Dorhoi et al., 2013; Zhang et al., 2009). Neutrophil depletion in BALB/c mice infected with 
Mtb led to lower bacterial loads at 6 weeks following infection with a lower level of IL-10 
accompanied by an increase in TNFα production (Zhang et al., 2009).  
 
The precise role of neutrophils in Mtb infection is unclear and will require further investigation. 
Although they possess the potential to kill mycobacteria, in some circumstances it appears they 
contribute to immunopathology. These opposing roles for neutrophils in Mtb infection could 
potentially be explained by timing. Early in infection neutrophils are protective, killing bacteria 
and influencing priming of an adaptive response. As infection progresses neutrophils contribute 
to immunopathology, with the development of neutrophilia signifying a pathogenic immune 
response.  
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1.4 Protective factors in the immune response to Mtb 
 
The immune response to Mtb encompasses factors that contribute to protection and factors that 
could contribute to pathology and maintenance of infection. The precise nature of a protective 
response to Mtb infection is not clearly understood. It is likely that a finely balanced immune 
response is required for protection, where the level of inflammation is adequate to combat 
infection but avoid host pathology (Orme et al., 2015). However, some aspects of the protective 
immune response to Mtb are known and will be discussed below. Key factors identified in 
experimental models and the resultant increase in susceptibility are shown in Figure 1.3.  
 
1.4.1 Innate immune factors involved in the protective response to Mtb infection 
1.4.1.1 Recognition of Mtb through Pattern Recognition Receptors 
Pattern Recognition Receptors (PRRs) are germline encoded receptors that recognise conserved 
molecules expressed by pathogens termed Pathogen Associated Molecular Patterns (PAMPs). 
Recognition of PAMPs by PRRs can facilitate phagocytosis of the pathogen by the innate cell 
as well as induction of an inflammatory response (Medzhitov and Janeway, 2000). There are 
several classes of PRR including Toll-Like Receptors (TLRs), C-type Lectin Receptors (CLRs), 
NOD-Like Receptors (NLRs) and RIG-Like Receptors (Takeuchi and Akira, 2010). Several 
classes of PRR have been implicated in the response to mycobacteria and will be discussed 
below. The activation of PRRs in response to mycobacteria is thought to shape the adaptive 
immune response and contribute to the regulation of inflammation. Upon infection it is likely 
that many PRRs work in concert to initiate and shape the immune response, perhaps explaining 
why in some cases deficiency in single PRRs does not impact the outcome of infection, despite 
their ability to recognise Mtb. 
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1.4.1.1.1. NOD2 
NOD2 is part of the NOD-Like Receptor (NLR) family of PRRs and is a cytoplasmic receptor. 
In mice a role for NOD2 is suggested through study of Nod2 deficient mice, although its precise 
importance in the immune response to Mtb is unclear. At early time points following Mtb 
infection Nod2 deficiency did not impact bacterial load, however, at later time points Nod2 
deficiency resulted in increased bacterial load and impaired survival (Divangahi et al., 2008). In 
contrast, a second study demonstrated that Nod2 deficiency did not impact susceptibility to Mtb 
infection although a late time point was not assessed (Gandotra et al., 2007). However, in vitro 
macrophages from Nod2 deficient mice displayed impaired production of nitric oxide (NO) and 
proinflammatory cytokines (Gandotra et al., 2007). The role of NLRP3, an inflammasome 
forming NLR, will be discussed below. 
 
1.4.1.1.2 CLRs and CARD9 
CARD9 is an adaptor molecule required for the downstream signalling of several classes of 
PRRs including CLRs. CARD9 deficient mice display increased susceptibility to Mtb infection 
with enhanced recruitment of neutrophils and higher levels of proinflammatory cytokines in 
both the lung and serum (Dorhoi et al., 2010). Neutrophils deficient in CARD9 were also 
observed to be incapable of producing IL-10 in response to Mtb infection, suggesting CARD9 
has a role in regulating inflammation in response to Mtb infection (Dorhoi et al., 2010). In 
addition, another study showed that IL-10 production by neutrophils in response to BCG was 
dependent upon MyD88 and Syk signalling downstream of CLRs (Zhang et al., 2009).  
 
Dectin-1 is a CLR that signals via the molecules Syk and CARD9. Dectin-1 has been 
demonstrated to recognise mycobacteria and was found to induce IL-12p40 expression in mouse 
splenic DCs (Rothfuchs et al., 2007). Dectin-1 is also suggested to be important in the induction 
of an IL-17 response to Mtb (van de Veerdonk et al., 2010; Zenaro et al., 2009). However, no 
impact on susceptibility to Mtb infection was reported in CLEC7A (the gene encoding dectin-1) 
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deficient mice (Marakalala et al., 2011). More recently a role Dectin-2 in Mtb infection has been 
suggested (Yonekawa et al., 2014). Clec4n (the gene encoding dectin-2) deficient dendritic cells 
produced lower levels of pro and anti-inflammatory cytokines in response to BCG and exhibited 
higher bacterial loads and lung pathology upon infection with M. avium complex (MAC), 
however, dectin-2 deficiency in virulent Mtb infection was not assessed (Yonekawa et al., 2014)  
 
Another CLR that is implicated in the recognition and initiation of the response to mycobacteria 
is Macrophage-Inducible C-type Lectin (Mincle), which also signals via Syk and CARD9 
(Philips and Ernst, 2012). Mincle expression was observed to be upregulated upon intra-tracheal 
BCG infection and Mincle deficient mice displayed higher bacterial loads in the draining lymph 
node and spleen throughout infection (Behler et al., 2012). Furthermore, following intravenous 
infection with BCG Mincle knockout mice displayed higher bacterial loads in the spleen and 
liver with reduced granuloma formation and lower TNFα and IFNγ levels in the spleen (Behler 
et al., 2015). In contrast, in another study Mincle deficient mice did not show enhanced 
susceptibility to Mtb infection, nor a defect in granuloma formation following either low or high 
dose aerosol infections with Mtb (Heitmann et al., 2013). Thus the precise importance of Mincle 
in the recognition of Mtb, and its role in Mtb infection remains unclear. 
 
DC-SIGN is primarily expressed on human DCs and has been demonstrated to bind to Mtb 
(Geijtenbeek and van Kooyk, 2003; Philips and Ernst, 2012). Recognition of Mtb via DC-SIGN 
was required for optimal IL-10, IL-12p35, IL-12p40 and IL-6 mRNA expression, although this 
was not evident at the protein level (Gringhuis et al., 2009). Genetic susceptibility studies 
provide conflicting data surrounding the association of polymorphisms in DC-SIGN with 
susceptibility to tuberculosis (Philips and Ernst, 2012). Elucidating the precise role for DC-
SIGN in the response to Mtb infection is hindered by the absence of a mouse ortholog (Philips 
and Ernst, 2012). 
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1.4.1.1.4 TLRs and MyD88 
TLRs contain a cytoplasmic domain that is shared with IL-1 and IL-18 receptors called the 
Toll/IL-1R domain (TIR). MyD88 is an adaptor molecule recruited to the TIR domain which is 
required for the subsequent signalling cascade of TIR containing molecules including all TLRs 
except TLR3 (Akira and Takeda, 2004). MyD88 is also involved in the signalling downstream 
of the IL-1 Receptor (IL-1R) and the IL-18 Receptor (IL-18R) (Akira and Takeda, 2004). Mice 
deficient in MyD88 have been reported to display considerable increased susceptibility to Mtb 
infection, with higher bacterial loads and decreased survival (Bafica et al., 2005a; Fremond et 
al., 2004; Mayer-Barber et al., 2010; Scanga et al., 2004).  
 
It was originally suggested that the susceptible phenotype displayed by the MyD88 deficient 
mice was solely due to loss of TLR signalling downstream of one or multiple TLRs. However, 
much conflicting data exists detailing the precise role of TLRs in susceptibility to Mtb infection. 
TLR2, TLR4 and TLR9 have been suggested to play a role in the recognition and response to 
Mtb. C3H/HeJ mice have a missense mutation in TLR4 and were shown to display increased 
susceptibility to low dose aerosol Mtb infection (Abel et al., 2002). In contrast, another study 
found no increase in bacterial load in low or high dose Mtb infection in the TLR4 mutant 
C3H/HeJ mice (Reiling et al., 2002). A further study suggested a protective role for TLR4 only 
in the immune response to infection with a more virulent Mtb strain of the Beijing lineage not 
with the lab-adapted strain H37Rv (Carmona et al., 2013). Mice deficient in TLR2 are 
suggested to show increased susceptibility to low and high dose Mtb infection (Drennan et al., 
2004), although others have demonstrated a role for TLR2 only in high dose infection (Reiling 
et al., 2002). However, in vitro, TLR2 has been reported to be required for the induction of pro-
inflammatory cytokines by macrophages in response to several Mtb strains (Carmona et al., 
2013). Mice deficient in TLR9 showed increased susceptibility to Mtb, which is most marked 
with high dose infection (Bafica et al., 2005a). Mice deficient for both TLR2 and TLR9 also 
display increased susceptibility to Mtb infection (Bafica et al., 2005a), but the phenotype 
displayed is milder than in MyD88 deficient mice (Mayer-Barber et al., 2010). In contrast, mice 
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triply deficient for TLR2/4/9 did not show enhanced susceptibility to aerosol Mtb infection, 
unlike those deficient for MyD88 (Holscher et al., 2008). Although MyD88 is required for 
signalling downstream of TLRs, mice deficient in single or multiple TLRs do not display the 
increased susceptibility seen in MyD88 deficient mice.  
 
1.4.1.2 IL-1 and the Inflammasome 
As none of the TLR deficient mice discussed above displayed a consistent phenotype that 
mirrored the severe MyD88 deficient phenotype, a role for IL-1 in protection against Mtb was 
proposed, as IL-1 also signals via MyD88. IL-1R1 deficient mice (Sugawara et al., 2001), or 
those doubly deficient in IL-1α/IL-1β (Yamada et al., 2000), displayed increased susceptibility 
to Mtb infection. This increase in susceptibility of the IL-1R1 deficient mouse was similar to 
that observed in MyD88 deficient mice (Fremond et al., 2007). Further support for the 
importance of IL-1 was provided by a study that showed that the phenotype of the MyD88 
deficient mouse was similar to that seen in the IL-1β deficient, IL-1R deficient or TRIF/MyD88 
deficient mice (Mayer-Barber et al., 2010). Mice deficient in IL-18 were more susceptible to 
Mtb infection than wild type mice but displayed a milder phenotype in comparison to MyD88 
deficient mice (Mayer-Barber et al., 2010). Subsequently, IL-1α and IL-1β were shown to have 
independent roles in defence to Mtb infection (Mayer-Barber et al., 2011). Recently IL-1 was 
seen to induce PGE2 in both human and mouse macrophages and this was suggested to 
contribute to the protective effect of IL-1 during Mtb infection (Mayer-Barber et al., 2014). 
Furthermore, administration of exogenous IL-1 to Mtb infected mouse bone marrow derived 
macrophages reduced production of type I IFNs, which are detrimental to control of Mtb 
infection (discussed in more detail later) and led to lower bacterial loads (Mayer-Barber et al., 
2014). 
 
IL-1β is processed to its active form by the inflammasome, a complex comprising a PRR of the 
NLR family, the CARD domain-containing molecule ASC, and caspase-1 (Lamkanfi, 2011). 
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Although the role of IL-1 in Mtb infection is established, the role for the inflammasome remains 
unclear. In vitro infection of macrophages or macrophage cell lines or DCs with Mtb showed 
IL-1β production to largely depend upon the NLRP3 inflammasome (Abdalla et al., 2012; 
Dorhoi et al., 2012; Mayer-Barber et al., 2010; Mishra et al., 2010). However, in vivo, mice 
deficient in components of the inflammasome did not show defects in IL-1β production (Dorhoi 
et al., 2012; Mayer-Barber et al., 2010). Mice lacking NLRP3 were not more susceptible to Mtb 
infection but those lacking caspase-1 or ASC did display increased susceptibility to Mtb 
infection (Dorhoi et al., 2012; Mayer-Barber et al., 2010). Therefore the precise role of the 
inflammasome and its importance in mediating IL-1 production in vivo remains unclear.  
 
1.4.1.3 Eicosanoids 
Eicosanoids are lipid mediators derived from arachidonic acid (AA). AA can be metabolised by 
Cyclo-oxygenase 1 or 2 (COX1/COX2) or 5-lipoxgenase to produce a variety of lipid mediators 
including prostaglandins, lipoxins and leukotrienes. The balance of various lipid mediators 
produced from AA has been found to be important in mediating the outcome of Mtb infection 
(Mayer-Barber and Sher, 2015). 
 
Cell death of infected cells by necrosis or apoptosis is important in determining the outcome of 
infection (Behar et al., 2011). Cell death by necrosis is beneficial to Mtb, allowing release of the 
bacilli from the infected cells, evasion of host defences and spread to other cells, whereas 
apoptosis promotes control of bacterial replication (Behar et al., 2011). PGE2 has been found to 
be beneficial to the outcome of Mtb infection through protecting against necrotic cell death by 
protecting the integrity of the plasma membranes (Chen et al., 2008; Divangahi et al., 2009). In 
keeping with a protective role for PGE2, pges knock mice (lacking the enzyme required for 
PGE2 production) displayed increased susceptibility to Mtb infection (Chen et al., 2008; 
Divangahi et al., 2009). However, the production of PGE2 is inhibited by LipoxinA4 (LXA4), 
which promotes necrotic cell death and is produced at higher levels upon infection with virulent 
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Mtb strains (Chen et al., 2008; Divangahi et al., 2009). Mice lacking Alox5, the enzyme required 
for production of LXA4, showed increased resistance to Mtb infection in vivo (Bafica et al., 
2005b; Divangahi et al., 2009). Inhibition of apoptosis by LXA4 also impacts the adaptive 
response through the prevention of cross presentation of Mtb antigens, and in keeping with this 
deficiency in Alox5 led to earlier and increased CD4+ and CD8+ T cell responses (Divangahi et 
al., 2010).  
 
Further support for a detrimental role of LXA4 during mycobacterial infection is provided by 
study of the zebrafish. In zebrafish, a mutation in the lta4h locus (encoding leukotriene A4 
hydrolase, which converts Leukotriene A4 to Leukotriene B4 (LTB4)) led to susceptibility to M. 
marinum infection, through increased LXA4 production accompanied by decreased LTB4 and 
TNFα production (Tobin et al., 2010). This was supported by observations in humans, where 
polymorphisms in the lta4h locus correlated with susceptibility to Mtb infection (Tobin et al., 
2010). However, modulation of the lta4h locus in zebrafish underlined the importance of the 
balance in the immune response in mycobacterial infection. Genotypes that led to high LXA4 
production were accompanied by low LTB4 and low TNFα production with increased 
susceptibility to infection (Tobin et al., 2012). However, genotypes that led to low LXA4 were 
accompanied by high LTB4 and excess TNFα and also led to host susceptibility, suggesting 
there is an optimal level of LXA4 to control infection (Tobin et al., 2012). This idea of balance 
in the level of production of LXA4 was supported in human patients with tuberculous 
meningitis. Patients with genotypes at the lta4h locus that led to either the high or low extreme 
inflammatory phenotypes had poorer survival (Tobin et al., 2012).  
 
1.4.1.4 Innate lymphocytes - NK cells, NKT cells, γδ T cells and MAIT cells 
The ability of innate lymphocytes such as Natural Killer (NK) cells, Natural Killer T cells 
(NKT) and γδ T cells to respond rapidly to infection makes it attractive to think they may play a 
role in the early events following Mtb infection (Orme et al., 2015). Furthermore it has been 
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suggested such innate lymphocytes could contribute to immunity in individuals thought to have 
cleared Mtb infection without mounting an adaptive response (Young et al., 2009). However, 
the role of these innate lymphocytes in response to Mtb infection remains unclear.  
 
γδ T cells are activated in response to Mtb infection and are a main source of IL-17 (Lockhart et 
al., 2006; Okamoto Yoshida et al., 2010). Deficiency in γδ T cells increased susceptibility to 
intravenous infection with Mtb with increased bacterial loads and decreased survival (Ladel et 
al., 1995). In contrast deficiency in γδ T cells did not impact control of bacterial load or survival 
in response to aerosol infection but did lead to increased inflammation (D'Souza et al., 1997). 
Thus the role of γδ T cells in the response to Mtb is uncertain, although it appears they can 
contribute to optimal control of inflammation (D'Souza et al., 1997).  
 
NKT cells are able to recognise antigens presented in the context of CD1. Mice deficient in 
CD1 did not show any increased susceptibility to Mtb infection (Behar et al., 1999). However, 
activation of NKT cells through administration of the ligand α-galactosylceramide was 
beneficial to the outcome of infection (Chackerian et al., 2002a). Furthermore NKT cells are 
capable of producing IFNγ or GM-CSF to restrict mycobacterial growth in vitro (Rothchild et 
al., 2014; Sada-Ovalle et al., 2008). GM-CSF producing NKT cells have been identified upon 
Mtb infection in mice, supporting the idea they may contribute to macrophage activation in vivo 
(Rothchild et al., 2014).  
 
The role of NK cells in the immune response to Mtb is unclear. IFNγ production by NK cells 
has been identified during Mtb infection in both wild-type mice and those lacking an adaptive 
immune system (Feng et al., 2006; Junqueira-Kipnis et al., 2003). In mice lacking an adaptive 
immune system NK cell-derived IFNγ was suggested to be important to regulate accumulation 
of granulocytes upon Mtb infection (Feng et al., 2006). In the absence of IFNγ this granulocyte 
accumulation was found to be protective during Mtb infection (Feng et al., 2006). However, 
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when NK cells were depleted in wild-type mice there was no impact on the outcome of 
infection (Junqueira-Kipnis et al., 2003). During BCG infection, IL-15 treatment decreased 
bacterial loads and expanded NK cell populations as well as leading to increased IFNγ 
production by CD8+ T cells (Umemura et al., 2001). This increased resistance to infection was 
not seen when NK cells or CD8+ T cells were depleted, suggesting NK cells are capable of 
providing protection (Umemura et al., 2001). In addition Il-15 deficient mice, which lack NK 
cells and have defects in CD8+ T cell memory populations, show slightly higher bacterial loads 
in chronic infection and defects in cell recruitment to the lung (Lazarevic et al., 2005). 
Deficiency in NK cells could contribute to this phenotype although this was not directly 
assessed (Lazarevic et al., 2005). In humans, NK cells have been shown to have the capacity to 
produce cytokines in response to infected cells and lyse Mtb infected cells in vitro, although 
their contribution to the immune response at the site of disease is unknown (Esin and Batoni, 
2015). NK cells have also been suggested to contribute to the efficacy of BCG vaccination 
through IL-22 production and lysis of Foxp3+ Treg cells, with depletion of NK1.1+ cells at the 
time of vaccination leading to higher bacterial loads upon Mtb challenge (Dhiman et al., 2012). 
In addition, NK cells producing IFNγ cells have been identified in the peripheral blood of BCG 
vaccinated infants, suggesting these cells could contribute to BCG induced immunity (Zufferey 
et al., 2013). 
 
Mucosal associated invariant T (MAIT) cells have also been implicated in the immune response 
to Mtb infection (Gold et al., 2015). MAIT cells are T cells with a semi-invariant T cell receptor 
(TCR) that have been described to recognise vitamin B2 metabolites in the context of MR1 
(Gold et al., 2015). These cells have been identified in the human airway and are capable of 
producing IFNγ and TNFα in response to Mtb infected epithelial cells (Gold et al., 2010; Gold 
et al., 2015). In the context of Mtb infection in humans, MAIT cells were found to be enriched 
in the lung and decreased in peripheral blood (Gold et al., 2010; Le Bourhis et al., 2010). The 
ability of these cells to respond rapidly and produce cytokines in response to Mtb infection may 
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indicate they could contribute to early control of Mtb infection (Gold et al., 2015; Orme et al., 
2015).  
 
The possibility exists that, although such innate lymphocytes appear to play minimal roles in the 
optimal response to Mtb, augmentation of their response may be beneficial to the outcome of 
infection.  
 
1.4.1.5 TNFα 
Various cell types can produce TNFα including macrophages, DCs as well as T cells (Flynn and 
Chan, 2001). The importance of TNFα in the control of Mtb infection has been demonstrated by 
the observation that treatment of patients with TNF neutralizing agents, for diseases such as 
Rheumatoid Arthritis, led to reactivation of latent tuberculosis (Keane et al., 2001). Earlier it 
had been shown in the mouse model that mice deficient in TNFα or the 55 kDa TNF receptor 
(TNFR), or those where TNF was neutralized during infection, all displayed increased 
susceptibility to Mtb infection (Bean et al., 1999; Flynn et al., 1995a). These mice had 
decreased survival, increase bacterial loads and disrupted granuloma formation (Bean et al., 
1999; Flynn et al., 1995a). Furthermore, neutralisation of TNFα in low dose chronic infection 
led to increased bacterial loads, disorganized granulomas and decreased survival despite 
maintained or increased expression of IL-12p40 and IFNγ (importance of which will be 
discussed later) (Chakravarty et al., 2008; Mohan et al., 2001; Scanga et al., 1999).  
 
The above studies suggested that TNFα might act through regulation of granuloma formation 
and maintenance. However, this concept was challenged in the NHPs where TNFα 
neutralisation during acute infection led to severe disseminated disease and during latent 
infection led to reactivation of disease, but granuloma structure was similar to controls (Lin et 
al., 2010). Further support that TNFα may not contribute to protection through formation of 
granulomas is provided by work in the zebrafish. Knockdown of the TNFα ortholog led to 
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accelerated granuloma formation, increased bacterial growth and increased necrotic death of 
infected macrophages (Clay et al., 2008). This study suggests that TNFα may act during Mtb 
infection to regulate intracellular killing of mycobacteria, given that in the absence of TNFα 
macrophages have increased bacterial burdens (Clay et al., 2008). The idea that TNF can 
regulate the ability of macrophages to restrict mycobacterial growth is supported by 
observations that it can synergise with IFNγ for induction of RNIs (Chan et al., 1992; Flynn and 
Chan, 2001).  
 
More recently the idea that there is an optimal level of TNFα during infection has been 
proposed. Zebrafish with genotypes that lead to extreme levels of TNFα (either low or high) are 
susceptible to M marinum infection (Tobin et al., 2012; Tobin et al., 2010). Excessive levels of 
TNFα in the zebrafish have been demonstrated to lead to ROS production and macrophage 
necrosis, allowing unchecked extracellular growth (Roca and Ramakrishnan, 2013). Thus it 
seems that whilst TNFα is essential for protection, a balanced response is vital.  
 
1.4.2 Adaptive immune factors protective in the immune response to Mtb infection 
1.4.2.1 CD4+ T cells 
Lymphocytes are crucial for control of Mtb infection, with early studies in mice showing that 
adoptive transfer of T cells from infected donors can confer protection against Mtb in T cell 
deficient recipients (Orme and Collins, 1983). Subsequently the importance of CD4+ T cells 
specifically in response to Mtb was demonstrated and is now well established in both mice and 
humans. Studies using CD4 deficient mice or depletion of CD4+ T cells using monoclonal 
antibody showed that CD4+ T cells were crucial for a protective response against Mtb (Mogues 
et al., 2001; Saunders et al., 2002; Scanga et al., 2000). Furthermore, MHC II deficient mice 
have increased susceptibility to Mtb (Mogues et al., 2001). A requirement for direct interaction 
of CD4+ T cells with infected cells to control bacterial loads has been demonstrated, with MHC 
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II deficient myeloid cell populations in the lung harbouring more bacteria than MHC II 
sufficient cells (Srivastava and Ernst, 2013). In humans, the importance of CD4+ T cells in 
control of Mtb infection is supported by reports that HIV positive patients are highly susceptible 
to Mtb infection and reactivation, particularly those with low CD4+ T cell counts (Cooper, 2009; 
Schutz et al., 2010). In addition, Mtb specific CD4+ T cells are suggested to be preferentially 
depleted following HIV infection, increasing susceptibility to TB (Geldmacher et al., 2012).  
 
Different populations of CD4+ T cells have been described during Mtb infection based on their 
expression of PD-1 and KLRG1, markers that correlate with an exhausted phenotype (Reiley et 
al., 2010). However, during Mtb infection PD-1+ CD4+ T cells were not exhausted, displaying 
proliferative capacity, but low cytokine production (Reiley et al., 2010). Upon transfer into 
infected mice PD-1+ CD4+ T cells were able to give rise to KLRG1+ cells which displayed 
higher cytokine production than PD1+ cells, but lower proliferative capacity (Reiley et al., 
2008). Subsequently it was found that PD-1+ KLRG1- CD4+ T cells, which were dependent 
upon ICOS and Bcl-6, persisted when transferred into an uninfected host, and induced a robust 
protective response upon Mtb infection (Moguche et al., 2015). PD-1 has been shown to be 
important in inhibiting excessive CD4+ T cell responses during Mtb infection (Barber et al., 
2011). Mice lacking PD-1 were shown to display decreased survival accompanied by increased 
bacterial load and immunopathology (Barber et al., 2011). Like many aspects of the immune 
response to Mtb infection, this demonstrates that a balance in the T cell response is required for 
optimal outcome (Barber et al., 2011).  
 
The PD-1+ T cells described above were found to localise to the lung parenchyma (Moguche et 
al., 2015). Distinct populations of T cells that localise to the lung parenchyma and populations 
that are retained in the vasculature have been described during Mtb infection (Sakai et al., 
2014). The localisation of T cells within the lung is described to be important in their capability 
to contribute to protection during Mtb infection, with parenchymal CD4+ T cells providing 
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superior protection against Mtb when transferred into susceptible hosts compared to those 
isolated from the vasculature (Sakai et al., 2014). 
 
Although it seems that different populations of CD4+ T cells have different capacities to 
produce cytokines and localise within the lung, CD4+ T cell derived cytokines are thought to be 
required during Mtb infection to stimulate anti-mycobacterial responses in innate cells 
(reviewed in Cooper, 2009; O'Garra et al., 2013). As discussed above, the phenotype and 
cytokine production displayed by activated T cells depends on the context in which CD4+ T 
cells are activated (reviewed in Zhu et al., 2010). Th1 cells differentiate in the presence of IL-12 
and produce IFNγ, Th2 cells differentiate in the presence of IL-4 and produce IL-4, IL-5 and IL-
13 and Th17 cells differentiate in the presence of IL-6, TGFβ and IL-1β and produce IL-17 
(Zhu et al., 2010). In the context of Mtb both Th1 and Th17 cells are induced and their roles will 
be discussed below. 
 
1.4.2.2 Th1 axis –IFNγ, IL-12 
Th1 cells express the transcription factor T-bet, produce IFNγ and differentiate in the context of 
APC-derived IL-12, a dimer formed of the subunits IL-12p40 and IL-12p35 12p35 (Hsieh et al., 
1993;  Macatonia et al., 1995; Trinchieri, 2003). IFNγ produced by Th1 cells can activate 
macrophage populations (via STAT1 signalling) to increase their anti-microbial capacity 
through mechanisms including induction of iNOS and production of RNIs, and production of 
ROS (North and Jung, 2004; Zhu and Paul, 2008). Th1 cells are known to be crucial for the 
immune response to intracellular pathogens but their inappropriate activation can also contribute 
to autoimmunity (Zhu and Paul, 2008).  
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1.4.2.2.1 Th1 axis –IFNγ, IL-12 in Mtb infection 
The Th1 axis is crucial in the immune response to Mtb infection. Administration of exogenous 
IL-12 during Mtb infection increased survival of mice and their resistance to Mtb infection 
(Cooper et al., 1995; Flynn et al., 1995b). Treatment with exogenous IL-12 increased 
production of IFNγ by splenocytes (Cooper et al., 1995) and was not protective in IFNγ 
deficient mice, suggesting that the protective effect of IL-12 is IFNγ dependent (Flynn et al., 
1995b). Furthermore neutralisation of IL-12 using antibody treatment led to increased 
susceptibility to Mtb infection (Cooper et al., 1995).  
 
Further support for the importance of IL-12 to induce IFNγ responses during Mtb infection was 
provided using IL-12p40 deficient mice. Mice deficient in IL-12p40 displayed increased 
susceptibility to Mtb infection, with dramatically reduced levels of IFNγ production by 
splenocytes and defective granuloma formation (Cooper et al., 2002; Cooper et al., 1997). 
However, comparison of IL-12p35 and IL-12p40 (the two subunits of IL-12 discussed above) 
deficient mice showed that IL-12p35 deficient mice were less susceptible to Mtb infection and 
were capable of inducing an IFNγ response, albeit at a reduced level (Cooper et al., 2002). A 
possible explanation for this is that IL-12p40 is also a subunit for IL-23 (discussed further 
below). In addition, IL-12p40 homodimers have been demonstrated to be required for optimal 
DC trafficking and T cell activation (Khader et al., 2006). As well as being required for the 
induction of Th1 immunity, IL-12 is suggested to have a role in the maintenance of the Th1 
response during Mtb infection. IL-12p40 deficient mice treated with exogenous IL-12 for the 
first 4 weeks of infection, displayed increased resistance to Mtb infection compared to no 
treatment, but this was lost over time and correlated with a decrease in IFNγ producing CD4+ T 
cells in the lung (Feng et al., 2005). 
 
That IFNγ is crucial for the control of Mtb infection has been demonstrated by the observation 
that administration of IL-12 to IFNγ deficient mice did not increase their survival, unlike IL-12 
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administration in wild type mice (discussed above) (Flynn et al., 1995b). The fundamental 
importance of IFNγ in the immune response to Mtb is also demonstrated in mice deficient for 
IFNγ, which displayed a marked increase in susceptibility to Mtb infection, with development of 
necrotic lesions and impaired induction of inducible Nitric Oxide Synthatase (iNOS) (Cooper et 
al., 1993; Flynn et al., 1993).  
 
IFNγ activates macrophages, inducing programmes that can control mycobacterial growth 
including iNOS, an enzyme that synthesises RNIs and NADPH-oxidase which synthesises ROS 
(North and Jung, 2004). Various studies provide evidence that RNIs are capable of controlling 
Mtb growth (Nathan and Shiloh, 2000). Indeed, deletion of the Nos2 gene (encoding iNOS) in 
mice resulted in increased susceptibility to Mtb infection (Cooper et al., 2000a; MacMicking et 
al., 1997; Scanga et al., 2001), although the role for NO in humans is less clear (reviewed in 
O'Garra et al., 2013). A role for NADPH-oxidase in the mouse model of Mtb is less clear than 
that for iNOS, with conflicting reports of increased bacterial loads following Mtb infection and 
no decrease in survival compared to wild-type mice (Cooper et al., 2000b; Nathan and Shiloh, 
2000; North and Jung, 2004). One mechanism by which Mtb survives intracellularly in 
macrophages is through inhibition of phagosome maturation leading to a less acidic 
environment (Russell et al., 2010). In addition to production of RNIs and ROS, activation of 
macrophages with IFNγ facilitates increased acidification of the phagosome (Russell et al., 
2010).  
 
In addition to the role for IFNγ in activating macrophages, IFNγ has also been shown to have a 
regulatory role protecting from immunopathology. IFNγ was shown to regulate neutrophil 
survival and also suppress neutrophil recruitment through suppression of IL-17 production 
(Nandi and Behar, 2011). In addition IFNγ mediated induction of NO inhibited IL-1β 
production and accumulation of neutrophils (Mishra et al., 2013). 
 
 -Chapter 1: Introduction-  
 
 60 
The vital role for the IL-12/ IFNγ pathway in the response to mycobacterial infection is also 
demonstrated in humans. Mutations in the IL-12/IFN-γ pathway lead to Mendelian 
Susceptibility to Mycobacterial Disease (MSMD) (Casanova, 2001; Fortin et al., 2007). Genes 
mutated in such patients include IFNGR1 and IFNGR2 (the chains of the IFNγ receptor), IL12B 
(encoding IL-12p40), IL12RB1 (encoding one chain of the IL-12 receptor) and STAT1 (a 
molecule required for IFNγ signal transduction) (Casanova, 2001). Such patients are more 
susceptible to infection with weakly virulent mycobacterial infection, such as BCG and 
nontuberculous environmental mycobacteria, as well as to Mtb (Casanova and Abel, 2002; 
Fortin et al., 2007). The most common manifestation of such genetic mutations is disease 
caused by BCG (following vaccination) or nontuberculous environmental mycobacteria 
(Casanova and Abel, 2002). However, more recently a small proportion of patients with 
mutations in IL-12Rβ1, IL-12B or IFNGR1 have been identified that were resistant to BCG 
infection (as evidenced by lack of disease following vaccination) and presented with severe or 
disseminated TB in childhood or even adulthood (Altare et al., 2001; Casanova and Abel, 2002; 
Tabarsi et al., 2011). The frequency of such patients and the reasons they to succumb to TB 
disease rather than atypical mycobacteria are unknown (Casanova and Abel, 2002).  
 
1.4.2.3 IFNγ independent T cell mediated protection  
As discussed above both CD4+ T cells and IFNγ are important for protection against Mtb 
infection and it is largely accepted that CD4+ T cell derived IFNγ is important (reviewed in 
O'Garra et al., 2013). However, IFNγ is a poor correlate of protection following vaccination 
(Abebe, 2012; Kagina et al., 2010; Mittrucker et al., 2007), suggesting other mechanisms may 
exist. Several studies suggest that CD4+ T cells can mediate a protective effect independently of 
IFNγ. Transfer of Th1 skewed cells incapable of producing IFNγ still provided protection 
against Mtb (Gallegos et al., 2011). CD4+ T cells were capable of activating macrophages to 
control Mtb growth in IFNGR deficient macrophages, suggesting an IFNγ independent 
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mechanism (Cowley and Elkins, 2003). Additionally, BCG vaccinated IFNγ deficient mice 
showed enhanced resistance to Mtb challenge compared to unvaccinated IFNγ deficient mice 
and this resistance was CD4+ dependent (Cowley and Elkins, 2003). Furthermore, depletion of 
CD4+ T cells using a monoclonal antibody increased bacterial loads without differences in IFNγ 
expression or the number of iNOS positive cells, suggesting existence of IFNγ independent 
functions of CD4+ T cells (Scanga et al., 2000). The recent observations that T cells that localise 
to the lung parenchyma can provide protection upon adoptive transfer but produce low levels of 
IFNγ also suggests IFNγ independent mechanisms of control of Mtb infection (Sakai et al., 
2014).  
 
1.4.2.4 IL-17 producing Th17 cells  
CD4+ T cells can differentiate towards a RORγt expressing Th17 phenotype when activated in 
the context of IL-6, TGFβ and IL-1β (reviewed in Gaffen et al., 2014). Th17 cells produce a 
variety of cytokines including IL-17, IL-22 and GM-CSF and are important in the immune 
response to infection with extracellular bacteria and fungi (reviewed in Gaffen et al., 2014; Zhu 
et al., 2010). Exposure of Th17 cells to IL-23 (a dimer formed of the subunits IL-12p40 and IL-
23p19 (reviewed in Trinchieri, 2003) can promote a highly inflammatory phenotype, where 
cells contribute to chronic inflammation following infection or autoimmunity (reviewed in 
Gaffen et al., 2014). IL-17, the hallmark cytokine of Th17 cells, is a pro-inflammatory cytokine 
that induces production of anti-microbial peptides and several chemokines that drive 
granulocyte accumulation and can also be produced by a variety of other cell types including γδ 
T cells, NKT cells and ILC3s (discussed in detail below) (reviewed in Gaffen et al., 2014). 
 
1.4.2.4.1 IL-23, Th17 cells and other sources of IL-17 during Mtb infection 
In addition to IFNγ producing Th1 cells, IL-17 producing Th17 cells are also induced following 
mycobacterial infection (Cruz et al., 2006). In addition to Th17 cells, other cellular sources of 
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IL-17 during mycobacterial infection are also described including γδ T cells and non 
CD4+/CD8+ cells (Lockhart et al., 2006; Okamoto Yoshida et al., 2010; Umemura et al., 2007), 
and it is thought that γδ T cells are the major source of IL-17 upon Mtb infection (Lockhart et 
al., 2006). The role of IL-17 in primary Mtb infection is unclear, although it is suggested to be 
important in vaccination against Mtb (discussed in more detail below). IL-17 was proposed to 
play a role in granuloma formation and Th1 enhancement following BCG infection (Umemura 
et al., 2007); (Okamoto Yoshida et al., 2010), although IL-17 deficiency was not reported to 
impact control of infection (Umemura et al., 2007). In the context of Mtb infection, IL-17 is 
suggested to be required for control of hyper-virulent HN878 infection, through CXCL13 
induction and localisation of T cells within the granuloma (Gopal et al., 2014). However, the 
same study reported that IL-17 was dispensable for protection against the lab-adapted Mtb strain 
H37Rv and a less virulent clinical isolate CDC1551 (Gopal et al., 2014). In contrast, IL-17 was 
required for control of bacterial loads following intra-tracheal infection with H37Rv (Okamoto 
Yoshida et al., 2010). In addition IL17RA deficient mice (mice deficient for the IL-17 receptor) 
show increased susceptibility to intra-tracheal H37Rv infection at chronic time points (Freches 
et al., 2013). Thus it seems IL-17 can contribute to protection to mycobacterial infections in 
some settings but the precise role of IL-17 in Mtb infection is unclear. 
 
The balance between Th1 and Th17 subsets is thought to influence immunopathology upon 
mycobacterial infection (Cruz et al., 2006). Excessive IL-17 responses have been demonstrated 
to be detrimental to control of mycobacterial infection. Mice deficient in IFNγ exhibited 
enhanced Th17 generation, accumulation of neutrophils and immunopathology in the lung upon 
BCG infection (Cruz et al., 2006) and also Mtb infection (Nandi and Behar, 2011). Furthermore 
increased IL-17 contributed to the granulocyte influx and immunopathology observed in Mtb 
infected mice that were repeatedly BCG vaccinated (Cruz et al., 2010). 
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As mentioned above, IL-23 is a heterodimeric cytokine, composed of 2 subunits IL-12p40 and 
IL-23p19 and is required for inflammatory Th17 responses (Gaffen et al., 2014). IL-23p19 is 
suggested to be required for IL-17 production by CD4+ T cells following Mtb infection, but IL-
23p19 deficiency did not impact control of infection (Khader et al., 2005). In addition, IL-12p40 
was also shown to be required for induction of IL-17 production by γδ T cells (Lockhart et al., 
2006). However, another study showed that IL-17 producing CD4+ T cells are induced 
following BCG vaccination in IL-12p40 deficient mice, which lack both IL-12 and IL-23 
(Wozniak et al., 2006). Thus the importance of IL-23 for induction of IL-17 following 
mycobacterial infection is unclear.  
 
In the absence of IL-12, IL-23 can compensate in the induction of Th1 responses to some extent 
following Mtb infection (Khader et al., 2005). IL-23 is required for a residual Th1 response to 
Mtb infection in mice lacking IL-12p35, a subunit of bioactive IL-12p70 (Khader et al., 2005). 
In addition, immunization of IL-12p40 deficient mice with a DNA vaccine encoding a 
mycobacterial antigen and a plasmid expressing IL-23 leads to induction of a Th1 response in 
the lung, again suggesting IL-23 can induce a Th1 response to mycobacterial antigens, in the 
absence of IL-12 (Wozniak et al., 2006). 
 
1.4.2.5 Granulocyte – Macrophage Colony Stimulating Factor (GM-CSF) 
GM-CSF (also known as Csf-2) was identified due to its ability to induce proliferation and 
differentiation of both macrophage and granulocyte populations from precursors (Burgess and 
Metcalf, 1980). Given its ability to induce differentiation of myeloid populations, it was 
surprising when it was found that mice deficient for GM-CSF had no obvious defects in 
myeloid cell numbers in peripheral blood in the steady state (Dranoff and Mulligan, 1994; 
Stanley et al., 1994). It was suggested that other cytokines could compensate for the lack of 
GM-CSF resulting in normal myeloid cell development (Dranoff and Mulligan, 1994). 
However, more recently GM-CSF has been found to be required for development of alveolar 
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macrophages through induction of PPARγ in precursors (Guilliams et al., 2013; Schneider et al., 
2014) and mice deficient for GM-CSF show deficiency in alveolar macrophage populations 
(Becher et al., 2014; Guilliams et al., 2013). Furthermore, GM-CSF is suggested to be required 
for the development of non-lymphoid CD103+ DC subsets, although there are opposing reports 
concerning this (Bogunovic et al., 2009; Hamilton, 2015; King et al., 2010). GM-CSF 
deficiency has also been shown to impact the function of NKT cells (Bezbradica et al., 2006). 
Thus, although not as dramatic as originally expected given the capability of GM-CSF to 
differentiate bone marrow precursors, GM-CSF deficient mice do have perturbations in myeloid 
populations as well as NKT cells.  
 
GM-CSF is vital for lung homeostasis (Trapnell and Whitsett, 2002). Mice deficient in GM-
CSF or the βc subunit of the GM-CSF receptor (also shared with IL-3 and IL-5) develop lung 
pathology that resembles the human disease Pulmonary Alveolar Proteinosis (PAP) (Dranoff et 
al., 1994; Nishinakamura et al., 1996; Stanley et al., 1994). This results from altered surfactant 
catabolism by alveolar macrophages (Dranoff 1994). PAP is a disease characterised by 
accumulation of surfactant and proteins within the alveolar space, which leads to progressive 
dyspnoea and impaired gas exchange (Trapnell and Whitsett, 2002). In humans causes of PAP 
can be genetic or acquired. Acquired causes are more common; accounting for more than 90% 
of cases (Seymour and Presneill, 2002). The majority of patients with an acquired cause of PAP 
have autoantibodies against GM-CSF (Seymour and Presneill, 2002). Patients with mutations in 
CSF2RA or CSF2RB, the two subunits of the GM-CSF receptor, or in surfactant protein B or C 
or the transporter ABCA3 account for genetic causes of PAP (Whitsett et al., 2015). Patients 
with PAP have increased susceptibility to various infections, with reports of infection with 
Nocardia, Pneumocystis, Acinetobacter, Aspergillus, Cladosporium, Mtb and other atypical 
mycobacteria (Borie et al., 2011; Seymour and Presneill, 2002). 
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In addition to a role in myeloid development, GM-CSF has pro-inflammatory roles in activation 
of myeloid populations. GM-CSF pre-treatment of bone marrow macrophages differentiated 
with Macrophage Colony Stimulating Factor (M-CSF) increased their production of pro-
inflammatory cytokines upon LPS stimulation (Fleetwood et al., 2007). Furthermore, GM-CSF 
increased the capacity of both CD8+ and CD8- DCs to present antigen and induced upregulation 
of costimulatory molecules (Min et al., 2010; Zhan et al., 2012). Further support for a pro-
inflammatory role of GM-CSF is provided by the observation that GM-CSF is crucial for the 
induction of experimental autoimmune encephalitis (Codarri et al., 2011; El-Behi et al., 2011), 
and also for the development of disease in a collagen induced model of arthritis (Campbell et 
al., 1998; Hamilton, 2008).  
 
 1.4.2.5.1 GM-CSF in Mtb infection 
Mice deficient in GM-CSF showed enhanced susceptibility to aerosol infection with both 
Erdman (Gonzalez-Juarrero et al., 2005) and H37Rv lab-adapted strains of Mtb and BCG 
(Szeliga et al., 2008). Deficiency in GM-CSF impaired granuloma formation in response to 
Mtb, ultimately leading to large necrotic lesions (Gonzalez-Juarrero et al., 2005; Szeliga et al., 
2008). Furthermore, a decrease in recruitment of IFNγ producing CD4+ T cells to the lung was 
observed in mice lacking GM-CSF upon Mtb infection (Gonzalez-Juarrero et al., 2005). 
However, these studies are difficult to interpret owing to the developmental defects in alveolar 
macrophage populations and the resultant lung pathology.  
 
A role for GM-CSF in activation of APCs and subsequent priming of the adaptive immune 
response is supported the observation that a BCG strain expressing GM-CSF, increased the 
number of antigen presenting cells in the lymph nodes and their expression of costimulatory 
molecules (Nambiar et al., 2010; Ryan et al., 2007). Vaccination with BCG expressing GM-
CSF also increased the number of IFNγ producing CD4+ T cells in the lymph node following 
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vaccination and lowered bacterial loads systemically upon Mtb challenge, compared to 
vaccination with the parental BCG strain (Nambiar et al., 2010; Ryan et al., 2007).  
 
A direct anti-mycobacterial role for GM-CSF is suggested by the ability of iNKT-derived GM-
CSF to restrict Mtb growth in mouse bone marrow derived macrophages in vitro (Rothchild et 
al., 2014). Furthermore treatment of Mtb infected mice with Keratinocyte Growth Factor 
(KGF), either throughout infection or after infection is established, is suggested to induce GM-
CSF production and lead to restriction of bacterial growth (Pasula et al., 2015). The proposed 
mechanism for this was through enhancing phagolysosome fusion in macrophages (Pasula et al., 
2015). In human macrophages GM-CSF has also been described to restrict growth of Mtb 
(Denis and Ghadirian, 1990), M. avium complex (Bermudez and Young, 1990) and M. avium 
(Denis, 1991). 
 
Higher and sustained levels of GM-CSF in the lung over infection in IL-10 knock-out mice 
correlates with increased resistance to Mtb infection, suggesting a protective role for GM-CSF 
in Mtb infection (Redford et al., 2010). However, the balance of GM-CSF levels is important as 
mice engineered to overexpress GM-CSF in the lung also demonstrate enhanced susceptibility 
to Mtb infection (Gonzalez-Juarrero et al., 2005; Szeliga et al., 2008).  
 
1.4.2.6 CD8+ T cells 
A role for CD8+ T cells during Mtb infection was suggested from studies where β2m, a 
component of MHC class I (MHC I) was deleted. These mice displayed increased susceptibility 
to Mtb infection and succumbed to disease faster than controls (Flynn et al., 1992); (Mogues et 
al., 2001). MHC I is required to present antigen to CD8+ T cells thus it was inferred the 
increased susceptibility to Mtb infection in β2m deficient mice was due deficiency in CD8+ T 
cells (Behar, 2013). However, other β2m associated proteins exist including non-classical class 
I molecules such as CD1 and HFE, which complicates the interpretation of the above studies. 
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HFE is an MHC class I-like molecule with an important role in iron homeostasis (Schaible et 
al., 2002). β2m deficient mice suffer from iron overload, normalisation of which recuses their 
increased susceptibility to Mtb infection, suggesting that the susceptibility of β2m deficient 
mice is not solely due to defects in CD8+ T cell responses (Schaible et al., 2002). 
 
A role for CD8+ T cells during Mtb was subsequently supported by the study of mice deficient 
in Transporter Associated with Antigen Processing (TAP). Antigen presentation via MHC class 
I requires translocation of antigens into the endoplasmic reticulum via the protein TAP (Behar, 
2013). TAP deficient mice displayed increased susceptibility to Mtb with reduced survival and 
increased bacterial loads, suggesting CD8+ T cells have a protective role in Mtb infection 
(Behar et al., 1999). Furthermore, depletion of CD8+ cells using a monoclonal antibody 
increases susceptibility of mice to Mtb infection (Mogues et al., 2001).  
 
CD8+ T cells could contribute to protective immunity in Mtb infection through cytokine 
production or lysis of infected cells (Behar, 2013). In vitro, Mtb specific CD8+ T cells from 
mice and humans have been demonstrated to lyse infected cells (Behar, 2013). In the mouse, 
Mtb specific CD8+ T cells are recruited to the lung upon Mtb infection (Kamath et al., 2004) 
and require perforin to lyse target cells and provide protection upon adoptive transfer 
(Woodworth et al., 2008). Cytotoxic activity has also been detected in CD8+ T cells specific for 
other Mtb antigens (Woodworth et al., 2008). IFNγ production by CD8+ T cells has been 
described, although the relative importance of this is unclear (Behar, 2013). IFNγ production by 
CD8+ T cells depends on the presence of CD4+ T cells and thus in CD4+ T cell deficient 
models, the contribution of CD8+ T cells to protective immunity may be underestimated (Bold 
and Ernst, 2012).  
 
 -Chapter 1: Introduction-  
 
 68 
Augmenting CD8+ T cell mediated immunity is thought to be an avenue by which vaccination 
against Mtb can be improved. For example, boosting BCG vaccination using an adenovirus 
encoding antigen 85A from Mtb has shown that increased CD8+ T cell responses correlated with 
increased protection to subsequent Mtb infection (Forbes et al., 2008). Furthermore, the vaccine 
candidate VPM1002 (discussed in further detail below) is suggested to increase cross-
presentation, thus augmenting CD8+ T cell immunity and provide increased protection against 
Mtb challenge (Grode et al., 2005).  
 
1.4.2.7 B cells 
Although the protective immune response to Mtb is classically regarded not to be antibody 
dependent, more recently a role for B cells in the immune response to Mtb has begun to be 
appreciated (Kozakiewicz et al., 2013; Maglione and Chan, 2009). Aggregates of B cells are 
described at the periphery of granulomas in mouse models, NHP models of Mtb infection and 
human TB patients (Gonzalez-Juarrero et al., 2001; Phuah et al., 2012; Ulrichs et al., 2004). 
However, reports of the impact of B cell deficiency on the outcome Mtb infection have been 
variable. For example, one study showed B cell deficiency did not impact early control of 
CDC1551 (a clinical isolate of Mtb) bacterial load in the lung but delayed inflammation in the 
lung and dissemination (Bosio et al., 2000). In contrast another study showed B cell deficient 
mice infected with the Mtb strain Erdman, displayed decreased survival accompanied by 
increased bacterial load, IL-10 levels and neutrophil infiltration upon Mtb infection (Maglione 
et al., 2007). B cells could impact the immune response to Mtb in multiple ways, for example, 
through antibody dependent mechanisms or through antigen presentation and cytokine 
production (Kozakiewicz et al., 2013; Maglione and Chan, 2009). A role for antibodies has been 
suggested by use of mice deficient in antibody receptors. Mice deficient in the inhibitory 
receptor FcγRII were more resistant to Mtb infection, whereas those deficient in activating 
receptors were more susceptible (Maglione et al., 2008). The precise role for B cells in the 
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immune response to Mtb is currently incompletely understood. Better understanding of their 
role could aid development of novel vaccine regimes that harness the B cell response. 
 
Overall there are many aspects of the immune response that contribute to protective immunity 
to Mtb infection. However, it is becoming clearer that a balanced response is required, as 
situations where there is too little or too much inflammation both lead to poor outcomes 
following infection (Orme et al., 2015). Increasing our understanding of a protective response 
will aid the design of novel vaccine regimes. 
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1.5 Factors detrimental to control of Mtb infection 
 
1.5.1 IL-10, a suppressive cytokine 
IL-10 is an immunosuppressive cytokine first identified in 1989 (Fiorentino et al., 1989). 
Although it was initially found to be produced by Th2 cells (Fiorentino et al., 1989), IL-10 is 
produced by many cell types from both the innate and adaptive arms of the immune system 
including macrophages, dendritic cells, other T cell subsets and B cells (Moore et al., 2001). IL-
10 signals via STAT3 and primarily acts on macrophages and dendritic cells which express the 
highest level of the IL-10 Receptor (IL-10R) (Murray, 2006). IL-10 inhibits production of pro-
inflammatory cytokines such as IL-12, suppresses antigen presentation and suppresses DC 
migration to the draining lymph node and thus supresses a subsequent adaptive immune 
response (Demangel et al., 2002; Moore et al., 2001; Redford et al., 2011). IL-10 can act 
directly on certain T cell subsets such as Th17 cells, where it suppresses their function (Huber et 
al., 2011) or on Foxp3+ Tregs to maintain their regulatory phenotype (Chaudhry et al., 2011; 
Murai et al., 2009). 
 
Although IL-10 is largely suppressive, it can also have stimulatory effects on B cells, increasing 
humoral responses (Moore et al., 2001). It can also increase CD8+ T cell and NK cell responses 
in some conditions (reviewed in O'Garra et al., 2008). These stimulatory properties of IL-10 
could be important in survival of some cancers and are thought to contribute to the pathogenesis 
of the autoimmune disease Systemic Lupus Erythematosus (reviewed in Moore et al., 2001; 
O'Garra et al., 2008). 
 
1.5.2 Role of IL-10 in infectious diseases 
A successful immune response is one that clears the invading pathogen but does not lead to 
immunopathology in the host (Figure 1.4). A delicate balance is required to achieve this perfect 
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scenario, allowing sufficient inflammation to control infection without this becoming excessive 
and detrimental to the host. In the response to many pathogens such a scenario is not achieved. 
IL-10 plays an important role in mediating the delicate balance of the immune response 
following infection, being able to constrain the immune response, avoiding pathology. 
However, the levels of IL-10 produced are sometimes inappropriate with high levels of IL-10 
promoting chronic infection and low levels of IL-10 allowing an excessive immune response 
and host pathology. 
 
Studies using mice deficient for IL-10 have identified several infections where IL-10 is required 
to control the excessive inflammation and pathology. Such pathogens include Toxoplasma 
gondii (Gazzinelli et al., 1996), Plasmodium chabaudi chabaudi (Li et al., 1999), Trypanosoma 
cruzi (Hunter et al., 1997), and Respiratory Syncytial Virus (RSV) (Loebbermann et al., 2012), 
where an absence of IL-10 during infection leads to death and pathology without affecting 
pathogen load. Interestingly the source of IL-10 in T. gondii and P. chabaudi chabaudi infection 
was found to be Th1 cells (do Rosario et al., 2012; Jankovic et al., 2007). This was also largely 
found to be the case during RSV infection (Loebbermann et al., 2012). This suggests that IL-10 
is a mechanism by which Th1 cells self-regulate.  
 
In contrast, infection of Il10 deficient mice or treatment with an IL-10 receptor blocking 
antibody with some pathogens can enhance their clearance, without increased pathology. These 
pathogens include Listeria monocytogenes (Dai et al., 1997; Silva and Appelberg, 2001), 
lymphocytic choriomeningitis virus (LCMV) (Brooks et al., 2006; Ejrnaes et al., 2006) and 
Leishmania major (Belkaid et al., 2001) and demonstrate how IL-10 can contribute to the 
establishment and maintenance of chronic infection. Both CD4+ Foxp3- Th1 cells and Foxp3+ 
Treg cells have been described to produce IL-10 and influence the establishment of chronic 
Leishmania infection, the different sources may be explained by the use of different 
Leishmanial substrains (Anderson et al., 2007; Belkaid et al., 2002).  
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Further support for the ability of IL-10 to contribute to the establishment and maintenance of 
chronic infection, is the observation that several viruses encode homologues of IL-10. Several 
herpes viruses and pox viruses encode viral IL-10 (vIL-10), displaying varying amounts of 
sequence identity to the human IL-10 (Slobedman et al., 2009). Epstein Barr Virus (EBV) also 
encodes a vIL-10. EBV vIL-10 has retained much of the immunosuppressive activity and is able 
to suppress the production of inflammatory cytokines, reduce macrophage activation and 
suppress antigen presentation (Hsu et al., 1990). However, it has lost many of the 
immunostimulatory properties of mammalian IL-10 (Hsu et al., 1990). Acquisition and 
maintenance of vIL-10 genes within the viral genome suggests this is beneficial to the virus, and 
could suggest a mechanism of immune evasion and which contributes to the ability to persist 
(Moore et al., 2001).  
 
1.5.3 The role of IL-10 during Mtb infection 
The role of IL-10 during Mtb infection has been controversial, with many conflicting studies. 
Reasons for these inconclusive results could include differences in the genetic background of 
the mice, strain of Mtb used for infection and also differences in microflora in mice from 
difference sources (Redford et al., 2011). Early studies suggested IL-10 deficiency in mice had 
no effect on bacterial load (North, 1998), and was not responsible for suppressing a Th1 
response, although early increases in IFNγ and iNOS mRNA were reported (Jung et al., 2003). 
Another study suggested that IL-10 only suppressed a protective response early in infection 
(Roach et al., 2001).  
 
The level of IL-10 production has been linked with susceptibility of different mouse strains to 
Mtb infection, with the susceptible CBA/J mice expressing higher levels of IL-10 in foamy 
macrophages than C57BL/6 mice at days 50 and 150 post infection (Turner et al., 2002). 
Genetic modification of the resistant mouse strain C57BL/6 such that IL-10 is expressed as a 
transgene under control of the IL-2 promoter enhanced its susceptibility (Turner et al., 2002). 
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Subsequently it was shown that resistant mice (C57BL/6 and BALB/c) or susceptible mice 
(CBA/J) either deficient in IL-10 or treated with monoclonal antibody to block IL-10 action had 
enhanced protection against Mtb (Beamer et al., 2008; Redford et al., 2010). This was 
accompanied by an earlier and enhanced Th1 immune response to aerosol Mtb infection 
(Redford et al., 2010). Subsequent work comparing CBA/J mice deficient in IL-10 or those 
treated with αIL-10R early in infection, demonstrated that IL-10 within the first month of 
infection was detrimental to control of Mtb infection (Cyktor et al., 2013b). Furthermore, IL-10 
inhibited the formation of mature, fibrotic granulomas capable of containing infection in the 
susceptible CBA/J (Cyktor et al., 2013b). It has also been found that CBA/J mice display a 
clonal accumulation of IL-10 producing CD8+ T cells during chronic Mtb infection, however, 
depletion of these cells did not enhance protection against Mtb, which was suggested to be 
because these cells also produced IFNγ (Cyktor et al., 2013a). 
 
Recently using in silico modelling based on data from NHPs, a role for IL-10 at the level of 
individual granuloma has been suggested (Cilfone et al., 2015). IL-10 was suggested to be 
detrimental to sterilisation of the granuloma but at the expense of caseation, with models of IL-
10 deficiency leading to increased sterilisation (Cilfone et al., 2015). In this model macrophage-
derived IL-10 was implicated as the important source of IL-10, with models of macrophage 
specific deletion increasing levels of TNFα within the granuloma and increasing lesion 
sterilisation (Cilfone et al., 2015).  
 
Further support for a detrimental role for IL-10 during Mtb infection is provided by the 
observation that more virulent Mtb strains induce higher levels of IL-10. The lab Mtb strain 
H37Rv and the clinical isolate CH, have been demonstrated to have different capacities to 
induce IL-10 upon infection of human monocyte derived macrophages (Newton et al., 2006). 
CH induced higher levels of IL-10 and lower levels of the protective IL-12p40, suggesting CH 
can induce an anti-inflammatory environment to further its survival (Newton et al., 2006). In 
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vivo, the hyper virulent Mtb strain HN878 induced higher levels of IL-10 producing Foxp3+ T 
cells upon aerosol infection in mice, which may contribute to its virulence (Ordway et al., 
2007).  
 
A role for IL-10 in contributing to the pathogenesis of Mtb infection is also suggested by studies 
in humans (Redford et al., 2011). In active TB patients elevated levels of IL-10 are seen in the 
lungs (Barnes et al., 1993), serum (Verbon et al., 1999) and sputum (Almeida et al., 2009) and 
reviewed in (Redford et al., 2011). CD4+ T cells isolated from BAL more frequently produce 
both IFNγ and IL-10 in active TB patients compared to CD4+ T cells from healthy controls or 
inactive subjects (Gerosa et al., 1999). Furthermore, IL-12p40 and IFNγ production by PBMCs 
from TB patients cultured with Mtb, was enhanced when IL-10 was neutralised, suggesting a 
suppressive role for IL-10 (Gong et al., 1996). The level of IL-10 expression has been correlated 
with bacterial load in TB patients, with the level of the Mtb antigen CFP32, correlating with IL-
10 in active TB patients (Huard et al., 2003). Furthermore, IL-10 production by CD8+ T cells 
correlated with bacterial load in the sputum (Silva et al., 2014).  
 
There are conflicting reports on the association of polymorphisms in the Il10 gene at -1082, -
819 and -592 and susceptibility to Mtb infection (reviewed in (Redford et al., 2011). A meta-
analysis employing 8 studies to assess association of polymorphism in the Il10 gene at -1082, 
showed that there was a trend towards association with susceptibility to pulmonary TB, but this 
did not reach significance (Pacheco et al., 2008). A subsequent meta-analysis evaluated the 
association of IL-10 polymorphisms at -1082, -819 and -592 (Liu et al., 2015). Analysis in all 
ethnic groups suggested that there is no association between IL-10 polymorphisms and 
susceptibility to TB (Liu et al., 2015). However, assessment within specific ethnic groups 
demonstrated that polymorphism at -1082 were associated with TB susceptibility in Caucasians, 
polymorphism at -819 were associated with TB susceptibility in Asians, and those at -592 were 
associated with TB susceptibility in Asians, Caucasians and Europeans (Liu et al., 2015). In 
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agreement with this, a second meta-analysis reported no association between IL-10 
polymorphisms at -1082, -819 and -592 and susceptibility to TB (Gao et al., 2015). When 
specific ethnic groups were assessed, polymorphism at -819 was associated with susceptibility 
to TB in Asians, and polymorphism at -592 associated with susceptibility to TB in Europeans 
(Gao et al., 2015). Thus the association of Il10 gene polymorphisms with susceptibility to TB 
remains unclear, and data suggests it is dependent upon ethnicity.  
 
1.5.4 Regulatory T cells in the suppression of the immune response to Mtb infection 
 
Regulatory T cells (Treg) are a subset of CD4+ T cells that express Forkhead box P3 (Foxp3) 
and suppress the immune response with the aim of avoiding immunopathology (Josefowicz et 
al., 2012). Numbers of Foxp3+ Tregs expand in the lung and spleen of Mtb infected mice over 
the course of Mtb infection (Kursar et al., 2007). Further work has shown that pathogen specific 
Tregs expand in the pulmonary lymph node following Mtb infection, but subsequently diminish 
following IL-12 induced expression of T-bet (Shafiani et al., 2013). Tregs are suggested to be 
detrimental to protective immunity to Mtb. Indeed, Rag deficient mice reconstituted with CD4+ 
CD25- T cells together with Tregs defined as CD4+ CD25+ show higher bacterial loads than 
those reconstituted with CD4+ CD25- T cells alone (Kursar et al., 2007). However, it should be 
noted that CD25 can also be expressed on activated T cells (Josefowicz et al., 2012). Use of 
Foxp3-GFP reporter mice (where cells expressing Foxp3 also express the green fluorescent 
protein (GFP)) showed that Tregs expand in the pulmonary lymph nodes and accumulate in the 
lung (Scott-Browne et al., 2007). Depletion of Foxp3+ Tregs reduced bacterial loads following 
Mtb infection (Scott-Browne et al., 2007). In addition, Mtb-specific Tregs in the lymph node 
were capable, even at low numbers, of delaying T cell priming and suppressing a protective 
immune response upon Mtb infection (Shafiani et al., 2010). Furthermore, the hyper-virulent 
Mtb strain HN878, induced higher numbers of IL-10 producing Foxp3+ Tregs in the lung 
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compared to virulent H37Rv, which may contribute to the waning Th1 response and impaired 
survival observed following infection with this strain (Ordway et al., 2007).  
 
1.5.5 Type 1 IFNs 
A detrimental role for type I IFNs during Mtb infection is suggested by the observation that 
infection with virulent clinical isolates of Mtb, such as HN878, induces high levels of type I 
IFNs (Manca et al., 2001; Manca et al., 2005). Furthermore, mice deficient for the type I IFN 
receptor (IFNαβR) displayed increased survival following infection with these clinical isolates 
(Manca et al., 2005). However, in contrast another study showed that IFNαβR deficient mice 
displayed lower bacterial loads in the lung when infected with several different strains of Mtb 
but that there was no impact upon survival (Ordway et al., 2007). A possible explanation for the 
differences observed in these studies is the different mouse strains assessed (McNab et al., 
2015). In humans a pathogenic role for type I IFNs was suggested by the identification of an 
IFN inducible gene profile has been seen in patients with active TB but not latent or healthy 
controls (Berry et al., 2010).  
 
Augmentation of type I IFNs during infection either through exogenous application of type I 
IFNs, or through administration of an agent that induces type I IFN (Poly IC) exacerbated 
bacterial load and disease in mice (Antonelli et al., 2010; Manca et al., 2001; Mayer-Barber et 
al., 2014). In addition, mice deficient for a negative regulator of type I IFN expression, TPL2, 
display increased susceptibility to Mtb infection in a type I IFN dependent manner (McNab et 
al., 2013). These mice also displayed increased susceptibility to Listeria monocytogenes 
infection, which was accompanied by increased IL-10 levels and decreased IL-12 levels 
(McNab et al., 2013). Furthermore co-infection with influenza A and Mtb resulted in a type I 
IFN dependent increase in bacterial loads in the lung (Redford et al., 2014). 
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The mechanism for the detrimental role for type I IFN is multifactorial (McNab et al., 2015). 
Type I IFNs have been demonstrated to suppress IL-1 production and promote IL-10 production 
in vivo (Mayer-Barber et al., 2011). This is supported by in vitro findings in mouse bone-
marrow derived macrophages, where induction of type I IFN using PolyIC decreased IL-1α and 
IL-1β expression (Mayer-Barber et al., 2011). This was shown to be at least partially dependent 
upon IL-10 (Mayer-Barber et al., 2011). Type I IFN was found to induce IL-10 expression in 
mouse bone marrow-derived macrophages in an IL-27 independent fashion and suppress TNFα 
and IL-12 production in a manner at least partially dependent upon IL-10 (McNab et al., 2014). 
Type I IFNs have also been shown to regulate the production of IL-1 in human macrophages 
and DCs (Mayer-Barber et al., 2011; Novikov et al., 2011).  
 
Inhibition of IL-1 production by type I IFN is suggested to result in uncontrolled bacterial 
growth, at least in part, through decreased PGE2 production and disruption of the eicosanoid 
balance (Mayer-Barber et al., 2014). Modulation of the eicosanoid balance by increasing PGE2 
in Mtb infected mice treated with PolyIC, increased their survival (Mayer-Barber et al., 2014). 
Furthermore, PGE2 suppresses type I IFN production contributing to control of infection 
(Mayer-Barber et al., 2014). This counter regulation of IL-1, PGE2 and type I IFN is suggested 
to influence outcome of infection (Figure 1.5). Situations where there is excessive type I IFN 
lead to low IL-1 and PGE2 levels compromising control of infection. Restoration of PGE2 levels 
decreases type I IFN levels and facilitates control of infection (Mayer-Barber et al., 2014).  
 
Type I IFNs have also been shown to inhibit the response to IFNγ, providing another way in 
which they are detrimental to control of Mtb infection. It has been shown that IFNβ can inhibit 
IFNγ induced antimicrobial activity in an IL-10 dependent manner in human monocytes 
infected with Mycobacterium leprae (Teles et al., 2013). Suppression of the response to IFNγ by 
type I IFNs has also been seen in mouse macrophages infected with Mtb (McNab et al., 2014). 
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However, it has also been suggested that in some circumstances type I IFNs could provide some 
level of protection. In the absence of type II IFN signalling, type I IFNs could act to limit the 
recruitment of myeloid cells permissible to Mtb infection (Desvignes et al., 2012). In support of 
a protective role for type I IFNs, patients with mutations in ISG15, a type I IFN inducible 
protein, are more susceptible to mycobacterial infection, due to a defect in induction of IFNγ 
(Bogunovic et al., 2012). However, ISG15 has also been shown to be a negative regulator of 
type I IFNs in patients with ISG15 deficiency (Zhang et al., 2015). Further investigation is 
required to determine whether the increased susceptibility to mycobacterial infections observed 
in patients with ISG15 mutations could also result from excessive type I IFN production. 
 
1.5.6 Myeloid suppressor cells as a marker of susceptibility to Mtb 
Myeloid derived suppressor cells (MDSC) were originally identified in tumours and have the 
capability to suppress T cell responses (Gabrilovich and Nagaraj, 2009). In mice they are 
defined based on their expression of Gr-1 and CD11b (Gabrilovich and Nagaraj, 2009). In 
humans they are most commonly defined as CD14- CD11b+ but also as CD33+ but lacking 
markers of mature lymphoid or myeloid populations (Gabrilovich and Nagaraj, 2009). MDSC 
are suggested to play a detrimental role during Mtb infection. Recently an increase in the level 
of Gr-1dim CD11b+ cells (suggested to represent a MDSC population) upon Mtb infection in 
mice was suggested to be a marker of severe infection (Tsiganov et al., 2014). These cells were 
capable of suppressing T cell proliferation and IFNγ production in vitro but did not affect 
bacterial loads in vivo when adoptively transferred (Tsiganov et al., 2014). Furthermore, 
numbers of both Ly6G+ Gr-1int and Ly6G- Gr1hi MDSCs were increased upon Mtb infection in 
susceptible 129S2 mice to a greater extent than in C57BL/6 mice (Knaul et al., 2014). These 
cells were capable of suppressing IFNγ production by splenocytes (Knaul et al., 2014). These 
cells were also capable of being infected with Mtb and specific depletion of these cells using all-
trans retinoic acid (an active form of vitamin A) decreased bacterial loads (Knaul et al., 2014), 
although all-trans retinoic acid may have also have other effects on the immune response. A 
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detrimental role for MDSC is also suggested in humans where increased frequencies of MDSCs 
have been identified in the blood and lungs of active TB patients, compared to healthy controls 
(El Daker et al., 2015).  
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1.6 Vaccination against Mtb 
 
In order to achieve the target set out by WHO to eradicate TB infection by 2050, an effective 
vaccine against Mtb is required. The BCG vaccine is one of the most widely administered 
vaccines, with over 4 billion children BCG vaccinated since 1974 (Abebe, 2012). Although it 
provides protection against childhood TB meningitis (Trunz et al., 2006), the efficacy it 
provides in protecting adults against a pulmonary disease is variable (Fine, 1995) (discussed in 
more detail below) and therefore improved vaccines or vaccine regimes are required. There are 
several issues that complicate the development of a new vaccine against TB. Firstly, there is an 
incomplete understanding of the protective immune response to Mtb infection and therefore 
there is a lack of correlates of protection that can predict vaccine efficacy. It was suggested that 
the presence of IFNγ producing CD4+ T cells correlated with protection against Mtb infection 
(Chackerian et al., 2001), although more recently this concept has been challenged (Abebe, 
2012; Kagina et al., 2010; Mittrucker et al., 2007). Subsequently it was suggested that the 
presence of IFNγ+ TNFα+ IL-2+ multifunctional T cells in the lung correlated with protection 
following vaccination (Forbes et al., 2008). More recently multifunctional T cells expressing 
IL-17, TNFα and IL-2 in the lung are suggested to correlate with protection (Cruz et al., 2015). 
However, in human infants no expression profile of IFNγ, IL-17, IL-2 or TNFα following BCG 
vaccination in CD4+, CD8+ or γδ T cells correlated with protection (Kagina et al., 2010). 
However, this was in peripheral blood rather than a disease site (Kagina et al., 2010). Without 
the knowledge of what guarantees a protective response the rational design and assessment of 
putative vaccines is hindered.  
 
Secondly, unlike other infectious diseases, the immune response to Mtb is not sterilizing. Indeed 
re-infection of mice with Mtb following clearance through drug treatment induces an earlier 
control of bacterial growth and reduced bacterial load but not sterilising immunity (Jung et al., 
2005). This phenomenon is also seen in humans where individuals successfully treated for Mtb 
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infection remain susceptible to reinfection (Verver et al., 2005). In addition, latently infected 
individuals, assumed to display an adequate immune response to prevent disease, can reactivate 
and develop disease. The change in the immune response that facilitates this reactivation in 
immunocompetent individuals is not understood. Such observations suggest that the boosting 
the natural immune response is insufficient to provide protective immunity and suggest 
targeting of other aspects on immunity, not naturally induced to Mtb infection, should be 
considered. 
 
Furthermore, use of appropriate animals models and Mtb strains in pre-clinical trials to assess 
vaccine efficacy is important (McShane and Williams, 2014). As discussed earlier there are 
several animal models of Mtb infection, some bearing more resemblance to human disease than 
others (Flynn, 2006). The responses to a vaccine and the efficacy of the vaccine will differ 
between these models and most likely will differ to humans (McShane and Williams, 2014). 
Therefore it is difficult to use preclinical models to assess vaccine efficacy. Further work is 
required to evaluate the capacity of various animal models to predict efficacy of vaccine 
candidates in humans (McShane and Williams, 2014). Methods that assess the restriction of 
mycobacterial growth in humans following vaccination may also aid the assessment of vaccine 
efficacy. For example, a BCG challenge model has been developed where patients are given an 
intradermal challenge with BCG following vaccination, and the restriction of BCG bacterial 
growth is assessed (Minassian et al., 2012). Alternatively the restriction of mycobacterial 
growth by whole blood or PBMCs in vitro following vaccination could be used assess vaccine 
efficacy (Fletcher et al., 2013). 
 
Finally, most vaccines currently in pre-clinical trials have been evaluated for their ability to 
protect against lab-adapted strains of Mtb such as H37Rv (McShane and Williams, 2014). 
However, such strains may not reflect the virulence of the clinical isolates infecting humans, 
against which these vaccines will have to protect. The importance of testing the ability of a 
vaccine to protect against clinical isolates is underlined by the observation that the protection 
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afforded by BCG in terms of control of bacterial load is more transient when mice are 
challenged with the hyper-virulent HN878 compared to the lab-adapted strain H37Rv (Grode et 
al., 2005; Ordway et al., 2011).  
 
1.6.1 BCG vaccination 
BCG is a live vaccine originally derived from serial passage of Mycobacterium bovis, a 
mycobacterial strain that causes bovine tuberculosis and can infrequently cause disease in 
humans (Pitt et al., 2012a). This serial passage resulted in loss of the virulence associated RD1 
locus (Mahairas et al., 1996). The RD1 locus encodes proteins important for virulence of 
mycobacteria and also for T cell responses including early secretory antigenic 6 kDa (ESAT-6) 
and culture filtrate protein 10 (CFP-10) (Andersen and Kaufmann, 2014).  
 
Despite BCG being a widely administered vaccine, there is considerable variation in reports of 
the efficacy it provides in protecting against adult pulmonary tuberculosis, with estimates 
ranging between 0-80% (Fine, 1995). Highest rates of efficacy are reported at higher latitudes 
for example in North America or Europe and low to no efficacy is reported in the tropics (Fine, 
1995; Rowland and McShane, 2011). Several reasons for the variation in the efficacy of BCG 
vaccination have been proposed. Firstly, exposure to environmental mycobacteria, which is 
higher in areas where efficacy is lowest, is suggested to mask any additional benefit of BCG 
vaccination or to inhibit the induction of a protective response by BCG vaccination (Brandt et 
al., 2002; Fine, 1995; Rowland and McShane, 2011). Another proposed reason for the variation 
in efficacy is due to differences in the immune responses induced by different BCG strains 
leading to different levels of protection (Rowland and McShane, 2011). There are 4 main BCG 
strains used for vaccination: Pasteur 1173 P2 strain, Danish SSI 1331 strains, Glaxo 1077 strain 
and Japanese Tokyo 172 strain (Rowland and McShane, 2011). It has been shown that the 
induction of an immune response differs between BCG strains and this is suggested to impact 
vaccine efficacy (Ritz et al., 2012; Ritz et al., 2008). 
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Although BCG is suboptimal for protection against an adult pulmonary disease, BCG does 
prove a much better vaccine in protecting infants from disseminated forms of tuberculosis such 
as TB meningitis (Trunz et al., 2006). However, there are limitations in the safety of BCG. 
Immunodeficiency is a contraindication for BCG vaccination in infants. For example BCG 
vaccination of infants with HIV, can lead to a disease caused by BCG itself termed BCG-osis 
(Hesseling et al., 2006).  
 
1.6.2 Prophylactic Vaccines in clinical trials 
As a result of the limitations of the BCG vaccine there are several new pre-exposure, 
prophylactic vaccine candidates in clinical trials, which are summarised in Figure 1.6. These 
vaccine candidates aim to improve immunity to Mtb and prevent TB disease. Other post-
exposure vaccines are also being developed that either aim to prevent reactivation from latent 
TB to active TB or act as therapeutic vaccines to aid chemotherapy of active TB patients 
(Andersen and Kaufmann, 2014).  
 
Broadly two different strategies to improve prophylactic vaccination have been taken. Firstly, to 
boost pre-existing BCG immunity using vectors expressing Mtb antigens or protein antigens 
delivered in adjuvant. Secondly, to replace BCG vaccination with recombinant BCG strains or 
genetically modified Mtb strains.  
 
1.6.2.1 Viral vectors 
Viral vectors employ replication deficient viruses to deliver Mtb antigens in order to boost an 
immune response. Candidates in clinical trials include MVA85A, AERAS 402, 
Ad35/MVA85A, and Ad5 Ag85A and have employed either adenoviruses or a modified 
vaccinia virus as a delivery vector (Figure 1.6).  
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MVA85A is a modified vaccinia virus Ankara, expressing antigen 85A (Ag85A) given as a 
boost to pre-existing BCG immunity. MVA85A was the first vaccine candidate to enter phase 
IIb clinical trials. Disappointingly it failed to show efficacy in prevent TB disease over BCG 
alone in both infants in South Africa and HIV+ adults in South Africa and Senegal (Ndiaye et 
al., 2015; Tameris et al., 2013). This lack of efficacy occurred despite evidence that MVA85A 
can induce long term, multifunctional T cell responses (Tameris et al., 2014). However, 
variation in the response to MVA85A vaccination has been described, with low responses 
correlating with increased Treg frequency following vaccination (Matsumiya et al., 2013) and 
increased basal levels of Indoleamine 2,3-dioxygenase activity (which suppresses T cell 
function) prior to vaccination (Tanner et al., 2014). This variation in response to MVA85A 
could have contributed to the observed lack of efficacy (Matsumiya et al., 2013; Tameris et al., 
2013). 
 
Aeras 402 and Ad5 Ag85A both employ replication deficient adenovirus as their delivery 
systems. Aeras 402 employs Ad35 as its delivery system for the following antigens: Ag85A, 
Ag85B and TB10.4 (Andersen and Kaufmann, 2014). It has been seen to induce a 
polyfunctional immune response in both adults and infants and has entered phase IIa trials (Abel 
et al., 2010; Kagina et al., 2014). In addition, Aeras 402 has entered clinical trials in 
combination with MVA85A (Andersen and Kaufmann, 2014).  
 
Ad5 Ag85A utilises adenovirus 5 to deliver antigen 85A in order to boost pre-existing BCG 
immunity (Andersen and Kaufmann, 2014). Concern surrounding the use of adenovirus 5 exists 
due to the high prevalence of neutralising antibodies to this adenovirus serotype in TB endemic 
areas (Andersen and Kaufmann, 2014). Despite this, Ad5 Ag85A has shown immunogenicity in 
healthy adults and the magnitude of the response did not correlate with the level of neutralising 
antibodies in the serum (Smaill et al., 2013). However, failure of the STEP trial, where 
vaccination with recombinant adenovirus 5 expressing HIV antigens increased HIV infection, 
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questions the use of adenoviruses as TB vaccine candidates given the endemics for Mtb and 
HIV largely overlap (Andersen and Kaufmann, 2014; Hanke, 2008). 
 
1.6.2.2 Proteins in adjuvant as TB vaccines 
Protein Mtb antigens delivered in adjuvant are also designed to boost pre-existing BCG 
immunity. Most of the vaccines in clinical trials combine multiple fused antigens. Candidates in 
clinical trials include H1, H4, H56, M72 and ID93 (Andersen and Kaufmann, 2014).  
 
H1 consists of a fusion of Ag85B and ESAT-6 given in adjuvant IC31, which is an agonist for 
TLR9. This vaccine induces a robust Th1 response and is currently in phase IIa trials (Andersen 
and Kaufmann, 2014). H1 has also been tested in the context of the adjuvant CAF01, which is a 
liposome base adjuvant. This formulation has completed phase I clinical trials (Andersen and 
Kaufmann, 2014). H4 is similar to H1 but contains Ag85B fused with TB10.4 given in IC31 
and has also completed phase I trials (Andersen and Kaufmann, 2014). 
 
 H56 is based on the H1 backbone, but includes the antigen Rv2660c (Aagaard et al., 2011). 
This antigen is induced under nutrient stress conditions and is termed a “late stage” antigen, as 
opposed to Ag85B and ESAT-6, which are acute antigens (Aagaard et al., 2011). Inclusion of a 
late stage antigen is suggested to enhance the immune response throughout infection. As well as 
serving as a prophylactic vaccine, inclusion of the late stage antigen in H56 is designed to 
prevent reactivation (Andersen and Kaufmann, 2014). Indeed in the NHP model, vaccination 
with BCG and H56, prevented reactivation of disease following αTNF treatment (Lin et al., 
2012). A phase I trial of H56 has recently been completed, demonstrating that it is safe and 
immunogenic in healthy adults with or without Mtb infection (Luabeya et al., 2015). 
 
M72 is a fusion of Rv1196 and Rv0125 given in the adjuvant AS01, which comprises 
monophosphryl lipid A (MPL) and QS21 in liposomes. This vaccine is currently undergoing 
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phase IIb clinical trials, having successfully shown safety and immunogenicity in Mtb infected 
and uninfected adults (Day et al., 2013) and infants in South Africa (Idoko et al., 2014).  
 
ID93 is the latest protein in adjuvant vaccine to be developed. It consists of the antigens 
Rv2608, Rv3619, Rv3620 and Rv1831 given in GLA-SE, an adjuvant composed of a synthetic 
MPL in a lipid stable emulsion (Bertholet et al., 2010). ID93 vaccination was able to protect 
mice against challenge with the lab strain of Mtb H37Rv and also a multi-drug resistant strain 
(TN5904) (Bertholet et al., 2010). Furthermore ID93 boost of BCG vaccination in a guinea pig 
model increased survival upon Mtb challenge (Bertholet et al., 2010). This vaccine is now 
undergoing phase I clinical trials (Andersen and Kaufmann, 2014). 
 
1.6.2.3 Live vaccines to replace BCG 
Currently two live candidates are in clinical development. These are VPM1002 and MTBVAC. 
VPM1002 is a recombinant BCG strain expressing listeriolysin from Listeria monocytogenes, 
which is a pore forming enzyme. This allows egress of Mtb antigens into the cytosol and 
increases cross presentation and apoptosis of macrophages, increasing the immunogenicity of 
BCG (Grode et al., 2005). Listeriolysin functions at an acidic pH, and to allow optimal function, 
Urease C has also been deleted in the VPM1002 vaccine to facilitate optimal acidification of the 
phagosome (Grode et al., 2005). This vaccine has successfully completed phase I trials, 
displaying safety in adults in Germany and South Africa, and is currently undergoing phase IIa 
trials in infants in South Africa (Kaufmann et al., 2014).  
 
MTBVAC is a genetically modified Mtb strain with deletion of PhoP and Fad26, which has 
progressed to phase I clinical trials. PhoP is a key transcription factor for Mtb virulence and 
Fad26 is required for synthesis of complex lipids also vital for virulence (Arbues et al., 2013).  
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1.6.2.4 Mucosal delivery of vaccine candidates 
As Mtb mainly infects via the aerosol route, it is argued that vaccination via this route may be 
superior, inducing local responses at the site of infection (Belyakov and Ahlers, 2009; Manjaly 
Thomas and McShane, 2015). Indeed, in mice, intranasal administration of BCG vaccination led 
to increased protection against Mtb challenge compared to subcutaneous BCG vaccination 
(Chen et al., 2004; Goonetilleke et al., 2003). In guinea pigs, aerosol vaccination with a spray 
dried BCG vaccine led to lower bacterial loads in the lung upon Mtb challenge, in a dose 
dependent manner compared to subcutaneous BCG vaccination (Garcia-Contreras et al., 2008). 
Furthermore boosting BCG vaccination using an adenovirus expressing Ag85A (Ad5 Ag85A) 
was only effective in controlling lung bacterial loads upon Mtb challenge, if the vaccine was 
administered intranasally (Forbes et al., 2008). Intranasal boosting with Ad5 Ag85A induced 
higher levels of multifunctional CD4+ and CD8+ T cells in the lung following vaccination, 
which were suggested to correlate with protection (Forbes et al., 2008). In addition, in a mouse 
model intranasal MVA85A as a boost to intranasal BCG vaccination led to lower bacterial loads 
upon Mtb challenge compared to intranasal BCG alone (Goonetilleke et al., 2003). In UK 
adults, aerosol administration of MVA85A led to greater induction of T cell responses in the 
BAL compared to parental administration of MVA85A (Satti et al., 2014), suggesting this could 
be a beneficial way to improve efficacy. However, a recent study in the NHP model, showed 
that although aerosolised Aeras-402, alone or following BCG vaccination, induced T cell 
responses in BAL, this did not lead to protection upon Mtb challenge (Darrah et al., 2014). 
Although this lack of protection was suggested to be due to the high bacterial load in challenge 
(Darrah et al., 2014), this could indicate that even aerosol administration of boosting vaccines 
will not be sufficient to increase the efficacy of BCG alone. 
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1.6.3 IL-23 and IL-17 as protective factors in Mtb vaccination. 
Although the role of IL-17 during primary infection is unclear, in the context of vaccination, IL-
17 is thought to be required for optimal vaccine responses. IL-17 is suggested to be required for 
recruitment of IFNγ producing CD4+ T cells upon Mtb challenge (Khader et al., 2007). IL-17 
neutralisation during Mtb challenge, following vaccination with a peptide epitope in adjuvant, 
led to decreased production of the chemokines CXCL9, 10 and 11 and lower recruitment of 
IFN-γ producing cells to the lung (although the effect of IL-17 neutralisation upon control of 
bacterial load was not assessed) (Khader et al., 2007). In a mucosal vaccination regime IL-17 
has also been shown to induce CXCL13 important for localising T cells mediating vaccine 
induced protection (Gopal et al., 2013). Adoptive transfer of Th17 cells into naïve hosts can also 
mediate protection. Indeed, in the absence of IL-12p40, BCG vaccinated mice induced robust 
Th17 responses and transfer of these Th17 cells into a Rag deficient host provided some 
protection against Mtb challenge (Wozniak et al., 2006; Wozniak et al., 2010). Furthermore, 
transfer of ESAT-6 specific, in vitro differentiated, Th17 cells into mice prior to Mtb challenge 
led to better control of Mtb bacterial load in an IL-23 dependent manner (Monin et al., 2015). 
IL-23 is also suggested to contribute to vaccine-mediated immunity. IL-23 dependent IL-17 is 
suggested to be required for induction of a protective Th1 response to Mtb challenge, following 
BCG vaccination (Gopal et al., 2012). Furthermore, co-immunization of mice deficient in IL-
12p40 (unable to produce IL-12 or IL-23) with a plasmid containing Ag85B and IL-23 led to 
induction of an antigen specific IFNγ response (although not an IL-17 response), which 
provided partial protection against Mtb challenge (Wozniak et al., 2006). However IL-17 and 
IL-23 have been reported to mediate immune pathology in Mtb infected mice subsequently 
vaccinated repeatedly with BCG, so attempts to boost IL-17 production may require caution 
(Cruz et al., 2010).  
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1.6.4 IL-10 and its role in vaccination 
IL-10 can suppress the immune response to a vaccine and therefore use of IL-10 or IL-10R 
blockade could enhance vaccination response and efficacy (reviewed in O'Garra et al., 2008). 
IL-10R blockade during vaccination with a viral vector expressing leishmanial proteins 
increased the Th1 response and protection against Leishmania infection (Darrah et al., 2010). 
Furthermore, therapeutic vaccination in LCMV infection was only effective at increasing the 
anti-viral immune response and clearing persistent infection in the context of IL-10R blockade 
(Brooks et al., 2008). In the context of mycobacterial infection, IL-10 neutralisation during 
vaccination with CFP increases protection against M. avium infection (Silva et al., 2001). 
During BCG vaccination IL-10 is suggested to suppress induction of an optimal Th1 response 
(Gopal et al., 2012). In addition, BCG vaccination of Il10 deficient mice increased their 
protection upon Mtb challenge at an early time point (Gopal et al., 2012). This increased 
protective effect of BCG vaccination in Il10 deficient mice was also shown at later time points 
(Pitt et al., 2012b). However, Il10 deficient mice have been shown to display increased 
resistance to primary Mtb infection (Redford et al., 2010). Thus it is difficult to determine 
whether the protective affects of BCG vaccination in the Il10 deficient mouse is a result of an 
absence of IL-10 during vaccination or during Mtb infection. The role of IL-10 specifically 
during BCG vaccination was assessed using IL-10R blockade during BCG vaccination. Anti-IL-
10 Receptor (αIL-10R) monoclonal antibody (mAb) treatment, during BCG vaccination, 
lowered bacterial load following Mtb infection and enhanced the IFNγ and IL-17 responses in 
the resistant C57BL/6 and susceptible CBA/J mice (Pitt et al., 2012b).  
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1.7 Innate Lymphoid cells 
Innate lymphoid cells (ILCs) are a family of recently described cells that are lymphoid in 
morphology, lack markers of myeloid lineages but express surface markers and cytokines 
associated with differentiated T cells (reviewed in Serafini et al., 2015). However, in contrast to 
T cells, ILCs develop independently of RAG recombinase (which is required for antigen 
specific receptor rearrangement) (reviewed in Spits et al., 2013). NK cells were the first 
described but the family of ILCs has expanded considerably to include subsets of cytokine 
producing ILCs referred to as ILC1, ILC2 and ILC3 (reviewed in Spits et al., 2013). Multiple 
roles for these cells have been described in response to infection, in allergy, autoimmunity and 
inflammatory bowel disease and also in metabolic regulation, although discussion will focus on 
their role in infection (reviewed in Artis and Spits, 2015) 
 
1.7.1 Development of ILCs 
ILC development is incompletely understood, although some progress has been made in 
determining how different lineages of ILC develop. Figure 1.7 summarises a model for their 
development.  
 
ILCs develop from the common lymphoid progenitor, which also gives rise to T and B cells 
(reviewed in Diefenbach et al., 2014). It is suggested that downstream of the CLP there is a 
precursor capable of giving rise to all ILC lineages including NK cells and this precursor has 
been termed Common Innate Lymphoid Progenitor (CILP) or α Lymphoid Precursor (αLP) 
(reviewed in Artis and Spits, 2015; Diefenbach et al., 2014; Yu et al., 2014). The transcription 
factors Tox and Nfil3 are suggested to be required for this early differentiation of ILCs and NK 
cells (reviewed in Artis and Spits, 2015). Nfil3 deficient mice have deficiencies in NK cells 
(Gascoyne et al., 2009), ILC2s and ILC3s (Geiger et al., 2014; Seillet et al., 2014; Yu et al., 
2014) and ILC1s (Klose et al., 2014; Yu et al., 2014). Although Nfil3 deficient mice had a 
defect in Peyer’s Patch formation, peripheral lymph nodes were unaffected suggesting some 
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functional LTi cells were still present (Seillet et al., 2014). More recently it has been described 
that Nfil3 is upregulated in response to the common γ chain cytokine IL-7 and is required for 
subsequent Id2 expression in the Common Helper-like Innate Lymphoid Progenitor (CHILP), 
which is downstream of these early ILC precursors (Figure 1.7) (Xu et al., 2015). Nfil3 has also 
been described to directly bind to the Tox promoter and regulate its expression, thus regulating 
subsequent ILC development (Yu et al., 2014). Tox deficiency led to a defect in the 
development of all ILC subsets, including NK cells (Seehus et al., 2015). In addition Tox 
deficient mice have a complete block in lymph node organogenesis (Seehus et al., 2015). 
 
A CHILP has been described in the bone marrow which expressed high levels of the 
transcription factor Id2 as well as the IL-7 receptor and the integrin α4β7 (Klose et al., 2014). 
These cells were suggested to be downstream of the CILP (αLP) as they had a more restricted 
potential, giving rise to all defined ILC subsets with the exception of NK cells (Klose et al., 
2014). The transcription factor Id2 is required for development of NK cells and other ILC 
subsets (Cherrier et al., 2012; Moro et al., 2010; Serafini et al., 2015; Yokota et al., 1999). 
Using Id2 fate reporter mice it was shown that all ILC subsets, including conventional NK cells 
expressed Id2 (Carotta et al., 2011; Hoyler et al., 2012). However, the observation that NK cell 
precursors are Id2 negative suggests Id2 expression does not occur at the CILP (αLP) stage, but 
later in ILC development (Klose et al., 2014).  
 
GATA3 is another transcription factor that has been found to be required for development of 
ILCs. Deletion of GATA3 in the haematopoietic compartment leads to defects in the 
development of all IL-7Rα expressing ILCs, but not IL-7Rα negative NK cells (Yagi et al., 
2014). Another study supporting this showed that GATA3 deficient foetal liver precursors were 
unable to generate ILC3s in the gut (Serafini et al., 2014). Although GATA3 is required for the 
development of all ILC subsets, only ILC2s require GATA3 for their maintenance following 
development (Hoyler et al., 2012; Yagi et al., 2014).  
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Another ILC progenitor, suggested to be downstream of the CHILP, has been identified based 
on the expression of the transcription factor PLZF. Using a fate-mapping approach it was found 
that most ILC subsets were positive for PLZF fate map, suggesting a PLZF+ precursor existed 
(Constantinides et al., 2014). The PLZF+ precursor identified was able to give rise to all ILC 
subsets with the notable exception of NK cells and Lymphoid Tissue inducer (LTi) cells 
(Constantinides et al., 2014).  
 
1.7.2 Subsets and effector functions of ILCs 
ILCs have been divided into different subsets: ILC1, ILC2 and ILC3 based on their 
transcription factor requirements and the cytokines they produce, which have many similarities 
with those of Th1, Th2 and Th17 cells respectively (Figure 1.7) (reviewed in Serafini et al., 
2015; Spits et al., 2013).  
 
1.7.1.1 ILC1  
ILC1s, like Th1 cells, produce IFNγ and are dependent on the transcription factor T-bet. ILC1s 
are reported to produce cytokines in response to IL-12, IL-15 and IL-18 (reviewed in Artis and 
Spits, 2015). Although NK cells are included in the ILC1 subset, there are differences between 
NK cells and other ILC1 subsets (Robinette et al., 2015). NK cells are cytotoxic as well as 
having the capacity to produce cytokines, whereas other ILC1s are not cytotoxic (reviewed in 
Serafini et al., 2015). Furthermore, it has been suggested that ILC1 subsets can be differentiated 
based on their expression of Eomes, with cytotoxic NK cells expressing Eomes and other ILC1 
subsets being Eomes negative (Klose et al., 2014; Serafini et al., 2015).  
 
Several ILC1 subsets distinct from Eomes positive NK cells have been described. In the mouse 
an ILC1 subset has been described in the gut (Klose et al., 2014). These cells are Lin- NK1.1+ 
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NKp46+ CD127+ CD27+ and are dependent upon IL-15 and T-bet but not Eomes for 
development and/or maintenance (Klose et al., 2014). In addition, distinct IL-15 and T-bet 
dependent subset of “tissue resident” NK cells have been described in the mouse liver, which 
are T-bet positive and express TRAIL but Eomes are negative (Daussy et al., 2014; Sojka et al., 
2014). An intraepithelial ILC1 which is implicated the pathology of a mouse model of colitis 
and is enriched in patients with Crohn’s disease has been described in humans and mice (Fuchs 
et al., 2013). These cells expressed NKp44, T–bet and Eomes, and produced IFNγ in response to 
IL-12 and IL-15 and were partly IL-15R independent (Fuchs et al., 2013). An additional ILC1 
subset has been described in the human tonsil and in the inflamed gut (Bernink et al., 2013). 
These cells expressed T-bet, lacked NK cell markers including granzyme B and perforin and 
produced IFNγ in response to IL-12 (Bernink et al., 2013). ILCs with an ILC1 type phenotype 
have also been described to develop from ILC3s. These cells upregulate T-bet and downregulate 
RORγt to acquire the ability to produce IFNγ in response to IL-12 (Bernink et al., 2013; Klose 
et al., 2014; Klose et al., 2013; Vonarbourg et al., 2010). Recently this plasticity from an ILC3 
phenotype to an ILC1 phenotype has been reported to be reciprocal, with human ILC1 capable 
of differentiating towards an ILC3 phenotype in the context of IL-23, IL-1β and retinoic acid 
(Bernink et al., 2015) 
 
In the context of infection, ILC1s (that are not NK cells) are implicated in the response to the 
intracellular parasite Toxoplasma gondii and also in colitis. In response to T. gondii infection 
ILC1s in the gut have been described to produce IFNγ and TNFα, which was important for the 
outcome of infection (Klose et al., 2014). ILC1s that were derived from RORγt expressing 
ILC3s and produced IFNγ were described to contribute to resistance to infection with 
Salmonella species through mucus release but can also contribute to enterocolitis (Klose et al., 
2013). In mice, IFNγ production from a RORγt dependent ILC also contributes to intestinal 
pathology following Helicobacter hepaticus infection (Buonocore et al., 2010). Conventional 
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NK cells have a well-described role in the response to viral infections and to other intracellular 
pathogens (Bancroft, 1993; Biron et al., 1999). Their role in Mtb infection was discussed above. 
 
1.7.1.2 ILC2 
ILC2 express high levels of GATA3 and produce cytokines associated with a T helper 2 (Th2) 
response (reviewed in Spits et al., 2013). They respond to a variety of cytokines including IL-
25, IL-33, TSLP, IL-2 and IL-9 with production of IL-4, IL-5, IL-9 and IL-13 as well as other 
factors such as amphiregulin (reviewed in Spits et al., 2013). An IL-25 responsive non- T non-B 
cell capable of producing IL-5 and IL-13 cell was suggested to exist in 2001 (Fort et al., 2001). 
Subsequently such cells were shown to also respond to IL-33 and identified as natural helper 
cells (Moro et al., 2010), nuocytes (Neill et al., 2010) and innate helper 2 cells (Price et al., 
2010), now referred to as ILC2s. ILC2s have been identified in a variety of organs including fat 
associated lymphoid tissue (Moro et al., 2010), adipose tissue (Brestoff et al., 2015; Hams et al., 
2013; Molofsky et al., 2013), lungs (Chang et al., 2011; Fort et al., 2001; Monticelli et al., 
2011), mesentertic lymph nodes (Neill et al., 2010; Price et al., 2010) and intestine (Hoyler et 
al., 2012). 
 
ILC2s depend upon GATA3 for their function and maintenance in both mice and humans 
(Hoyler et al., 2012; Klein Wolterink et al., 2013; Yagi et al., 2014); (Mjosberg et al., 2012). 
ILC2s also depend on RORα for development. Deficiency in RORα leads to deficiency of 
ILC2s systemically and impaired induction of an allergic immune response and immunity to 
helminths (Halim et al., 2012; Wong et al., 2012). In addition, ILC2s depend upon the 
transcription factor TCF-1 (encoded by Tcf7). Deletion of Tcf7 leads to a defect in ILC2 
development and an impaired response to helminth infection (Mielke et al., 2013; Yang et al., 
2013). The transcription factor Gfi1 is also required in ILC2 development to suppress 
expression of ILC3 specific genes (Spooner et al., 2013), similarly to that described in Th2 cells 
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where Gfi1 suppresses non-Th2 cell lineages (Zhu et al., 2010). Recently Bcl11b was found to 
be required for ILC2 development (Walker et al., 2015a; Yu et al., 2015).  
 
ILC2s are an important source of type 2 cytokines in the immune response to helminth 
infections. In response to Nippostrongylus brasiliensis ILC2s production of IL-13 is required 
for protective immunity (Moro et al., 2010; Neill et al., 2010; Price et al., 2010). ILCs have 
been shown to interact with T cells via MHC class II and in the context of N. brasiliensis 
infection (Oliphant et al., 2014). This interaction is required for optimal Th2 responses and the 
ability of transferred ILC2s to reduce worm burden in IL-13 deficient mice (Oliphant et al., 
2014). In addition ILC2s are required to promote tissue repair to the lung stages of N. 
brasiliensis infection (Turner et al., 2013). In this context ILC2 accumulation, promotion of 
tissue repair and amphiregulin expression was dependent upon IL-9 signalling (Turner et al., 
2013). In the context of influenza infection ILC2s are described to induce airway hyper-
reactivity (Chang et al., 2011). In contrast to this detrimental role during influenza infection, 
ILC2-derived amphiregulin was required to the restoration of tissue homeostasis following 
infection (Monticelli et al., 2011).  
 
1.7.1.3 ILC3 
ILC3s have many developmental and functional similarities with Th17 cells. ILC3s express 
RORγt and respond to IL-1β, IL-23 and in some cases IL-12 and produce, IL-22, IL-17, IFNγ 
and GM-CSF (reviewed in Artis and Spits, 2015; Mortha et al., 2014; Spits et al., 2013; 
Vonarbourg et al., 2010). Several different subtypes of ILC3 have been described: CCR6+ LTi 
cells, CCR6- NKp46+ ILC3s and CCR6- NKp46- ILC3s, each having different capabilities to 
produce the cytokines described above (reviewed in Artis and Spits, 2015; Serafini et al., 2015; 
Spits et al., 2013). All ILC3 subtypes are dependent upon RORγt for development, with RORγt 
deficient mice lacking lymph nodes (Artis and Spits, 2015; Eberl et al., 2004; Satoh-Takayama 
et al., 2008). ILC3s also require Ahr for development, with Ahr deficient mice showing defects 
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in development of ILC3s, decreased IL-22 production and increased susceptibility to 
Citrobacter rodentium infection (Lee et al., 2012; Qiu et al., 2012). Transfer experiments have 
shown that NKp46+ ILC3s develop from NKp46- cells (Vonarbourg et al., 2010). Furthermore, 
this differentiation was accelerated by IL-12 (Vonarbourg et al., 2010) and required 
upregulation of T-bet (Klose et al., 2013; Rankin et al., 2013). In addition Notch signalling and 
the Notch target TCF-1, downstream of T-bet, was shown to be required for the differentiation 
of NKp46+ ILC3s (Mielke et al., 2013; Rankin et al., 2013).  
 
ILC3s are important in the immune response to bacterial and fungal infection. ILC3 derived IL-
22 is crucial for the response to both intestinal and respiratory pathogens. ILC3 derived IL-22, 
and its appropriate localisation, has been seen to be required for the innate response to C. 
rodentium infection (Qiu et al., 2012; Satoh-Takayama et al., 2014; Satoh-Takayama et al., 
2008; Sonnenberg et al., 2011). In Streptococcus pneumoniae infection ILC3 derived IL-22 is 
also important to the immune response (Van Maele et al., 2014). IL-17 production by ILC3s has 
also been shown to be protective in the innate response to Candida albicans (Gladiator et al., 
2013).  
 
ILC3s also have an important role in maintaining intestinal homeostasis. IL-22 producing ILC3s 
were seen to be required for anatomical containment of commensal bacteria (Sonnenberg et al., 
2012). Furthermore, ILC3-derived GM-CSF production in response to commensal bacteria, was 
essential to promote Tregs and for intestinal homeostasis (Mortha et al., 2014). More recently, 
ILC3s have been described to possess the capability to process and present antigen to T cells 
and this function has been shown to be required to maintain intestinal homeostasis (Hepworth et 
al., 2013). ILC3s were subsequently shown to induce death of T cells specific for commensal 
bacteria (Hepworth et al., 2015).  
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1.7.5 Innate lymphoid cells in Mtb infection? 
The response of innate lymphoid cells, other than NK cells (discussed above), to Mtb infection 
is unknown. Cytokine production by an “innate like”, Thy1.2+ CD3- CD4- CD8- γδ TCR- 
population upon Mtb challenge has been described in mice vaccinated with BCG in the context 
of IL-10R blockade but these were not characterised further (Pitt et al., 2012b). Furthermore the 
response of ILCs to primary infection is unknown. It is possible they could impact the immune 
response to Mtb at several stages. They could provide an early source of cytokine influencing 
the development of the granuloma in lung and/or they could provide some level of protection 
when T cell immunity is failing to control infection.  
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Figure 1.1 Clinical outcomes following infection with Mtb 
 
Following infection with Mtb there are several possibility clinical outcomes. An individual can 
develop a primary active disease (red), displaying symptoms including fever, night sweats and 
haemoptysis. The majority of individuals will develop latent disease, where there is evidence of 
infection through demonstration of an adaptive response but lack of clinical symptoms. This 
latent state could encompass different diverse responses from those controlling infection but 
with bacterial persistence (purple) to those who may have eradicated the bacteria (Molofsky et 
al.) or to those with subclinical disease (yellow). An individual with latent disease can progress 
to active disease in a process termed reactivation. An additional scenario is suggested to exist 
where an individual is capable of eradicating infection without initiating an adaptive response 
(green), although this is difficult to prove. Figure based on O'Garra et al., 2013.   
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Figure 1.2 The structure of the tuberculous granuloma  
 
Following aerosol inhalation of Mtb, alveolar macrophages are thought to be the first cell type 
infected. Subsequently other phagocytic cells are recruited including DCs and neutrophils, 
which may also become infected with Mtb. Mtb creates a niche within this early collection of 
cells where uncontrolled growth occurs. Following migration of DCs to the draining lymph 
node and priming of an adaptive immune response bacterial growth can be controlled. T and B 
cells form a lymphocytic cuff surrounding infected and activated macrophages. The centre of 
the granuloma contains the majority of bacteria and can become necrotic. Macrophages can 
differentiate into foamy macrophages or fuse to form giant cells. DCs and neutrophils are also 
found within the granuloma. Figure based on Ramakrishnan, 2012.  
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Figure 1.3 Factors of the immune response known to be protective from studies in 
mice.  
 
In a “resistant” mouse strain bacterial growth occurs exponentially until 3-4 weeks post 
infection where a plateau in bacterial load is observed. Mice deficient in the 55 kDa TNRα 
receptor (TNFR), IFNγ, inducible nitric oxide synthase (iNOS), αβ T cell receptor (αβTCR), 
IL-12p40 or MHC class II (MHC II) all fail to obtain this plateau and display increased bacterial 
loads past 3-4 weeks and succumb to infection earlier than wild-type mice. Mice deficient in 
MHC class I (MHC I) are able to control infection, albeit at higher bacterial loads. Modified 
from North and Jung, 2004.  
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Figure 1.4 IL-10 regulates the balance of the immune response 
 
The level of IL-10 production is important in controlling the balance of an immune response. 
Too much IL-10 leads to low production of pro-inflammatory cytokines and can contribute to 
the establishment of chronic infection. In contrast, too little IL-10 leads to excessive production 
of pro-inflammatory cytokines, including TNFα and IL-12, and results in immunopathology. A 
balance between production of pro-inflammatory cytokines and IL-10 is required to control 
infection but avoid immunopathology  
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Figure 1.5 Counter regulation of IL-1, PGE2 and type I IFN influences outcome of 
Mtb infection 
 
A balance between IL-1, PGE2 and type I IFN levels is required for containment of bacterial 
growth and avoidance of immunopathology. When high levels of type I IFN are present during 
Mtb infection this suppresses IL-1 production, at least partially via IL-10, leading to low PGE2 
levels and exacerbated bacterial growth. Figure based on Mayer-Barber et al., 2014.  
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Figure 1.6 Prophylactic vaccine candidates currently in clinical trials  
 
Novel vaccine candidates broadly fall into 3 categories: 1. Recombinant mycobacterial strains 
designed to replace BCG. 2. Viral vectors capable of expressing Mtb antigens designed to boost 
pre-existing BCG immunity. 3. Protein antigens from Mtb given in adjuvant to boost pre-
existing BCG immunity. Phase I clinical trials assess the safety of the vaccine candidate. Phase 
IIa clinical trials determine the dose and/or route of administration. Phase IIb clinical trials 
assess the immunogenicity of the vaccine and provide the first evidence vaccine efficacy. 
Finally candidate vaccines are assessed in Phase III clinical trials, which assess vaccine 
efficacy. Figure based on Andersen and Kaufmann, 2014. 
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Figure 1.7 Model of the development of innate lymphoid cells  
 
ILCs develop from the Common Lymphoid Progenitor (CLP) via the Common Innate 
Lymphoid Progenitor (CILP) also referred to as the α Lymphoid Progenitor (αLP), capable of 
giving rise to all ILC subsets including NK cells. The Common Helper-like Innate Lymphoid 
Progenitor (CHILP) is downstream of the CILP/αLP and can give rise to all non-cytotoxic 
ILCs. The expression of the transcription factor PLZF confers more restricted potential. ILCs 
are divided into ILC1, ILC2 and ILC3 subsets based on their requirements for various 
transcription factors and the cytokines they produce. A precursor with further restricted 
potential has also been described, capable of giving rise to ILC2s only (Hoyler et al., 2012). 
Figure based on Artis and Spits, 2015 and Diefenbach et al., 2014. 
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2.1 Mice 
All mice were kept under Specific Pathogen Free conditions at the Francis Crick Institute Mill 
Hill Laboratories in accordance with UK Home Office regulations and the Animals (Scientific 
Procedures) Act 1986. C57BL/6, B6.129S7-Rag1tm1MOM, B6.129S7-Rag1tm1MOM x B6;129X1-
Il15ratm1Ama, B6.129S7-Rag1tm1MOM x C57BL/6J-Il7hlb368 and B6.129-Rag2tm1Fwa x 
129Ola.BALB/c.B6 Il2rgtm1Cgn (only mice homozygous for mutated alleles were used in 
experiments) mice were bred under Specific Pathogen Free (SPF) conditions at the Francis 
Crick Institute Mill Hill Laboratories. CBA/J mice were either bred at the Francis Crick 
Institute Mill Hill Laboratories in SPF conditions or purchased from Jackson Laboratories (Bar 
Harbour, USA) as indicated. Female mice were appropriately age matched between 8 and 18 
weeks for all in vivo experiments.  
 
2.2 Growth of Bacteria  
2.2.1 Mtb 
The Mtb strain H37Rv was originally obtained from The London School of Hygiene and 
Tropical Medicine. Hyper-virulent Mtb strain HN878 was obtained from Barry Kreisworth at 
the Public Health Research Institute, Newark,USA. 
 
To grow stock batches of both strains of Mtb, they were plated on solid 7H11 (BD 
Middlebrook) supplemented with 10% albumin dextrose catalase (ADC; BD, Middlebrook) 
plates. Up to 10 colonies from these cultures were used to inoculate fast rolling (rotation at 
25rpm) 10ml cultures of 7H9 media (BD, Middlebrook) supplemented with 10% oleic albumin 
dextrose catalase (OADC; BD, Middlebrook) and 0.5% glycerol and 0.05% Tween (Sigma). 
The optical density at 600nm (OD600) was used to monitor bacterial growth. When an OD600 of 
1 was reached, 1ml was used to inoculate a 50ml slow rolling culture (rotation at 2.5 rpm) of 
fresh 7H9 media (supplemented as above). The OD600 was again monitored and at OD600 of 1 the 
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culture was split into two 50ml tubes and centrifuged at 3000rpm for 20mins. HN878 pellets 
were washed once with PBS supplemented with 0.05% Tween-80 (Sigma) then in PBS and 
centrifuged at 800rpm to remove clumps. The supernatant was the collected and made up to 
100ml in PBS and aliquots of 1ml were frozen at -80°C until use. H37Rv pellets were washed 
once with PBS supplemented with 0.05% Tween-80 (Sigma) then twice in PBS. H37Rv pellets 
were then resuspended in PBS + 10% glycerol before being centrifuged at 600rpm to remove 
clumps. The supernatant was made to 100ml in PBS + 10% glycerol and aliquots of 1ml were 
frozen at -80°C until use.  
 
To determine stock concentrations for both strains, 2-3 vials were thawed and serially diluted in 
PBS. Dilutions were plated on solid 7H11 (BD, Middlebrook) supplemented with 10% OADC 
(BD, Middlebrook) and incubated at 37°C for 2-3 weeks before colonies were counted and 
concentrations calculated. In order to ensure stocks were not contaminated, they were also 
plated on blood agar plates (10% sheep’s blood) and incubated for up to 5 days.  
 
2.2.2 BCG 
BCG strain Danish 1331 was obtained from Statens Serum Institute, Denmark. Stock batches of 
BCG were grown in 7H9 media (BD, Middlebrook) supplemented with 0.5% glycerol, 0.05% 
Tween-80 (Sigma) and 10% ADC (BD Middlebrook). 10ml fast cultures were inoculated with 
approx. 4 colonies of BCG, previously plated on solid 7H11 (BD, Middlebrook) supplemented 
with OADC (BD, Middlebrook). The OD600 was monitored and when this reached 1, 1ml was 
used to inoculate a 90ml slow rolling culture of fresh supplemented 7H9 media. The OD600 was 
again monitored. At OD600 of 1 the culture was split into two 50ml tubes and centrifuged at 
2500rpm for 25mins. Pellets were washed in PBS supplemented with 5% glycerol and 0.1% 
Tween-80 (Sigma) and spun again at 2500rpm for 25 minutes. The two pellets were then 
combined, resuspended in PBS supplemented as above and spun again. The pellet was 
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resuspended in 50-75ml PBS supplemented as above and aliquoted into 1ml aliquots. These 
were frozen at -80°C until use. 
 
As for Mtb strains, stock concentrations were determined by thawing 2-3 vials and serially 
diluting them in PBS. Dilutions were plated on solid 7H11 (BD, Middlebrook) supplemented 
with 10% OADC (BD, Middlebrook) and incubated at 37°C for 2-3 weeks before colonies were 
counted and concentrations calculated. In order to ensure stocks were not contaminated, they 
were also plated on blood agar plates (10% sheep’s blood) and incubated for up to 5 days.  
 
2.3 Reagents 
2.3.1 Monoclonal antibodies used for injections in vivo 
2.3.1.1 anti-IL-10 Receptor 
Anti-IL-10 Receptor (αIL-10R) monoclonal antibody (clone 1B1.3A, rat IgG1) and isotype 
control (clone GL113, rat IgG1) were gifts from DNAX (now Merck, USA). These were grown 
up and purified by Harlan Laboratories, USA, and contained less than 0.5 EU/mg endotoxin. 
The required concentrations were obtained through dilutions in PBS (Gibco). For in vivo 
vaccination experiments mice were injected intraperitoneally with 300µl containing 1mg of 
either αIL-10R antibody or isotype control the day prior to vaccination. Subsequently they 
received a total of 6 300µl intraperitoneal (i.p.) injections weekly containing 0.35mg αIL-10R 
antibody or isotype control.  
 
2.3.1.2 anti-GM-CSF 
anti-GM-CSF (αGM-CSF) monocloncal antibody (clone MP1-22E9) and isotype control (clone 
GL117, rat IgG2a) were gifts from DNAX (now Merck, USA). These were grown up and 
purified by Harlan Laboratories, USA and contained 0.5EU/mg endotoxin or less. The required 
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concentrations were obtained through dilutions in PBS (Gibco). For in vivo experiments mice 
were injected intraperitoneally with 300µl containing 1mg of either αGM-CSF antibody or 
isotype control the day prior to Mtb infection. Subsequently they received twice weekly i.p. 
injections of 300µl containing 0.3mg αGM-CSF antibody or isotype control for the course of 
the experiment. 
 
2.3.1.3 anti-Ly6G 
anti-Ly6G (αLy6G) monoclonal antibody (clone 1A8) was purchased from BioXCell and 
contained less than 0.76EU/mg endotoxin. Isotype (Rat IgG2a clone GL117) was a gift from 
DNAX (now Merck, USA) and was grown up and purified by Harlan Laboratories, USA and 
contained 0.5EU/mg endotoxin. Required concentrations of αLy6G or isotype control were 
acquired by dilution in PBS. For in vivo experiments mice received a total of 5 i.p. injections 
containing 0.2mg of αLy6G or isotype control on days 10, 12, 14, 16 and 18 post Mtb infection. 
 
2.3.2 Media for cell culture 
Cell were cultured in RPMI 1640 (BioWhittaker, Lonza) complemented with 5 or 10% heat-
inactivated FCS (BioWhittaker, Lonza), 0.05mM 2-ME (Sigma-Aldrich), 10mM HEPES buffer 
(BioWhittaker, Lonza), 100U/ml penicillin (BioWhittaker, Lonza), 100U/ml streptomycin 
(BioWhittaker, Lonza), 2mM L-glutamine (BioWhittaker, Lonza), 1mM sodium pyruvate 
(BioWhittaker, Lonza).  
 
2.4 BCG Vaccination 
Vaccination was carried out under Biological Safety Level-2 (BSL) or BSL-3 conditions. Mice 
received 2 intradermal (i.d.) injections of 5µl in the thigh containing approximately 5x105 CFU 
of BCG in PBS (Gibco) or PBS (Gibco) as a control.  
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2.5 Aerosol Mtb Infection 
All experiments using Mtb were carried out under BSL-3 conditions. Mice were exposed to 
approximately 5x106 Mtb CFU aerosolised using a 3-jet Collision nebulizer unit (BGI, USA) for 
a period of 30mins. This delivered approximately 100-200 CFU to the lung. Delivery of bacteria 
to the lung was determined by plating homogenised lung on 7H11 (BD Middlebrook) media 
supplemented with 10% OADC (BD Middlebrook) and BBl MIGIT PANTA antibiotic cocktail 
(BD, Middlebrook which contains the following antibiotics: Polymyxin B 6,000 units/L, 
Amphotericin B 600 g/L, Nalidixic acid 2,400g/L, Trimethroprim 600 g/L, and Azlocillin 600 
g/L, plates were produced at NIMR) on the day of infection. Visible colonies were counted 4 
weeks later and bacterial load per lung determined. 
 
In experiments that required BCG vaccination, aerosol challenge with Mtb was performed 6-9 
weeks following BCG vaccination. 
 
2.6 Harvest of Mtb infected organs for cell culture and CFU 
determination 
Lung and spleens from infected animals were aseptically dissected and placed into 5ml RPMI 
(BioWhittaker, Lonza) or 2ml of collagenase D at 1mg/ml (Roche) as indicated. Organs placed 
into collagenase D were incubated at 37°C 5% CO2 for 45 minutes. Organs were homogenised 
by passage through a 70µm filter with the piston of a 2ml syringe. 3ml RPMI (BioWhittaker, 
Lonza) were added to organs digested with collagenase.  
 
Serial dilutions were made of the cell suspensions and streaked onto 7H11 media (BD 
Middlebrook) supplemented with OADC (BD Middlebrook) and BBl MIGIT PANTA antibiotic 
cocktail (see above; plates produced at NIMR). Plates were incubated for 2-3 weeks before 
colonies were counted and bacterial load per lung calculated. 
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2.7 Restimulation of cell cultures with PPD 
For cell culture 0.83% ammonium chloride (produced at the Francis Crick Institute Mill Hill 
Laboratories) or ACK lysis buffer (Life technologies, Thermo Fischer Scientific) was used to 
lyse red cells. Numbers of live cells were determined using trypan blue exclusion. 1x106 lung 
cells and 5x106 spleen cells were cultured with 20µg/ml PPD (Statens Serum Institute, 
Denmark) and 2µg/ml anti-CD28 (αCD28, clone 37.51, Harlan Laboratories, USA) for 16 
hours at 37°C, 5% CO2. Supernatants were harvested before addition of 10µg/ml Brefeldin A 
for a further 4 hours to allow cytokine assessment by intra-cellular cytokine staining (total 
stimulation time=20hrs). 
 
2.8 Restimulation of cell cultures with PMA and Ionomycin 
For cell culture 0.83% ammonium chloride (produced at the Francis Crick Institute Mill Hill 
Laboratories) or ACK lysis buffer (Life technologies, Thermo Fischer Scientific) was used to 
lyse red cells. Numbers of live cells were determined using trypan blue exclusion. 5x105 cells 
were cultured with 50ng/ml PMA (Sigma-Aldrich) and 500ng/ml ionomycin (Calbiochem) and 
10µg/ml Brefeldin A (Sigma-Aldrich) at 37°C, 5% CO2 for 2h as indicated.  
 
2.9 Flow cytometry and intracellular staining 
Direct ex vivo cell suspensions or cells harvested following restimulation were aliquoted into 
capped polystyrene 5 ml tubes (BD Falcon) and washed with 2ml PBS (Gibco) and incubated 
with 2µg anti-FcγRI/FcγRII (24G2, National Institute for Medical Research, now Francis Crick 
Institute Mill Hill Laboratories). To identify live cells, cells were stained with a red 
LIVE/DEAD cell stain kit (Invitrogen), according to manufacturer’s instructions. Cells were 
then resuspended in 100µl of a cocktail of antibodies against extracellular markers as indicated 
and incubated for 20 minutes. For details of antigens and fluorochromes used see table 2.1. 
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Cells were then washed with 2ml PBS and, if intracellular staining was not required, 
resuspended in 250µl BD stabilising fix (BD Biosciences).  
 
Intracellular staining for transcription factors was carried out using the Foxp3 staining kit 
(eBioscience) in line with the manufacturer’s instructions. Intracellular staining for cytokines 
was carried out using Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer’s 
instructions. Following fixation and permeabilisation cells were resuspended in 100µl of a 
cocktail of antibodies against intracellular antigens for 30mins. For details of antigens and 
fluorochromes used see table 2.1. Cells were then washed and resuspended in 250µl BD 
stabilising fix (BD Biosciences). Samples were incubated overnight at 4°C before acquisition a 
nine-colour CyAN ADP analyzer (Dako, Ely, UK) using Summit software (Cytomation), under 
BSL-3 conditions. Analysis was carried out using Flow Jo version 9.4.11 (Treestar). Gates for 
CD127, CD25 and T1/ST2 were set using Fluorescence Minus One (FMO) controls. Gates for 
cytokine staining were set using isotype controls. Gates for transcription factor staining were set 
using either isotype or FMO controls. 
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Table 2.1 Antibodies used for flow cytotometry  
 
 
Antigen Fluorochrome Clone Species and Isotype Source Concentration used
B220 PerCP Cy5.5 RA3-6B2 Rat IgG2a k eBiosciences 1µg
B220 APC RA3-6B2 Rat IgG2a k eBiosciences 1µg
CD115 APC AFS98 Rat IgG2a k eBiosciences 1µg
CD11b PerCP Cy5.5 M1/70 Rat IgG2b k eBiosciences 0.5µg
CD11b PE Cy7 M1/70 Rat IgG2b k eBiosciences 1µg
CD11b APC M1/70 Rat IgG2b k eBiosciences 1µg
CD11b v500 M1/70 Rat IgG2b k BD Horizon 1µg
CD11c PE HL3 Armenian Hamster IgG1 BD Horizon 1µg
CD11c v450 HL3 Armenian Hamster IgG1 BD Horizon 1µg
CD11c PerCP Cy5.5 N418 Armenian Hamster IgG eBiosciences 1µg
CD11c APC HL3 Armenian Hamster IgG1 BD Horizon 1µg
CD127 PE A7R34 Rat IgG2a k eBiosciences 2µg
CD25 APC e780 PC61.5 Rat IgG1 l eBiosciences 2µg
CD27 PerCP Cy5.5 LG.3A10 Armenian Hamster IgG BioLegend 1µg
CD27 APC LG.7F9 Armenian Hamster IgG eBiosciences 1µg
CD3 APC 145-2C11 Armenian Hamster IgG1 eBiosciences 1µg
CD3 APC e780 17A2 Rat IgG2b eBiosciences 2ug
CD3 PerCP Cy5.5 145-2C11 Armenian Hamster IgG1 eBiosciences 1µg
CD4 e450 RM4-5 Rat IgG2a k eBiosciences 1µg
CD4 v500 RM4-5 Rat IgG2a k BD Horizon 1µg
CD49b PerCP Cy5.5 DX5 Rat IgM k eBiosciences 2µg
CD49b APC DX5 Rat IgM k eBiosciences 2µg
CD5 APC 53-7.3 Rat IgG2a k eBiosciences 0.5µg
CD5 PerCP Cy5.5 53-7.3 Rat IgG2a k eBiosciences 0.5µg
CD8 PerCP e710 53-6.7 Rat IgG2a k eBiosciences 1µg
CD8 v500 53-6.7 Rat IgG2a k BD Horizon 1µg
CD86 Brilliant Violet 421 GL-1 Rat IgG2a k BioLegend 2.5µg
F4/80 PE Cy7 BM8 Rat IgG2a k eBiosciences 1µg
F4/80 APC BM8 Rat IgG2a k eBiosciences 1µg
γδ TCR FITC eBioGL3 Armenian Hamster IgG eBiosciences 2.5µg
Ly6C PerCP Cy5.5 HK1.4 Rat IgG2c eBiosciences 0.5µg
Ly6G FITC 1A8 Rat IgG2a k BD Pharmingen 2.5µg
MHC II (I-A/I-D) APCe780 M5/114.15.2Rat IgG2b k eBiosciences 1µg
NK1.1 PE PK136 Mouse IgG2a k eBiosciences 1µg
NK1.1 PerCP Cy5.5 PK136 Mouse IgG2a k eBiosciences 1µg
NK1.1 APC PK136 Mouse IgG2a k eBiosciences 1µg
NKp46 PE 29A1.4 Rat IgG2a k eBiosciences 4µg
Sca-1 v500 D7 Rat IgG2a k BD Horizon 2µg
T1/ST2 FITC DJ8 Rat IgG1 MD Bioproducts 5µg
TCR β PerCP Cy5.5 H57-597 Armenian Hamster IgG eBiosciences 0.5µg
TCR β APC H57-597 Armenian Hamster IgG eBiosciences 0.5µg
Thy1.2 (CD90) PE Cy7 53-2.1 Rat IgG2a k eBiosciences 1µg
Rat IgG1 e450 eBRG1 n/a eBiosciences 2µg
Rat IGg2a APC eBR2a n/a eBiosciences 2µg
Rat IGg2a PE eBR2a n/a eBiosciences 2µg
Rat IGg2a FITC eBR2a n/a eBiosciences 2µg
Mouse IgG1 Pacfic Blue MOPC-21 n/a BioLegend 5µg
Rat IgG1k PerCP e710 eBRG1 n/a eBiosciences 2µg
Rat IGg2ak Brilliant Violet 421 RTK2758 n/a BioLegend 2.5µg
Rat IgG1k Brillian Violet 510 RTK2071 n/a BioLegend 5µg
GM-CSF PE MP1-22E9 Rat IGg2a eBiosciences 2µg
GM-CSF FITC MP1-22E9 Rat IGg2a eBiosciences 2µg
IFNγ e450 XMG1.2 Rat IgG1 eBiosciences 2µg
IL-17 Brilliant Violet 510 TC11-18H10.1Rat IgG1k BioLegend 4µg
IL-17 APC eBio17B7 Rat IGg2a eBiosciences 2µg
IL-22 APC IL22JOP Rat IGg2a eBiosciences 2µg
RoRγt PerCP e710 B2D Rat IgG1k eBiosciences 2µg
T-bet Pacific Blue 4B10 Mouse IgG1 BioLegend 5µg
Extracellular
Isotypes
Intracellular
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2.10 Enzyme Linked Immunosorbent Assay (ELISA) 
Cell free supernatants from restimulated cultures were assessed by ELISA for cytokines 
following sterilisation by gamma-irradiation (20kGrays, Synergy Health, UK). IL-17 and GM-
CSF levels were assessed using commercially available kits from eBiosciences. A sandwich 
ELISA was used to assess IFNγ levels (capture: R46A2 detection: AN-18). 
Table 2.2 Reagents used for ELISAs, their concentrations and sources 
 
2.11 Statistical Analysis 
Data was analysed using GraphPad Prism software. A 2–way ANOVA with Tukey’s post test 
analysis or an unpaired Student’s t-test was performed as indicated in the figure legends. 
Differences were considered significant when p<0.05. * p<0.05, ** p<0.01, *** p<0.001, **** 
p<0.0001 
 
Cytokine
Capture 
Antibody 
(concentration 
used)
Standard (top 
concentration)
Detection 
antibody 
(concentration 
used)
HRP-
strepdavidin
Developing 
substrate Source
GM-CSF Kit Recombinant GM-CSF (10ng/ml) kit kit TMB eBiosciences
IL17A Kit Recombinant IL-17A (10ng/ml) kit kit TMB eBiosciences
IFNγ R46A2 (2.72µg/ml)
HDK1 Recombinant 
IFNγ
(50ng/ml, DNAX)
AN‐18
(1 µg/ml)
1ug/ml
(Jackson 
Immunoresearch) ABTS
The Francis 
Crick 
Institute Mill 
Hill 
Laboratories
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3.1 Does αIL-10R mAb treatment during BCG vaccination impact 
early cytokine production in susceptible CBA/J mice? Aims of the 
investigation  
 
To determine how IL-10 during BCG vaccination impacts the early immune response upon Mtb 
challenge in susceptible CBA/J mice, we aimed to investigate: 
 
1) Whether BCG vaccination in the context of IL-10R blockade impacted early control of 
bacterial load  
 
2) If there was earlier recruitment of T cells to the lung upon Mtb challenge 
 
3) Whether differences in the early T cell cytokine response to Mtb challenge, which could 
contribute to increased control of infection, correlated with increased protection in mice 
vaccinated with BCG in the context of IL-10R blockade  
 
3.2 Background 
Although BCG vaccination is one of the most widely given vaccines and the only licensed 
vaccine against tuberculosis, the efficacy it provides against adult pulmonary disease is variable 
with reports ranging from 0-80% (Fine, 1995). As a result, better vaccines or vaccine regimes 
are required. Development of such vaccines is complicated by several factors including lack of 
correlates of protection, and an incomplete understanding of what constitutes a protective 
immune response to Mtb infection (Andersen and Kaufmann, 2014).  
 
Immunosuppressive mechanisms, including regulatory T cells, can negatively impact the 
immune response to vaccination and impair the level of protection they provide (Boer et al., 
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2015). The immunosuppressive cytokine IL-10 has also been shown to negatively impact the 
protective capacity of vaccines in various scenarios. Indeed, vaccination against Leishmaniasis 
using leishmanial proteins was improved by blockade of IL-10 signalling (Darrah et al., 2010). 
Furthermore, DNA vaccination during chronic LCMV infection was only effective in the 
context of IL-10R blockade (Brooks et al., 2008). With respect to mycobacterial infection, the 
protective effect of vaccination with CFP-10 against subsequent M. avium challenge was 
enhanced in the absence of IL-10 signalling (Silva et al., 2001). 
 
IL-10 is also able to suppress the immune response to BCG with IL-10 deficient mice 
displaying superior control of BCG bacterial loads (Murray and Young, 1999). IL-10 can also 
negatively impact the ability of BCG to provide protection towards subsequent Mtb challenge. 
Indeed, BCG vaccination in IL-10 deficient mice led to better control of Mtb bacterial loads 
upon challenge compared to wild type controls (Gopal et al., 2012). This higher control of 
bacterial load following BCG vaccination of IL-10 deficient mice, has also been shown at later 
time points (Pitt et al., 2012b). However, the specific role for IL-10 in vaccination rather than 
infection is difficult to delineate when using an Il10 deficient mouse. It is unclear whether 
effects in the BCG vaccinated mouse are a result of an absence of IL-10 during vaccination, or a 
result of the absence of IL-10 during Mtb infection, as IL-10 deficient mice also display lower 
bacterial loads upon primary infection (Redford et al., 2010).  
 
The suppressive role of IL-10 specifically during BCG vaccination has been addressed using 
treatment with anti-IL-10R monoclonal antibody (αIL-10R mAb) throughout vaccination in 
both resistant C57BL/6 and susceptible CBA/J mouse models (Pitt et al., 2012b). αIL-10R mAb 
treatment during BCG vaccination led to lower bacterial loads upon Mtb challenge at late time 
points (day 63 (C57BL/6 and CBA/J) and day 112 post infection (CBA/J only)) and was 
accompanied by increased and sustained IL-17 and IFNγ production in both mouse strains (Pitt 
et al., 2012b).  
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Different strains of mice display different levels of susceptibility to Mtb infection (North and 
Jung, 2004). Resistant strains include C57BL/6 and BALB/c mice, which succumb to primary 
infection approximately 300 days post infection (Medina and North, 1998). Susceptible mouse 
strains include CBA, DBA, C3H and I/St mouse strains (Eruslanov et al., 2005; Medina and 
North, 1998). These strains display higher bacterial loads than resistant mouse strains (from 
approximately 4 weeks post Mtb infection) and succumb to infection earlier at approximately 
150 days post infection (Eruslanov et al., 2005; Medina and North, 1998; Turner et al., 2001). It 
is argued that susceptible mouse strains may provide a model more representative of human 
tuberculosis disease than the more commonly used resistant strains (Apt and Kramnik, 2009), 
suggesting that they may represent a better model in which to test the efficacy of vaccine 
regimes.  
 
The susceptibility of the CBA/J strains to Mtb infection has been linked to increased levels of 
IL-10 production compared to resistant C57BL/6 mice (Beamer et al., 2008; Turner et al., 
2002), suggesting this is a good model in which to study the suppressive effects of IL-10. 
Indeed, BCG vaccination in the context of αIL-10R mAb treatment led to a greater protective 
effect in the susceptible CBA/J mouse than in the resistant C57BL/6 mouse (Pitt et al., 2012b).  
 
In the resistant C57BL/6 mouse model, IL-10R blockade during BCG vaccination led to an 
accelerated and enhanced Th1 response, with IFNγ producing T cells evident in the lung at day 
20 post infection, however this was not assessed in the susceptible CBA/J model (Pitt et al., 
2012b). Given that the immune response to Mtb is slow to develop in comparison to other 
infectious diseases (reviewed in Cooper, 2009; Robinson et al., 2015) and that the delayed onset 
of adaptive immune responses is linked to susceptibility to Mtb infection (Beamer et al., 2011; 
Chackerian et al., 2002b), this acceleration in the onset of the immune response could be an 
important mechanism by which protection in increased. The idea that acceleration in the onset 
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of an adaptive immune response can positively impact outcome of infection is supported by the 
observation that transfer of activated Mtb specific Th1 cells prior to infection is beneficial to 
control of bacterial load (Gallegos et al., 2011).  
 
IL-10R blockade during BCG vaccination had a large effect upon control of bacterial load late 
in infection in the susceptible CBA/J mouse (Pitt et al., 2012b). One way in which this 
increased protection could occur is through the acceleration of the development of the adaptive 
immune response, as discussed above. As this was not assessed, further investigation is required 
to determine whether the development of an adaptive immune response is accelerated in the 
same way as in the resistant mouse strain. Furthermore, although it is known that IFNγ and 
CD4+ T cells are crucial for the immune response to Mtb infection (Cooper, 2009; Cooper et al., 
1993; Flynn et al., 1993; Flynn et al., 1992; Mogues et al., 2001), studies in both mouse models 
and humans have demonstrated that IFNγ production by CD4+ T cells does not correlate with 
protection against Mtb (Abebe, 2012; Kagina et al., 2010; Mittrucker et al., 2007; Pitt et al., 
2012a). Therefore, investigation of other aspects of the immune response may also provide 
insight into how IL-10R blockade during BCG vaccination could increase protection upon Mtb 
challenge. 
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3.3 Assessing the impact of IL-10R blockade during BCG vaccination 
on the early events in the lung following Mtb challenge 
 
3.3.1 BCG vaccination in the context of αIL-10R mAb enhances control of Mtb bacterial 
load in chronic infection but this does not manifest early following challenge 
 
Blockade of IL-10R signalling during BCG vaccination in susceptible CBA/J mice, enhances 
control of bacterial load in chronic infection (Pitt et al., 2012b), however the impact on the early 
control of bacterial load was not assessed. In order to determine whether this increased control 
of bacterial load begins early following infection we assessed bacterial loads at day 14, day 21 
and day 28 post Mtb challenge. CBA/J mice received 1mg αIL-10R mAb or an isotype control 
antibody (clone 1B1.3A or GL113 respectively) via intraperitoneal (i.p.) injection one day prior 
to receiving intradermal BCG or PBS (PBS vaccinated mice are described as “unvaccinated”). 
Mice then received weekly i.p. injections containing 0.35mg αIL-10R mAb or the isotype 
control antibody for 6 weeks. Three weeks after the final i.p. injection, mice were challenged 
with aerosol Mtb infection and tissues harvested at 14, 21, 28 or 112 days following Mtb 
challenge, as shown in Figure 3.1. 
 
Bacterial loads were determined in the lung and spleens as described in Materials and Methods 
and are shown in Figure 3.2. As expected we found that BCG vaccination alone led to lower 
bacterial loads in the lung compared to unvaccinated controls from day 14 post Mtb challenge 
and this was also evident at day 21 and day 28 (Figure 3.2A) (day 14 p<0.001, day 21 
p<0.0001, day 28 p<0.001 BCG vaccination compared to unvaccinated controls). However we 
found that blockade of IL-10R through mAb treatment during vaccination did not increase this 
control of Mtb bacterial load any further than BCG vaccination alone at day 14, 21 or 28 post 
infection (Figure 3.2A). We did however find, as described by Pitt et al 2012, that BCG 
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vaccination in the context of αIL-10R mAb treatment led to better control of bacterial load at 
day 112 post Mtb challenge (Figure 3.2A) (p<0.01 BCG vaccination alone compared to BCG 
vaccination in the context of IL-10R mAb). 
 
In the spleen we did not detect bacteria at day 14 or day 21 post Mtb challenge in vaccinated or 
unvaccinated mice (Figure 3.2B). At day 28 post Mtb challenge BCG vaccination alone led to 
lower Mtb bacterial loads in the spleen compared to unvaccinated mice. We did not find any 
additional benefit of αIL-10R mAb treatment during BCG vaccination upon the bacterial load 
in the spleen following Mtb challenge (Figure 3.2B). At day 112 post infection, BCG 
vaccination alone led to a strong trend towards lower bacterial loads in the spleen compared to 
no vaccination (p=0.07 BCG vaccination compared to no vaccination) but there was no 
additional control in mice vaccinated with BCG in the context of αIL-10R mAb (Figure 3.2B).  
 
3.3.2 Early and enhanced production of IL-17 and GM-CSF upon Mtb challenge in mice 
vaccinated with BCG in the context of αIL-10R mAb 
 
Although BCG vaccination in the context of αIL-10R blockade did not impact early control of 
Mtb bacterial load, it did impact control of Mtb bacterial load in chronic infection. We 
hypothesised that differences in the early immune response in the lung, as a result of IL-10R 
blockade during vaccination, could impact the control of Mtb bacterial load in chronic infection 
following challenge. We therefore assessed how IL-10R blockade during vaccination impacts 
the cytokine response in the lung at early time points following Mtb challenge. 
 
Mice were vaccinated as shown in Figure 3.1. At days 14, 21 and 28 post infection lungs were 
harvested, homogenised and cultured for 16 hours with Purified Protein Derivative (PPD), 
which is an assortment of Mtb antigens, as described in the Materials and Methods. 
Supernatants from these cultures were harvested and levels of IFNγ, IL-17A and GM-CSF were 
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assessed by ELISA. We chose to assess levels of IFNγ, because it is well established that this 
cytokine is crucial for control of Mtb infection (Cooper et al., 1993; Flynn et al., 1993). 
Although the role of IL-17 in primary Mtb infection is unclear, IL-17 is suggested to be 
important in Mtb vaccination so levels of IL-17 were assessed (Gopal et al., 2012; Khader et al., 
2007). We additionally chose to assess levels of GM-CSF, as this cytokine is also important for 
control of Mtb infection (Gonzalez-Juarrero et al., 2005; Szeliga et al., 2008) and is elevated 
throughout infection in IL-10 deficient mice, suggesting its expression is regulated by IL-10 
(Redford et al., 2010).  
 
At day 14 post Mtb challenge IFNγ, IL-17 and GM-CSF were undetectable following 
restimulation (Figure 3.3A). At day 21 post Mtb challenge IFNγ, IL-17 and GM-CSF were also 
undetectable in unvaccinated mice. Low, but elevated levels of IFNγ, IL-17 and GM-CSF were 
detected at day 21 post Mtb challenge in mice vaccinated with BCG in the context of IL-10R 
mAb, compared to those vaccinated with BCG alone (Figure 3.3B). By day 28 post infection 
IFNγ, IL-17A and GM-CSF protein was produced by all groups (Figure 3.3C). Levels of IFNγ, 
IL-17A and GM-CSF were higher in vaccinated groups compared to unvaccinated groups. In 
mice vaccinated with BCG in the context of αIL-10R mAb, levels of IL-17A and GM-CSF 
were higher in the lung at d28 post infection than in mice vaccinated with BCG alone (GM-CSF 
p<0.05, IL-17A p<0.001 BCG vaccination with αIL-10R mAb compared to BCG vaccination 
alone). αIL-10R mAb treatment during vaccination did not significantly impact IFNγ 
production at day 28 post infection (Figure 3.3C).  
 
3.3.3 BCG vaccination in the context of αIL-10R mAb does not impact early recruitment of 
CD4+ and CD8+ T cells to the lung 
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We next investigated whether BCG vaccination in the context of αIL-10R mAb influenced the 
recruitment of total T cell populations to lung, as this could indicate an acceleration in the 
kinetics of the immune response. In order to assess T cell recruitment to the lung, mice were 
vaccinated as described in Figure 3.1. At days 14, 21 and 28 post Mtb challenge lungs were 
harvested and processed to achieve single cell suspensions. These were stained to identify 
CD4+, CD8+ and γδ T cells by flow cytometry and a gating strategy for their identification is 
shown in Appendix 1. 
 
At every time point assessed there was no significant difference in recruitment of total CD4+ or 
CD8+ T cell populations between mice vaccinated with BCG or with BCG in the context of 
αIL-10R mAb, either in their percentage or number (Figure 3.4A and 3.4B). There was a small 
but consistent increase in the percentage of γδ T cells present in the lung at day 21 post Mtb 
challenge in mice vaccinated with BCG in the context of IL-10R mAb compared to BCG 
vaccination alone (Figure 3.4C) (p<0.05 BCG vaccination with αIL-10R mAb compared to 
BCG vaccination alone). However, there was not a significant increase in the number of γδ T 
cells present in the lung in mice vaccinated with BCG in the context of IL-10R blockade 
compared to BCG vaccination alone. This increase in the percentage of γδ T cells present 
appeared to be transient as no significant differences were observed at day 14 or 28 post 
infection.  
 
3.3.4 BCG vaccination in the context of αIL-10R mAb does not significantly impact early IL-
17 or IFNγ  production by CD4+ T cells in the lung but accelerates and enhances their 
production of GM-CSF  
 
Although no large differences in the early recruitment of T cells to the lung following 
vaccination with BCG in the context of αIL-10R mAb were found, there were differences in the 
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levels of cytokine production early after Mtb challenge. We therefore aimed to assess T cell 
function by assessing cytokine production to determine whether vaccination in the context of 
αIL-10R mAb impacted this, in an attempt to explain the differences in total cytokine levels. 
Mice were vaccinated as described in Figure 3.1. Single cell suspensions were generated from 
the lungs at days 14, 21 and 28 post Mtb challenge and were restimulated with PPD and anti-
CD28 (αCD28) for 16 hours before the addition of Brefeldin A for a further 4 hours. Cells were 
then harvested and intra-cellular cytokine staining was performed in order to identify IFNγ, IL-
17A and GM-CSF production by T cells. The gating strategy to identify cytokine-producing 
populations is shown in Appendix 2. 
 
We first assessed IFNγ and IL-17A production by CD4+ T cells. In keeping with the total 
cytokine levels in the culture supernatant, we could not detect cytokine production by CD4+ T 
cells at day 14 post Mtb challenge in any group (Figure 3.5A (flow cytometry plots) Figure 
3.6A (percentage and number graphs)). At day 21 post Mtb challenge there was no difference in 
the proportion of IL-17A producing CD4+ T cells between mice vaccinated with BCG in the 
context of αIL-10R mAb compared to BCG vaccination alone. IFNγ producing CD4+ T cells 
were detected in both BCG vaccinated groups and, although there was a strong trend towards an 
increase in IFNγ producing CD4+ T cells in mice vaccinated with BCG in the context of αIL-
10R mAb compared to BCG vaccination alone, this did not reach significance (Figure 3.5B 
(flow cytometry plots) Figure 3.6B (percentage and number graphs)). By day 28 post Mtb 
challenge, IFNγ producing CD4+ T cells were detected in all groups, but the proportion and 
number were higher in both BCG vaccinated groups compared to unvaccinated groups (Figure 
3.5C (flow cytometry plots) Figure 3.6C (percentage and number graphs)). Compared to BCG 
vaccination alone, αIL-10R mAb treatment during vaccination did not significantly enhance 
IFNγ production by CD4+ T cells at this time point (Figure 3.5C (flow cytometry plots) Figure 
3.6C (percentage and number graphs)). IL-17A production by CD4+ T cells was only detected 
in BCG vaccinated mice and, similarly to IFNγ production, αIL-10R mAb treatment did not 
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impact this (Figure 3.5C (flow cytometry plots) Figure 3.6C (percentage and number graphs)). 
At all time points assessed we found that CD4+ T cells largely produced either IFNγ or IL-17A 
and comparatively few were producing both IFNγ and IL-17A.  
 
No significant differences in the proportions, numbers or timing of IFNγ or IL-17A producing 
CD4+ T cells were found in mice vaccinated with BCG in the context of αIL-10R mAb 
compared to mice vaccinated with BCG alone. Having found that total GM-CSF levels are 
elevated in the lung when mice are vaccinated with BCG in the context of IL-10R blockade, we 
assessed production of GM-CSF by CD4+ T cells. Similarly to IFNγ and IL-17A, we did not 
detect GM-CSF producing CD4+ T cells at day 14 post Mtb challenge in any group (Figure 
3.7A (flow cytometry plots) Figure 3.8A (percentage and number graphs)). In keeping with the 
total protein levels of GM-CSF, at day 21 post Mtb challenge, GM-CSF producing by CD4+ T 
cells were detected only in mice vaccinated with BCG in the context of αIL-10R mAb (Figure 
3.7B (flow cytometry plots) Figure 3.8B (percentage and number graphs)). Furthermore, some 
of these cells co-produced IFNγ (Figure 3.7B (flow cytometry plots) Figure 3.8B (percentage 
and number graphs)). GM-CSF production by CD4+ T cells was also increased at day 28 post 
Mtb challenge when vaccination occurred in the context of IL-10R blockade compared to BCG 
vaccination alone. Similarly to day 21 post infection, we identified CD4+ T cells co-producing 
IFNγ and GM-CSF (Figure 3.7C (flow cytometry plots) Figure 3.8C (percentage and number 
graphs)). GM-CSF producing CD4 T cells were only detected in mice that had been BCG 
vaccinated (Figure 3.7C (flow cytometry plots) Figure 3.8C (percentage and number graphs)), 
although as discussed above were increased in mice vaccinated with BCG in the context of αIL-
10R mAb.  
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3.3.5 BCG vaccination in the context of αIL-10R mAb enhances IL-17 production by γδ  T 
cells at day 21 and by CD8+ T cells at day 28 post infection in the lung 
 
In addition to cytokine production by CD4+ T cells, CD8+ T cells and γδ T cells can be sources 
of cytokines during Mtb infection (Behar, 2013; Bold and Ernst, 2012; Lockhart et al., 2006; 
Okamoto Yoshida et al., 2010). We therefore also assessed cytokine production by these T cell 
subsets.  
  
Similar to CD4+ T cells, we did not detect significant cytokine production by γδ T cells at day 
14 post Mtb challenge (Figure 3.9A (flow cytometry plots) Figure 3.10A (percentage and 
number graphs)). However, at day 21 post infection there was a higher proportion (p<0.001) 
and number (p<0.01) of IL-17A producing γδ T cells in mice vaccinated with BCG in the 
context of αIL-10R mAb compared to BCG vaccination alone (Figure 3.9B (flow cytometry 
plots) Figure 3.10B (percentage and number graphs)). By day 28 post Mtb challenge IL-17A 
producing γδ T cells were detected in all groups, although this was considerably higher in BCG 
vaccinated groups (Figure 3.9C (flow cytometry plots) Figure 3.10C (percentage and number 
graphs)). In contrast to day 21 post Mtb challenge, there was no difference in the proportion or 
number of γδ T cells producing IL-17A between mice vaccinated with BCG in the context of 
αIL-10R mAb and BCG vaccination alone at day 28 post Mtb challenge (Figure 3.9C (flow 
cytometry plots) Figure 3.10C (percentage and number graphs)). Low levels of IFNγ 
production by γδ T cells were detected in vaccinated mice at day 28 post Mtb challenge but 
αIL-10R mAb treatment did not significantly impact this (Figure 3.9C (flow cytometry plots) 
Figure 3.10C (percentage and number graphs)). 
 
Cytokine production by CD8+ T cells was undetectable in any unvaccinated or vaccinated group 
at day 14 post Mtb challenge (Figure 3.11A (flow cytometry plots) Figure 3.12A (percentage 
and number graphs)). At day 21 post Mtb challenge low and variable production of IFNγ 
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production was detected by CD8+ T cells in mice vaccinated with BCG in the context of αIL-
10R mAb (Figure 3.11B (flow cytometry plots) Figure 3.12B (percentage and number 
graphs)). At day 28 post Mtb challenge IFNγ production by CD8+ T cells was higher in BCG 
vaccinated groups but there was no impact of αIL-10R mAb treatment (Figure 3.11C (flow 
cytometry plots) Figure 3.12C (percentage and number graphs)). In contrast, we found a small 
but significant increase in the percentage (p<0.05) and number (p<0.01) of IL-17 producing 
CD8+ T cells at day 28 post Mtb infection in mice vaccinated with BCG in the context of αIL-
10R mAb compared to BCG vaccination alone (Figure 3.11C (flow cytometry plots) Figure 
3.12C (percentage and number graphs)). However the significance of such a small population of 
IL-17 producing CD8+ T cells is unclear.  
 - Chapter 3: Determining whether IL-10 during BCG vaccination influences the early cytokine response to Mtb challenge in susceptible mice- 
 128 
3.4 Determining how IL-10R blockade during BCG vaccination 
impacts the splenic response to Mtb challenge 
 
3.4.1 Early and increased GM-CSF and IL-17 production in the spleen following BCG 
vaccination in the context of αIL-10R mAb 
 
Having identified differences in early cytokine production in the lung upon Mtb challenge of 
mice vaccinated with BCG in the context of IL-10R blockade, we next assessed whether these 
differences in cytokine production were also evident systemically by assessing the response in 
the spleen. Mice were vaccinated as described in Figure 3.1 and single cell suspensions from 
the spleen generated at days 14, 21 and 28 post Mtb challenge. Ex vivo splenocytes were 
restimulated with PPD and αCD28 for 16 hours as described in Materials and Methods and 
levels of IFNγ, IL-17A and GM-CSF in the culture supernatants were determined.  
 
IFNγ, IL-17A and GM-CSF levels were low to undetectable in all groups at day 14 post Mtb 
challenge and no significant differences were seen in mice vaccinated with BCG in the context 
of IL-10R blockade as compared to BCG vaccination alone (Figure 3.13A). Similarly to the 
lung, increased amounts of IFNγ, IL-17A and GM-CSF were detected in mice vaccinated with 
BCG in the context of IL-10R blockade at day 21 post Mtb compared to BCG vaccination alone 
(Figure 3.13B). By day 28 post Mtb challenge IFNγ, IL-17A and GM-CSF were detectable in 
all groups but we did not observe differences in IFNγ production between any of the groups. In 
contrast levels of both GM-CSF and IL-17 were significantly elevated in mice vaccinated with 
BCG in the context of αIL-10R mAb compared to BCG vaccination alone (Figure 3.13C). 
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3.4.2 BCG vaccination in the context of αIL-10R mAb does not significantly impact early IL-
17 or IFNγ  production by CD4+ T cells in the spleen but enhances the proportion producing 
GM-CSF  
 
We next aimed to assess the T cell sources of IFNγ, IL-17A and GM-CSF in the spleen 
following Mtb challenge. Splenocyte cultures, as for lung cultures, were restimulated with PPD 
for 16 hours before the addition of brefeldin A and culture for a further 4 hours. Cells were then 
harvested and intracellular cytokine staining was performed to identify IFNγ, IL-17A and GM-
CSF producing CD4+, CD8+ and γδ T cells, with the gating strategy shown in Appendix 2.  
 
We first assessed cytokine production by CD4+ T cells. In contrast to the lung, at day 14 post 
Mtb challenge we detected IFNγ producing CD4+ T cells in BCG vaccinated mice, however, 
BCG vaccination in the context of αIL-10R did not increase this production over BCG 
vaccination alone. We could not detect IL-17A production by CD4+ T cells at this time point 
(Figure 3.14A (flow cytometry plots) Figure 3.15A (percentage and number graphs). At day 21 
post Mtb challenge we identified IFNγ producing CD4+ T cells in BCG vaccinated groups, and 
in some cases unvaccinated groups, although there was considerable variation within the groups 
(Figure 3.14B (flow cytometry plots) Figure 3.15B (percentage and number graphs). There 
was a trend towards an increased proportion of IFNγ producing CD4+ T cells in the spleens of 
those mice vaccinated with BCG in the context of αIL-10R compared to BCG vaccination alone 
but this did not reach significance. IL-17A producing CD4+ T cells were not detected in any 
group. (Figure 3.14B (flow cytometry plots) Figure 3.15B (percentage and number graphs). By 
day 28 post Mtb infection, similarly to the lung, IFNγ producing CD4+ T cells were identified in 
both vaccinated and unvaccinated groups. However, in contrast to the lung, the proportion of 
IFNγ producing CD4+ T was equivalent between vaccinated and unvaccinated groups (Figure 
3.14C (flow cytometry plots) Figure 3.15C (percentage and number graphs). We found a small 
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increase in the percentage of IL-17A producing CD4+ T cells in mice vaccinated with BCG in 
the context of IL-10R mAb compared to BCG vaccination alone, although there was no 
difference in the number of IL-17A producing CD4+ T cells (Figure 3.14C (flow cytometry 
plots) Figure 3.15C (percentage and number graphs). Like in the lung, CD4+ T cells largely 
produced either IFNγ or IL-17A and few IFNγ, IL-17A double producing T cells were detected 
at any time point (Figure 3.14 (flow cytometry plots) Figure 3.15 (percentage and number 
graphs). 
 
GM-CSF levels were elevated in the spleen at days 21 and 28 post infection (Figure 3.13B and 
3.13C). As GM-CSF producing CD4+ T cells were identified in the lung, we also assessed 
CD4+ T cell production of GM-CSF in the spleen. At day 14 post Mtb challenge variable 
proportions and numbers of GM-CSF producing CD4+ cells were detected in mice vaccinated 
with BCG in the context of αIL-10R mAb. No significant difference in the proportion or 
number of GM-CSF producing CD4+ T cells between mice vaccinated with BCG in the context 
of αIL-10R compared to BCG vaccination alone was detected at this time point (Figure 3.16A 
(flow cytometry plots) Figure 3.17A (percentage and number graphs). In contrast, at day 21 
post infection an increase in percentage and number of GM-CSF producing CD4+ T cells was 
found in mice vaccinated with BCG in the context of αIL-10R blockade, compared to BCG 
vaccination alone (Figure 3.16B (flow cytometry plots) Figure 3.17B (percentage and number 
graphs). Like in the lung, more cells co-produced both IFNγ and GM-CSF than only GM-CSF, 
although both patterns of GM-CSF expression were higher in mice vaccinated with BCG in the 
context of αIL10R compared to BCG vaccination alone (Figure 3.16B (flow cytometry plots) 
Figure 3.17B (percentage and number graphs). This pattern of GM-CSF producing CD4+ T 
cells was also largely maintained at day 28 post infection, although no significant increase in the 
number of GM-CSF single producing CD4+ T cells was found (Figure 3.16C (flow cytometry 
plots) Figure 3.17C (percentage and number graphs).  
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3.4.4 BCG vaccination in the context of αIL-10R mAb minimally impacts cytokine 
production by γδ  T cells and by CD8+ T cells in the spleen 
 
CD8+ T cells and γδ T cells were also sources of cytokines in the lung early following Mtb 
challenge and thus we also assessed their cytokine production in the spleen. At day 14 post Mtb 
challenge IFNγ and IL-17A producing γδ T cells in the spleen were not detected (Figure 3.18A 
(flow cytometry plots) Figure 3.19A (percentage and number graphs). There was a trend 
towards an increase in IFNγ producing by γδ T cells in mice vaccinated with BCG in the context 
of IL-10R blockade in the spleen at day 21 post Mtb challenge, although this did not reach 
significance. We did observe a significant increase in the number of IL-17 producing γδ T cells 
in mice vaccinated with BCG in the context of IL-10R blockade, although there was no 
significant difference in the percentage of IL-17A producing γδ T cells (Figure 3.18B (flow 
cytometry plots) Figure 3.19B (percentage and number graphs). At day 28 post infection we did 
not observe any significant differences in percentage of IFNγ or IL-17A producing γδ T cells in 
mice vaccinated with BCG alone compared to those vaccinated with BCG in the context of αIL-
10R mAb. Although there was a significant increase in the number of IL-17A producing γδ T 
cells, this varied between experiments (Figure 3.18C (flow cytometry plots) Figure 3.19C 
(percentage and number graphs).  
 
 
CD8+ T cells producing IFNγ or IL-17A were barely detectable in the spleen at day 14 post 
infection, although very low levels of IFNγ production by CD8+ T cells was evident in some 
mice vaccinated with BCG in the context of αIL-10R (Figure 3.20A (flow cytometry plots) 
Figure 3.21A (percentage and number graphs). The percentage and number of IFNγ producing 
CD8+ T cells was also low at day 21 post Mtb challenge in the spleen and no significant 
difference was found between mice vaccinated with BCG and those vaccinated with BCG in the 
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context of αIL-10R mAb. (Figure 3.20B (flow cytometry plots) Figure 3.21B (percentage and 
number graphs). At day 28 post Mtb challenge we observed IFNγ producing CD8+ T cells in 
unvaccinated and vaccinated mice and there was no significant difference between mice 
vaccinated with BCG in the context of αIL-10R and those that received BCG alone (Figure 
3.20C (flow cytometry plots) Figure 3.21C (percentage and number graphs). In the lung we 
identified a small population of CD8+ T cells producing IL-17A in mice vaccinated with BCG 
in the context of αIL-10R mAb, in the spleen however, this population was not evident (Figure 
3.20C (flow cytometry plots) Figure 3.21C (percentage and number graphs).  
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3.5 Establishing a role for GM-CSF in the immune response to Mtb 
challenge following BCG vaccination 
 
3.5.1 GM-CSF is crucial for optimal protection upon Mtb challenge following BCG 
vaccination 
 
We have observed early and enhanced production of IL-17A and GM-CSF upon Mtb challenge 
in both the lung and spleen of mice vaccinated with BCG in the context of αIL-10R compared 
to BCG vaccination alone. IL-17A is known to be important in recruiting Th1 cells following a 
vaccination regime with an ESAT-6 epitope in adjuvant (Khader et al., 2007). Furthermore, 
transfer of in vitro differentiated ESAT-6 specific Th17 cells are capable of controlling bacterial 
loads upon Mtb challenge (Monin et al., 2015).  
 
Augmentation of GM-CSF expression at the time of BCG vaccination suggests that GM-CSF is 
beneficial to the outcome of vaccination. Indeed, augmentation of GM-CSF expression at the 
time of BCG vaccination either through genetic modification of BCG strains (Nambiar et al., 
2010; Ryan et al., 2007) or administration of GM-CSF expressing viral vectors along with BCG 
vaccination (Dou et al., 2010; Wang et al., 2002) led to lower bacterial loads systemically upon 
mycobacterial challenge compared to controls. Furthermore, vaccination using a plasmid 
expressing Ag85A and GM-CSF led to increased induction of CD4+ and CD8+ T cell responses 
compared to Ag85A alone (Kamath et al., 1999; Zhang et al., 2007). However the role of GM-
CSF in the recall response to Mtb challenge following BCG vaccination in unknown. We were 
therefore interested in determining how GM-CSF expression upon Mtb challenge impacted the 
protective affect of BCG vaccination. In order to address this, susceptible CBA/J mice were 
intradermally vaccinated with BCG or PBS (PBS vaccinated mice described as unvaccinated) 
and rested for at least 6 weeks. The day prior to Mtb infection they received an i.p. injection 
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containing 1mg of αGM-CSF mAb or isotype control (clone MP1-22E9 or GL117 
respectively). After Mtb infection, mice received twice weekly i.p. injections containing 0.3 mg 
of αGM-CSF mAb or isotype before being sacrificed at day 63 post Mtb challenge. Bacterial 
loads in the lung were then determined as described in the materials and methods. 
 
Neutralisation of GM-CSF during Mtb challenge in unvaccinated mice led to a dramatic 
increased in bacterial load (Figure 3.22). As expected BCG vaccination led to lower bacterial 
loads in the lung at day 63 post Mtb challenge. In BCG vaccinated mice, GM-CSF 
neutralisation during Mtb challenge led to higher bacterial loads compared to isotype controls 
(Figure 3.22). 
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3.6 Discussion 
 
BCG vaccination is currently the only licensed vaccination against TB, and provides inadequate 
levels of protection against adult pulmonary disease (Fine, 1995). Improved vaccines or vaccine 
regimes are therefore required. IL-10 suppresses the response to BCG vaccination, with 
blockade of the IL-10R during BCG vaccination in both resistant and susceptible mouse models 
leading to lower Mtb bacterial chronic infection (Pitt et al., 2012b). As the immune response to 
Mtb is slow to develop (reviewed in Cooper, 2009), acceleration of the onset of adaptive 
immunity is one potential way in which to improve vaccination. In a resistant mouse model, 
IFNγ production by CD4+ T cells was accelerated in mice vaccinated with BCG in the context 
of αIL-10R mAb (Pitt et al., 2012b). However, acceleration of the immune response in 
susceptible mice vaccinated with BCG and αIL-10R mAb was not assessed. As susceptible 
mouse strains are proposed to better reflect human disease (Apt and Kramnik, 2009), 
determination of how IL-10R blockade during BCG vaccination impacts the early immune 
response could provide insight into improving vaccination against TB. 
 
3.6.1 Enhanced control of pulmonary Mtb bacterial load in mice vaccinated with BCG in the 
context αIL-10R mAb does not manifest at early time points 
 
The data in this thesis confirms that BCG vaccination of susceptible CBA/J mice in the context 
of αIL-10R mAb leads to lower bacterial loads in the lung compared to BCG alone at day 112 
post Mtb challenge, suggesting IL-10 suppresses BCG vaccination (Pitt et al., 2012b). A 
suppressive role for IL-10 during vaccination has also been demonstrated in other vaccine 
platforms. Protection against Leishmaniasis through vaccination with leishmanial proteins is 
enhanced in the absence of IL-10 signalling (Darrah et al., 2010). In addition, therapeutic DNA 
vaccination led to clearance of chronic LCMV infection only in the absence of IL-10 signalling 
(Brooks et al., 2008). 
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Increased control of bacterial load in the lung in mice vaccinated with BCG in the context of 
αIL-10R mAb, compared to BCG vaccination alone is not evident early following Mtb 
challenge. At these early time points following infection, BCG vaccination alone was sufficient 
to lower bacterial loads in the lung, with no additional benefit of IL-10R blockade during 
vaccination observed. In the spleen Mtb bacterial loads were not detectable until day 28 post 
infection and BCG vaccination alone decreased bacterial loads with no additional effect of αIL-
10R mAb treatment, even in chronic infection. This suggests that the beneficial effect of this 
vaccine regime is local to the lung.  
 
The reasons for the delayed increased control of pulmonary Mtb bacterial loads when mice are 
vaccinated with BCG in the context of αIL-10R mAb are unclear. A similar pattern of delayed 
control of bacterial load compared to BCG vaccination was also evident for the novel vaccine 
VPM1002, a recombinant BCG strain (Grode et al., 2005). Increased control of Mtb bacterial 
load when vaccinated with VPM1002 compared to BCG was not evident in the lung until day 
90 post infection when challenged with the lab-adapted strain H37Rv, or day 200 when 
challenged with a clinically relevant Beijing/W strain (Grode et al., 2005). Control of 
pulmonary Mtb bacterial loads following BCG vaccination has been shown to wane over the 
course of infection, which may be somewhat dependent upon the length of time between 
vaccination and challenge (Cruz et al., 2015; Kamath and Behar, 2005). A possible explanation 
for our findings is that when BCG vaccination is administered in the context of αIL-10R mAb, 
control of bacterial load is maintained through chronic infection unlike BCG vaccination alone, 
thus improving the outcome of infection. 
 
Further investigation into how BCG vaccination in the context of αIL-10R affects the immune 
response in chronic infection will further our understanding of protective vaccine strategies. 
Recently it has been demonstrated that IL-2 producing KLRG1- CD4+ T cells, that retain 
proliferative capacity, are induced following boosting of BCG immunity with H1 (fusion of 
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antigen85B and ESAT-6) with the adjuvant CAF01, or vaccination with cryptic ESAT-6 
epitopes (Lindenstrom et al., 2013; Woodworth et al., 2014). This increase in IL-2+ KLRG1- 
CD4+ T cells in mice vaccinated with BCG and H1 CAF01 correlated with maintained control 
of Mtb bacterial load upon challenge, compared to BCG vaccination alone (Lindenstrom et al., 
2013). Investigation into whether cells with this phenotype are also induced in BCG vaccination 
in the context of αIL-10R and correlate with increased protection could provide a possible 
explanation for the maintenance of the immune response and control of bacterial loads.  
 
3.6.2 IL-10R blockade during BCG vaccination impacts early cytokine responses upon Mtb 
challenge 
 
Although maintenance of the immune response is a possible explanation for the observation that 
increased control of pulmonary bacterial loads in mice vaccinated with BCG in the context of 
αIL-10R, another possibility is that early changes in the immune response influence the events 
in chronic infection. Indeed, in resistant C57BL/6 mice BCG vaccinated in the context of αIL-
10R mAb there was accelerated recruitment of IFNγ producing CD4+ T cells, but increased 
control of bacterial load was not evident until day 63 post Mtb challenge (Pitt et al., 2012b). In 
addition, early elevation of cytokine responses following Mtb challenge of mice vaccinated with 
the recombinant BCG strain VPM1002 were observed (Desel et al., 2011), but increased control 
of Mtb bacterial load was not evident until 90 days post infection (when challenged with the 
lab-adapted Mtb strain H37Rv) (Desel et al., 2011; Grode et al., 2005).  
 
3.6.2.1 Early IFNγ production upon Mtb challenge following BCG vaccination in the context of 
αIL-10R mAb 
IFNγ activates macrophages to control mycobacterial growth and is crucial for control of Mtb 
infection, so could be important for mediating enhanced control of bacterial load (Cooper et al., 
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1993; Flynn et al., 1993; North and Jung, 2004). Furthermore, IFNγ is important in regulating 
immunopathology and thus influencing the outcome of infection (Nandi and Behar, 2011). We 
found that IL-10R blockade during BCG vaccination led to accelerated production of IFNγ at 21 
days post Mtb challenge, but at day 28 post Mtb challenge IFNγ production was equivalent in 
BCG vaccinated groups. Although we saw a strong trend towards an increase in IFNγ producing 
CD4+ T cells in CBA/J mice vaccinated with BCG in the context of αIL-10R mAb at day 21 
post Mtb challenge, this did not reach significance. This contrasts to resistant C57BL/6 mice 
where there was accelerated recruitment of IFNγ producing CD4+ T cells in mice vaccinated 
with BCG in the context of αIL-10R mAb (Pitt et al., 2012b). This finding highlights the 
differences in the immune responses between susceptible and resistant mouse models of Mtb, 
and the importance of assessing the immune response in susceptible mouse strains. CBA/J mice 
have been reported to have defects in the upregulation of adhesion molecules on T cells 
compared to C57BL/6 mice (Turner et al., 2001), which is not overcome by BCG vaccination 
(Gruppo et al., 2002). An inability to upregulate adhesion molecules on T cells, even when mice 
are vaccinated with BCG in the context of αIL-10R mAb, may explain the difference in 
recruitment of IFNγ producing T cells between CBA/J and C57BL/6 mice.  
 
Given that we did not find significant differences in the presence of IFNγ producing CD4+ T 
cells at day 21 post Mtb challenge, it is possible there are other cellular sources of IFNγ 
contributing to the accelerated production of IFNγ we observed at this time point when mice 
were vaccinated with BCG in the context of αIL-10R mAb. Indeed NK cells and other ILCs can 
produce IFNγ in response to activation by myeloid or epithelial-derived cytokines (reviewed in 
Artis and Spits, 2015). An “innate-like” source of IFNγ was described in CBA/J mice 
vaccinated with BCG in the context of αIL-10R mAb at day 112 post Mtb infection (Pitt et al., 
2012b). Furthermore, IFNγ production by NK cells has been reported in the peripheral blood of 
BCG vaccinated infants, suggesting these cells could contribute to BCG induced immunity 
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(Zufferey et al., 2013). Further investigation would be required to determine whether BCG 
vaccination in the context of αIL-10R impacts the ability of NK cells or other ILCs to respond 
early upon Mtb challenge in CBA/J mice.  
 
3.6.2.2 IL-10R blockade during BCG vaccination leads to early and enhanced IL-17A 
production upon Mtb challenge  
We show that in both the lung and the spleen there is earlier IL-17A production, beginning at 
day 21 post Mtb challenge, and increased production of IL-17A at day 28 post Mtb challenge, in 
mice vaccinated with BCG in the context on αIL-10R mAb. These results correlating increased, 
early production of IL-17 with increased control of bacterial load in chronic infection are in 
keeping with a report where early, increased production of IL-17 correlated with increased 
protection later after Mtb challenge following vaccination with the recombinant BCG strain 
VPM1002 (Desel et al., 2011).  
 
We did not identify increased proportions or numbers of IL-17A producing CD4+ T cells in 
mice vaccinated with BCG in the context of αIL-10R at any time point, however we did 
identify increases in the percentage and number of other cell populations producing IL-17A. In 
the lung at day 21 post Mtb challenge there was an increase in γδ T cells producing IL-17A. The 
role of γδ T cells during primary Mtb infection is unclear, with reports of mice deficient in γδ T 
cells displaying increased susceptibility to intravenous but not aerosol Mtb infection (D'Souza et 
al., 1997; Ladel et al., 1995). γδ T cells are reported to be a major source of IL-17 following 
Mtb infection (Lockhart et al., 2006). In the context of vaccination against Mtb little is known 
about the role of γδ T cells, although it has been suggested that they could participate in a 
protective response (Andersen and Kaufmann, 2014). γδ T cells producing IL-17 have been 
identified in mice vaccinated with the recombinant BCG strain VPM1002 (Desel et al., 2011), 
although the significance of this is not known. In addition, γδ T cells have been described to 
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produce IFNγ in BCG vaccinated infants (Kagina et al., 2010; Zufferey et al., 2013), supporting 
the idea they could be involved in protection following vaccination. 
 
At day 28 post infection we found a small population of CD8+ T cells producing IL-17A in the 
lung only in mice vaccinated with BCG in the context of IL-10R blockade. IL-17 production by 
CD8+ T cells has been described in the blood of TB patients (Silva et al., 2014), although not in 
mice. Vaccination in the context of IL-10R blockade may change the quality of the CD8 T cell 
response, leading to their production of IL-17 upon Mtb challenge. 
 
Increased production of IL-17 could contribute to increased protection in mice vaccinated with 
BCG in the context of αIL-10R mAb. Although the role of IL-17 in primary infection is 
unclear, IL-17 has been described to be protective in recall responses (Freches et al., 2013; 
Gopal et al., 2014; Khader and Cooper, 2008). For example, transfer of in vitro differentiated 
ESAT-6 specific CD4+ T cells producing IL-17, into naive hosts leads to enhanced control of 
bacterial load upon Mtb challenge (Monin et al., 2015). Furthermore CD4+ T cells producing 
IL-17, primed in an IL-12p40 deficient mouse in response to BCG, are capable of mediating 
protection when transferred into Rag deficient mice in response to intravenous Mtb challenge 
(Wozniak et al., 2010).  
 
The protective consequence of increased IL-17 production following vaccination in the context 
of IL-10R blockade could be through induction of chemokines. Indeed, IL-17 was required for 
optimal expression of CXCL9, CXCL10 and CXCL11, required to recruit CXCR3 expressing T 
cells, following vaccination with ESAT-6 peptide in adjuvant (Khader et al., 2007). In a 
mucosal vaccination model, IL-17 is required for induction of CXCL13, a CXCR5 ligand, 
which is required for appropriate localisation of T cells within lymphoid structures (Gopal et al., 
2013). CXCR5 deficient mice show increased susceptibility to Mtb infection, which is 
associated with poor localisation of T cells within ectopic lymphoid structures and poor 
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macrophage activation (Slight et al., 2013). Assessment of the induction of chemokines early 
following Mtb challenge in mice vaccinated with BCG in the context of αIL-10R mAb, as well 
as the location of T cells within the lung, could provide further information as to how this 
vaccine regime increases protection against Mtb challenge. 
 
In addition to increased production of IL-17, its timing is also suggested to be important, with 
an early Th17 response proposed to be required for expression of a subsequent Th1 response 
(Khader et al., 2007). Following vaccination with an ESAT-6 epitope in adjuvant, early Th17 
responses were observed, and IL-17 was required for induction of chemokines to recruit IFNγ 
producing T cells upon Mtb challenge (although the importance of this in terms of control of 
infection was not assessed) (Khader et al., 2007). However, in contrast to this study, we 
identified IL-17 producing T cells at a later time point and this did not appear to precede IFNγ 
production by CD4+ T cells. There are several possible reasons for this. Firstly, we conducted 
this study in a susceptible mouse strain as opposed to the resistant C57BL/6. As discussed 
above, CBA/J mice have been shown to have a defect in the upregulation of adhesion molecules 
on lymphocytes which affects their recruitment to the lung (Turner et al., 2001). This could be 
an important explanation to the different kinetics of the response. Secondly, we are assessing 
the T cell response to multiple Mtb antigens, through PPD restimulation, rather than to ESAT-6 
in isolation. Finally we use a different vaccine regime. 
 
Although we have identified early increased IL-17 to correlate with subsequent control of 
infection, excessive levels of IL-17 can also have detrimental affects on the outcome of Mtb 
infection. For example, IL-17 driven neutrophilia leading to host pathology is described 
following repeated BCG vaccination of Mtb infected mice (Cruz et al., 2010). In addition, IFNγ 
has been demonstrated to control IL-17 production and subsequent neutrophil accumulation 
(Nandi and Behar, 2011). Thus a balanced immune response is required for optimal control of 
Mtb infection.  
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3.6.2.3 Early and enhanced GM-CSF production upon Mtb challenge in mice vaccinated with 
BCG in the context of αIL-10R mAb  
In addition to early production of IFNγ in the lung and early and increased production of IL-
17A in the lung and spleen, we also show early and increased production of GM-CSF in the 
lung and spleen in mice vaccinated with BCG in the context of IL-10R blockade. Thus we 
identify early and increased production of GM-CSF, as well as IL-17A, to correlate with 
increased control of bacterial load in chronic infection. Such a pattern of increased cytokine 
production was also demonstrated early in Mtb challenge in mice vaccinated with the 
recombinant BCG strain VPM1002 and correlated with increased control of bacterial loads in 
chronic infection (Desel et al., 2011). 
 
Although GM-CSF was originally described as a factor capable of directing the differentiation 
of haematopoietic cells towards macrophages and granulocytes (Burgess and Metcalf, 1980), 
and is crucial for the development of alveolar macrophages from foetal monocytes (Guilliams et 
al., 2013; Schneider et al., 2014), it also has roles in inflammation (Hamilton, 2008). Indeed in 
the context of Mtb infection, GM-CSF plays a protective role with mice deficient for this 
cytokine displaying increased susceptibility to infection with disorganised granulomas and 
reduced recruitment of IFNγ producing Th1 cells to the lung through lower levels of chemokine 
induction (Gonzalez-Juarrero et al., 2005; Szeliga et al., 2008). However, a caveat of these 
studies utilising GM-CSF deficient mice is that these mice develop lung pathology resembling 
Pulmonary Alveolar Proteinosis (PAP) (Dranoff et al., 1994; Stanley et al., 1994; Trapnell and 
Whitsett, 2002), which complicates interpretation of results (discussed in more detail in Chapter 
4). Despite this it is possible that the accelerated and enhanced GM-CSF production observed in 
mice vaccinated with BCG in the context of αIL-10R mAb could contribute to increased 
protection later following Mtb challenge through induction of chemokines with the capacity to 
recruit Th1 cells. Although we identified GM-CSF+ IFNγ+ co-producing CD4+ T cells, 
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suggesting that Th1 cells are already recruited, GM-CSF could act to promote further or 
continued recruitment of IFNγ producing T cells. 
 
GM-CSF has also been described to directly activate macrophages to restrict growth of 
mycobacteria (Denis and Ghadirian, 1990; Pasula et al., 2015; Rothchild et al., 2014). It is 
possible that increased levels of GM-CSF at early time points in mice vaccinated with BCG in 
the context of αIL-10R, following Mtb infection could influence the function of macrophages at 
leading to lower bacterial loads in chronic infection.  
 
Although GM-CSF is protective in the immune response to Mtb infection, mice overexpressing 
GM-CSF in the lung are also susceptible to Mtb infection, suggesting there is an optimal level 
of GM-CSF upon infection (Gonzalez-Juarrero et al., 2005; Szeliga et al., 2008). Despite this, 
mice vaccinated with a the recombinant BCG strain VPM 1002 were more protected against 
Mtb challenge compared to parental BCG vaccination and expressed higher levels of GM-CSF, 
along with other cytokines, including IL-17 (Desel et al., 2011). Furthermore, as mentioned 
above, IL-10 deficient mice, which are more resistant to Mtb infection, also have an increased 
level of GM-CSF in the lung through Mtb infection (Redford et al., 2010). It is possible that 
augmented GM-CSF expression in the context of increased expression of other cytokines does 
not lead to the increase in susceptibility or alternatively, the mouse overexpressing GM-CSF 
does so at higher non-physiological levels. 
 
3.6.4 GM-CSF is required for optimal BCG mediated protection upon Mtb challenge 
 
Subcutaneous or intranasal vaccination with a recombinant BCG strain engineered to express 
GM-CSF led to increased activation of APC populations in the draining lymph node and 
decreased bacterial loads in the spleen upon Mtb challenge (Nambiar et al., 2010; Ryan et al., 
2007). Furthermore boosting of BCG vaccination using a viral vector expressing GM-CSF or 
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the Mtb antigen, antigen 85A (Ag85A), and GM-CSF led to lower mycobacterial loads 
following challenge (Dou et al., 2010; Wang et al., 2002). In addition, vaccination using a 
plasmid expressing Ag85A and GM-CSF led to increased induction of CD4+ and CD8+ T cell 
responses compared to vaccination with Ag85A alone (Kamath et al., 1999; Zhang et al., 2007). 
This suggests that vaccines or vaccine regimes against Mtb where GM-CSF expression is 
increased at the time of vaccination are beneficial to the protective effect of vaccination.  
 
However, the role of GM-CSF in the recall response to Mtb infection is unknown. Having 
identified that early, increased production of GM-CSF correlated with increased protection in 
chronic infection, we investigated the impact of GM-CSF neutralisation during Mtb challenge 
upon the protection afforded by BCG vaccination in a susceptible mouse model. We show that 
GM-CSF during Mtb challenge following BCG vaccination is required for the protective effect 
of BCG in chronic infection. We also show that in primary infection neutralisation of GM-CSF 
leads to a much higher level of susceptibility to Mtb infection.  
 
Further investigation will be required to determine the function of GM-CSF in the recall 
response and how, if at all, this differs to the primary response. Studies using BCG strains that 
express GM-CSF suggest that it could function to activate APCs (Nambiar et al., 2010; Ryan et 
al., 2007) and thus loss of this function could lead to inadequate priming of a T cell response. In 
BCG vaccinated mice, such priming events have already occurred and thus the function of GM-
CSF to activate APCs may be less important. This could explain the smaller increase in 
bacterial load upon GM-CSF neutralisation in BCG vaccinated mice compared to unvaccinated 
mice. In GM-CSF deficient mice a defect in the recruitment of Th1 cells was reported 
(Gonzalez-Juarrero et al., 2005). A defect in the recruitment of Th1 cells could explain the 
increased susceptibility of mice when GM-CSF is neutralised in both vaccinated and 
unvaccinated mice, although in vaccinated mice other factors induced by BCG vaccination such 
as IL-17, could at least partially compensate for the defect in GM-CSF. Another possibility is 
that GM-CSF is required for optimal activation and function of macrophages to restrict 
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mycobacterial growth (Denis and Ghadirian, 1990; Pasula et al., 2015; Rothchild et al., 2014) as 
well as for APC function. These functions of GM-CSF are not mutually exclusive, and it is 
likely that several mechanisms contribute to the increase in susceptibility of both vaccinated and 
unvaccinated mice when GM-CSF is neutralised. 
 
3.6.3 Summary 
 
We show that IL-10R blockade during BCG vaccination leads to increased control of 
pulmonary bacterial loads at late time points following Mtb challenge, but this is not evident at 
early time points. We also show that lower pulmonary bacterial load at late time points 
following Mtb challenge correlate with early and enhanced production of IL-17 and GM-CSF 
and early production of IFNγ in susceptible CBA/J mice. We highlight the difference in the 
immune response between resistant and susceptible mouse strains as in contrast to resistant 
C57BL/6 mice (Pitt et al., 2012b) there was no significant acceleration in the recruitment of 
IFNγ producing CD4+ T cells in susceptible CBA/J mice. We suggest the mechanism for 
increased control of pulmonary bacterial loads upon Mtb challenge in CBA/J mice vaccinated 
with BCG in the context of αIL-10R could be twofold. Firstly, accelerated and increased 
production of protective cytokines limits the ability of Mtb to manipulate the lung environment, 
potentially through chemokine induction and localisation of the T cell response. Secondly, 
maintenance of the immune response, as shown by much higher IL-17A and IFNγ production 
by CD4+ at day 112 post Mtb challenge in CBA/J mice vaccinated with BCG in the context of 
αIL-10R mAb (Pitt et al., 2012b), leads to lower bacterial loads late in infection. 
 
We also show that GM-CSF is required for optimal protection following BCG vaccination. This 
finding suggests that augmentation of GM-CSF production upon Mtb challenge could be a 
beneficial strategy to improve vaccination. Further investigation is required to determine 
 - Chapter 3: Determining whether IL-10 during BCG vaccination influences the early cytokine response to Mtb challenge in susceptible mice- 
 146 
whether enhanced levels of GM-CSF, in mice vaccinated with BCG in the context of αIL-10R 
mAb, are important for mediating increased control of bacterial loads.   
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Figure 3.1 Experimental design 
 
CBA/J mice received an intraperitoneal (i.p.) injection containing 1mg isotype (ISO) or 
anti-IL-10R (αIL-10R) the day prior to intradermal vaccination with approximately 
5x105 CFU BCG or PBS. Mice then received weekly i.p. injections containing 0.35mg 
ISO or αIL-10R monoclonal antibody (mAb) for 6 weeks. Mice were then rested for 3 
weeks before aerosol challenge with approx. 100-200 CFU of the Mtb strain H37Rv. 
Mice were sacrificed at indicated time points post Mtb challenge.  
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Figure 3.2 Increased control of bacterial load upon Mtb infection in mice BCG 
vaccinated in the context of αIL-10R mAb does not manifest until chronic infection  
 
CBA/J mice were BCG vaccinated and challenged with Mtb as shown in Figure 3.1. Mice were 
sacrificed at 14, 21, 28 and 112 days post Mtb challenge and the lungs and spleens harvested. 
Bacterial loads in the lung (A) and spleen (B) were determined as described in Materials and 
Methods. Time points shown are from independent experiments and are representative of 2 (d14 
and d112) or 3 (d21 and d28) identical experiments. 4-5 mice per group. Graphs show mean ± 
SD. ns – not significant *p<0.05, **p<0.01, **p<0.001, ****p<0.0001 by unpaired students t 
test.  
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Figure 3.3 Early and enhanced IL-17 and GM-CSF production in the lung upon Mtb 
challenge following BCG vaccination in the context of αIL-10R mAb 
 
CBA/J mice were BCG vaccinated and challenged with Mtb as shown in Figure 3.1. Mice were 
sacrificed and lungs harvested at 14, 21 and 28 days post Mtb challenge. Lung cell suspensions 
were restimulated with 20µg PPD and 2µg αCD28 for 16h after which supernatants were 
harvested. Enzyme Linked Immunosorbent Assays (ELISA) were performed for IFNγ, IL-17 
and GM-CSF in supernatants from cultures at day 14 (A), day 21 (B) and day 28 (C) post 
infection. Data pooled from 2 (d14 and d28) or 3 (d21) independent experiments. 9-15 mice per 
group. Graphs show mean ± SD. ns – not significant *p<0.05, **p<0.01, ***p<0.001, by 2-way 
ANOVA with Tukey post test.  
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Figure 3.4 BCG vaccination in the context of αIL-10R mAb does not significantly 
impact the early recruitment of CD4+ or CD8+ T cells to the lung 
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CBA/J mice were BCG vaccinated and challenged with Mtb as shown in Figure 3.1. 
Mice were sacrificed and lungs harvested at 14, 21 and 28 days post Mtb challenge. 
Lungs were homogenized by passage through a 70µm filter. Samples were stained with 
the following antibodies to assess percentages and calculate numbers of lymphoid 
populations by flow cytometry: γδ TCR FITC, Thy1.2 PECy7, CD4 e450, CD8 v500 
and CD3 APC. Percentage and number of CD4+ T cells defined as CD3+ Thy1.2+ CD4+ 
at day 14, 21 and 28 post infection (A). Percentage and number of CD8+ T cells defined 
as CD3+ Thy1.2+ CD8+ at day 14, 21 and 28 post infection (B). Percentage and number 
of γδ T cells defined as CD3+ Thy1.2+ CD4- CD8- γδTCR+ at day 14, 21 and 28 post 
infection (C). Time points shown are from independent experiments and data is 
representative of 2 (d14) or 3 (d21 and d28) independent experiments. 4-5 mice per 
group. Graphs show individual mice with mean ± SD. ns – not significant *p<0.05, by 
2-way ANOVA with Tukey post test.  
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Figure 3.5 BCG vaccination in the context of αIL-10R mAb does not significantly 
accelerate recruitment of IFNγ  or IL-17 producing CD4+ T cells to the lung upon 
Mtb challenge. (Flow cytometry plots) 
 
CBA/J mice were BCG vaccinated and challenged with Mtb as shown in Figure 3.1. 
Mice were sacrificed and lungs harvested at 14, 21 and 28 days post Mtb challenge. 
Lungs were homogenized by passage through a 70µm filter. 1x106 cells were 
restimulated with 20µg PPD and 2µg αCD28 mAb for 16h before the addition of BFA 
for a further 4h. Cells were then harvested and stained with the following to assess 
cytokine production: γδ TCR FITC, GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, 
IFNγ e450, CD4 v500, IL-17A APC, CD3 APCe780. CD4+ T cells were identified as 
CD3+ Thy1.2+ CD4+. Representative flow cytometry plots from day 14 (A), day 21 (B) 
or day 28 post infection (C) are shown. Individual time points are from independent 
experiments. Data representative of 2 (d14 and d28) or 3 (d21) independent 
experiments. 4-5 mice per group. 
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Figure 3.6 BCG vaccination in the context of αIL-10R mAb does not significantly 
accelerate recruitment of IFNγ  or IL-17 producing CD4+ T cells (percentage and 
number cytokine producing) to the lung upon Mtb challenge 
 
CBA/J mice were BCG vaccinated and challenged with Mtb as shown in Figure 3.1. 
Mice were sacrificed and lungs harvested at 14, 21 and 28 days post Mtb challenge. 
Lungs were homogenized by passage through a 70µm filter. 1x106 cells were 
restimulated with 20µg PPD and 2µg αCD28 mAb for 16h before the addition of BFA 
for a further 4h. Cells were then harvested and stained with the following to assess 
cytokine production: γδ TCR FITC, GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, 
IFNγ e450, CD4 v500, IL-17A APC, CD3 APCe780. CD4+ T cells were identified as 
CD3+ Thy1.2+ CD4. Percentage and number of cytokine producing CD4+ T cells at day 
14 (A), day 21 (B) or day 28 post infection (C). Graphs show individual mice with 
mean ± SD. Individual time points are from independent experiments. Data 
representative of 2 (d14 and d28) or 3 (d21) independent experiments. 4-5 mice per 
group. ns – not significant by 2-way ANOVA with Tukey post test.   
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Figure 3.7 Production of GM-CSF by CD4+ T cells in the lung upon Mtb challenge is 
accelerated and enhanced by BCG vaccination in the context of αIL-10R mAb. (Flow 
cytometry plots) 
 
CBA/J mice were BCG vaccinated and challenged with Mtb as shown in Figure 3.1. 
Mice were sacrificed and lungs harvested at 14, 21 and 28 days post Mtb challenge. 
Lungs were homogenized by passage through a 70µm filter. 1x106 cells were 
restimulated with 20µg PPD and 2µg αCD28 mAb for 16h before the addition of BFA 
for a further 4h. Cells were then harvested and stained with the following to assess 
cytokine production: γδ TCR FITC, GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, 
IFNγ e450, CD4 v500, IL-17A APC, CD3 APCe780. CD4+ T cells were identified as 
CD3+ Thy1.2+ CD4+. Representative flow cytometry plots from day 14 (A), day 21 (B) 
or day 28 post infection (C) are shown. Individual time points are from independent 
experiments. Data representative of 2 (d14 and d28) or 3 (d21) independent 
experiments. 4-5 mice per group 
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Figure 3.8 Production of GM-CSF by CD4+ T cells (percentage and number cytokine 
producing) in the lung upon Mtb challenge is accelerated and enhanced by BCG 
vaccination in the context of αIL-10R mAb.  
 
CBA/J mice were BCG vaccinated and challenged with Mtb as shown in Figure 3.1. 
Mice were sacrificed and lungs harvested at 14, 21 and 28 days post Mtb challenge. 
Lungs were homogenized by passage through a 70µm filter. 1x106 cells were 
restimulated with 20µg PPD and 2µg αCD28 mAb for 16h before the addition of BFA 
for a further 4h. Cells were then harvested and stained with the following to assess 
cytokine production: γδ TCR FITC, GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, 
IFNγ e450, CD4 v500, IL-17A APC, CD3 APCe780. CD4+ T cells were identified as 
CD3+ Thy1.2+ CD4+. Percentage and number of cytokine producing CD4+ T cells at day 
14 (A), day 21 (B) or day 28 post infection (C). Data representative of 2 (d14 and d28) 
or 3 (d21) independent experiments. 4-5 mice per group. Graphs show mean ± SD. ns – 
not significant *p<0.05, **p<0.01, ***p<0.001 by 2-way ANOVA with Tukey post 
test.   
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Figure 3.9 Increased production of IL-17 by gamma delta T cells in the lung in mice 
BCG vaccinated in the context of αIL-10R mAb (Flow cytometry plots) 
 
CBA/J mice were BCG vaccinated and challenged with Mtb as shown in Figure 3.1. 
Mice were sacrificed and lungs harvested at 14, 21 and 28 days post Mtb challenge. 
Lungs were homogenized by passage through a 70µm filter. 1x106 cells were 
restimulated with 20µg PPD and 2µg αCD28 mAb for 16h before the addition of BFA 
for a further 4h. Cells were then harvested and stained with the following to assess 
cytokine production: γδ TCR FITC, GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, 
IFNγ e450, CD4 v500, IL-17A APC, CD3 APCe780. γδ T cells were identified as CD3+ 
Thy1.2+ γδ TCR+. Representative flow cytometry plots from day 14 (A), day 21 (B) or 
day 28 post infection (C) are shown are shown. Individual time points are from 
independent experiments. Data representative of 2 (d14 and d28) or 3 (d21) independent 
experiments. 4-5 mice per group. 
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Figure 3.10 Increased production of IL-17 by gamma delta T cells (percentage and 
number cytokine producing) in the lung in mice BCG vaccinated in the context of 
αIL-10R mAb.  
 
CBA/J mice were BCG vaccinated and challenged with Mtb as shown in Figure 3.1. 
Mice were sacrificed and lungs harvested at 14, 21 and 28 days post Mtb challenge. 
Lungs were homogenized by passage through a 70µm filter. 1x106 cells were 
restimulated with 20µg PPD and 2µg αCD28 mAb for 16h before the addition of BFA 
for a further 4h. Cells were then harvested and stained with the following to assess 
cytokine production: γδ TCR FITC, GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, 
IFNγ e450, CD4 v500, IL-17A APC, CD3 APCe780. γδ T cells were identified as CD3+ 
Thy1.2+ γδ TCR+. Percentage and number of cytokine producing γδ T cells at day 14 
(A), day 21 (B) or day 28 post infection (C). Data representative of 2 (d14 and d28) or 3 
(d21) independent experiments. 4-5 mice per group. Graphs show mean ± SD. ns – not 
significant *p<0.05, **p<0.01, ***p<0.001 by 2-way ANOVA with Tukey post test.   
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Figure 3.11 Increased IL-17 production by CD8+ T cells in the lung in mice BCG 
vaccinated in the context of αIL-10R mAb (Flow cytometry plots) 
 
CBA/J mice were BCG vaccinated and challenged with Mtb as shown in Figure 3.1. 
Mice were sacrificed and lungs harvested at 14, 21 and 28 days post Mtb challenge. 
Lungs were homogenized by passage through a 70µm filter. 1x106 cells were 
restimulated with 20µg PPD and 2µg αCD28 mAb for 16h before the addition of BFA 
for a further 4h. Cells were then harvested and stained with the following to assess 
cytokine production: γδ TCR FITC, GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, 
IFNγ e450, CD4 v500, IL-17A APC, CD3 APCe780. CD8+ T cells were identified as 
CD3+ Thy1.2+ CD8+. Representative flow cytometry plots from day 14 (A), day 21 (B) 
or day 28 post infection (C) are shown are shown. Individual time points are from 
independent experiments. Data representative of 2 (d14 and d28) or 3 (d21) independent 
experiments. 4-5 mice per group. 
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Figure 3.12 Increased IL-17 production by CD8+ T cells (percentage and number 
cytokine producing) in the lung in mice BCG vaccinated in the context of αIL-10R 
mAb.  
 
CBA/J mice were BCG vaccinated and challenged with Mtb as shown in Figure 3.1. 
Mice were sacrificed and lungs harvested at 14, 21 and 28 days post Mtb challenge. 
Lungs were homogenized by passage through a 70µm filter. 1x106 cells were 
restimulated with 20µg PPD and 2µg αCD28 mAb for 16h before the addition of BFA 
for a further 4h. Cells were then harvested and stained with the following to assess 
cytokine production: γδ TCR FITC, GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, 
IFNγ e450, CD4 v500, IL-17A APC, CD3 APCe780. CD8+ T cells were identified as 
CD3+ Thy1.2+ CD8+. Percentage and number of cytokine producing γδ T cells at day 14 
(A), day 21 (B) or day 28 post infection (C). Data representative of 2 (d14 and d28) or 3 
(d21) independent experiments. 4-5 mice per group. Graphs show mean ± SD. ns – not 
significant *p<0.05, **p<0.01 by 2-way ANOVA with Tukey post test.   
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Figure 3.13 Increased GM-CSF and IL-17 production in the spleen upon Mtb 
challenge following BCG vaccination in the context of αIL-10R mAb 
 
CBA/J mice were BCG vaccinated and challenged with Mtb as shown in Figure 3.1. Mice were 
sacrificed and lungs harvested at 14, 21 and 28 days post Mtb challenge. 5x106 cells were 
restimulated with 20µg PPD and 2µg αCD28 for 16h after which supernatants were harvested. 
ELISAs were performed for IFNγ, IL-17 and GM-CSF in supernatants from cultures at day 14 
(A), day 21 (B) and day 28 (C) post infection. Data pooled from 2 (d14 and d28) or 3 (d21) 
independent experiments. 5-15 mice per group. Graphs show mean ± SD. ns – not significant 
*p<0.05, **p<0.01, ***p<0.001 by 2-way ANOVA with Tukey post test.  
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Figure 3.14 BCG vaccination in the context of αIL-10R mAb does not significantly 
affect IFNγ  or IL-17 production by CD4+ T cells in the spleen upon Mtb challenge. 
(Flow cytometry plots) 
 
CBA/J mice were BCG vaccinated and challenged with Mtb as shown in Figure 3.1. 
Mice were sacrificed and lungs harvested at 14, 21 and 28 days post Mtb challenge. 
Spleens were homogenized by passage through a 70µm filter. 5x106 cells were 
restimulated with 20µg PPD and 2µg αCD28 mAb for 16h before the addition of BFA 
for a further 4h. Cells were then harvested and stained with the following to assess 
cytokine production: γδ TCR FITC, GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, 
IFNγ e450, CD4 v500, IL-17A APC, CD3 APCe780. CD4+ T cells were identified as 
CD3+ Thy1.2+ CD4+. Representative flow cytometry plots from day 14 (A), day 21 (B) 
or day 28 post infection (C) are shown are shown. Individual time points are from 
independent experiments. Data representative of 2 independent experiments at each 
time point. 2-5 mice per group. 
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Figure 3.15 BCG vaccination in the context of αIL-10R mAb does not significantly 
affect IFNγ  or IL-17 production by CD4+ T cells (percentage and number cytokine 
producing) in the spleen upon Mtb challenge.  
 
CBA/J mice were BCG vaccinated and challenged with Mtb as shown in Figure 3.1. 
Mice were sacrificed and lungs harvested at 14, 21 and 28 days post Mtb challenge. 
Spleens were homogenized by passage through a 70µm filter. 5x106 cells were 
restimulated with 20µg PPD and 2µg αCD28 mAb for 16h before the addition of BFA 
for a further 4h. Cells were then harvested and stained with the following to assess 
cytokine production: γδ TCR FITC, GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, 
IFNγ e450, CD4 v500, IL-17A APC, CD3 APCe780. CD4+ T cells were identified as 
CD3+ Thy1.2+ CD4+. Percentage and number of cytokine producing CD4+ T cells at day 
14 (A), day 21 (B) or day 28 post infection (C). Data representative of 2 independent 
experiments at each time point. 2-5 mice per group. Graphs show mean ± SD. ns – not 
significant *p<0.05, **p<0.01 by 2-way ANOVA with Tukey post test.   
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Figure 3.16 GM-CSF production by CD4+ T cells is increased in the spleen upon Mtb 
challenge in mice vaccinated with BCG in the context of αIL-10R mAb. (Flow 
cytometry plots) 
 
CBA/J mice were BCG vaccinated and challenged with Mtb as shown in Figure 3.1. 
Mice were sacrificed and lungs harvested at 14, 21 and 28 days post Mtb challenge. 
Spleens were homogenized by passage through a 70µm filter. 5x106 cells were 
restimulated with 20µg PPD and 2µg αCD28 mAb for 16h before the addition of BFA 
for a further 4h. Cells were then harvested and stained with the following to assess 
cytokine production: γδ TCR FITC, GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, 
IFNγ e450, CD4 v500, IL-17A APC, CD3 APCe780. CD4+ T cells were identified as 
CD3+ Thy1.2+ CD4+. Representative flow cytometry plots from day 14 (A), day 21 (B) 
or day 28 post infection (C) are shown are shown. Individual time points are from 
independent experiments. Data representative of 2 independent experiments at each 
time point. 2-5 mice per group. 
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Figure 3.17 GM-CSF production by CD4+ T cells (percentage and number cytokine 
producing) is increased in the spleen upon Mtb challenge in mice vaccinated with 
BCG in the context of αIL-10R mAb 
 
CBA/J mice were BCG vaccinated and challenged with Mtb as shown in Figure 3.1. 
Mice were sacrificed and lungs harvested at 14, 21 and 28 days post Mtb challenge. 
Spleens were homogenized by passage through a 70µm filter. 5x106 cells were 
restimulated with 20µg PPD and 2µg αCD28 mAb for 16h before the addition of BFA 
for a further 4h. Cells were then harvested and stained with the following to assess 
cytokine production: γδ TCR FITC, GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, 
IFNγ e450, CD4 v500, IL-17A APC, CD3 APCe780. CD4+ T cells were identified as 
CD3+ Thy1.2+ CD4+. Percentage and number of cytokine producing CD4+ T cells at day 
14 (A), day 21 (B) or day 28 post infection (C). Data representative of 2 independent 
experiments at each time point. 2-5 mice per group. Graphs show mean ± SD. ns – not 
significant *p<0.05, **p<0.01 by 2-way ANOVA with Tukey post test.   
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Figure 3.18 BCG vaccination in the context of αIL-10R mAb does not impact 
cytokine production by γδ  T cells in the spleen upon Mtb challenge. (Flow cytometry 
plots) 
 
CBA/J mice were BCG vaccinated and challenged with Mtb as shown in Figure 3.1. 
Mice were sacrificed and lungs harvested at 14, 21 and 28 days post Mtb challenge. 
Spleens were homogenized by passage through a 70µm filter. 5x106 cells were 
restimulated with 20µg PPD and 2µg αCD28 mAb for 16h before the addition of BFA 
for a further 4h. Cells were then harvested and stained with the following to assess 
cytokine production: γδ TCR FITC, GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, 
IFNγ e450, CD4 v500, IL-17A APC, CD3 APCe780. γδ T cells were identified as CD3+ 
Thy1.2+ γδ TCR+. Representative flow cytometry plots from day 14 (A), day 21 (B) or 
day 28 post infection (C) are shown are shown. Individual time points are from 
independent experiments. Data representative of 2 independent experiments at each 
time point. 2-5 mice per group. 
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Figure 3.19 BCG vaccination in the context of αIL-10R mAb does not impact 
cytokine production by γδ  T cells (percentage and number cytokine producing) in the 
spleen upon Mtb challenge.  
 
CBA/J mice were BCG vaccinated and challenged with Mtb as shown in Figure 3.1. Mice were 
sacrificed and lungs harvested at 14, 21 and 28 days post Mtb challenge. Spleens were 
homogenized by passage through a 70µm filter. 5x106 cells were restimulated with 20µg PPD 
and 2µg αCD28 mAb for 16h before the addition of BFA for a further 4h. Cells were then 
harvested and stained with the following to assess cytokine production: γδ TCR FITC, GM-CSF 
PE, CD8 PerCP e710, Thy1.2 PE Cy7, IFNγ e450, CD4 v500, IL-17A APC, CD3 APCe780. γδ 
T cells were identified as CD3+ Thy1.2+ γδ TCR+. Percentage and number of cytokine 
producing γδ T cells at day 14 (A), day 21 (B) or day 28 post infection (C). Data representative 
of 2 independent experiments at each time point. 2-5 mice per group. Graphs show mean ± SD. 
ns – not significant *p<0.05 by 2-way ANOVA with Tukey post test.  
BCG + aIL-10R
BCG + ISO
PBS + aIL-10R
PBS + ISOd14
d21
d28
0
5
10
15
20
0
5
10
15
20
0
20000
40000
60000
80000
IFNŠ+ IL-17A+ IFNŠ+ IL-17A+
0
20000
40000
60000
80000
ns ns
ns
ns
ns
ns
ns *
C
el
l N
um
be
r
%
 C
yt
ok
in
e 
pr
od
uc
in
g
C
el
l N
um
be
r
%
 C
yt
ok
in
e 
pr
od
uc
in
g
C
el
l N
um
be
r
%
 C
yt
ok
in
e 
pr
od
uc
in
g
B
A
C
0
20000
40000
60000
80000
0
5
10
15
20
ns *
ns ns
IFNŠ+ IL-17A+ IFNŠ+ IL-17A+
IFNŠ+ IL-17A+ IFNŠ+ IL-17A+IFNŠ+ IL-17A+ IFNŠ+ IL-17A+
IFNŠ+ IL-17A+ IFNŠ+ IL-17A+IFNŠ+ IL-17A+ IFNŠ+ IL-17A+
 - Chapter 3: Determining whether IL-10 during BCG vaccination influences the early cytokine response to Mtb challenge in susceptible mice- 
 167 
 
Figure 3.20 BCG vaccination in the context of αIL-10R mAb does not impact 
cytokine production by CD8+ T cells in the spleen upon Mtb challenge. (Flow 
cytometry plots) 
 
CBA/J mice were BCG vaccinated and challenged with Mtb as shown in Figure 3.1. 
Mice were sacrificed and lungs harvested at 14, 21 and 28 days post Mtb challenge. 
Spleens were homogenized by passage through a 70µm filter. 5x106 cells were 
restimulated with 20µg PPD and 2µg αCD28 mAb for 16h before the addition of BFA 
for a further 4h. Cells were then harvested and stained with the following to assess 
cytokine production: γδ TCR FITC, GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, 
IFNγ e450, CD4 v500, IL-17A APC, CD3 APCe780. CD8+ T cells were identified as 
CD3+ Thy1.2+ CD8+. Representative flow cytometry plots from day 14 (A), day 21 (B) 
or day 28 post infection (C) are shown are shown. Individual time points are from 
independent experiments. Data representative of 2 independent experiments at each 
time point. 2-5 mice per group. 
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Figure 3.21 BCG vaccination in the context of αIL-10R mAb does not impact 
cytokine production by CD8+ T cells (percentage and number cytokine producing) in 
the spleen upon Mtb challenge.  
 
CBA/J mice were BCG vaccinated and challenged with Mtb as shown in Figure 3.1. Mice were 
sacrificed and lungs harvested at 14, 21 and 28 days post Mtb challenge. Spleens were 
homogenized by passage through a 70µm filter. 5x106 cells were restimulated with 20µg PPD 
and 2µg αCD28 mAb for 16h before the addition of BFA for a further 4h. Cells were then 
harvested and stained with the following to assess cytokine production: γδ TCR FITC, GM-CSF 
PE, CD8 PerCP e710, Thy1.2 PE Cy7, IFNγ e450, CD4 v500, IL-17A APC, CD3 APCe780. 
CD8+ T cells were identified as CD3+ Thy1.2+ CD8+. Percentage and number of cytokine 
producing CD8+ T cells at day 14 (A), day 21 (B) or day 28 post infection (C). Data 
representative of 2 independent experiments at each time point. 2-5 mice per group. Graphs 
show mean ± SD. ns – not significant by 2-way ANOVA with Tukey post test.  
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Figure 3.22 GM-CSF is required for optimal protection during Mtb challenge 
following BCG vaccination  
 
CBA/J mice were intradermally vaccination with approximately 5x105 CFU BCG or PBS. 6 
weeks after BCG vaccination mice received 1mg i.p. injection with αGM-CSF or isotype 
(GL117; ISO) control. The following day mice were challenged with approx. 100-200 CFU of 
the Mtb strain H37Rv, via aerosol route. Twice weekly i.p. injections containing 0.3mg or 
αGM-CSF or ISO (GL117) were given. Mice were sacrificed and lungs harvested at 9 weeks 
post infection and bacterial load was determined. Graphs show mean ± SD. Data representative 
of 2 independent experiments (experiment not shown performed with mice purchased from 
Jackson Laboratories). **p<0.01, ****p<0.0001 by students t-test. 
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4.1 Evaluating the importance of GM-CSF during primary Mtb 
infection: aims of the investigation  
In order to determine the role of GM-CSF specifically during primary Mtb infection, we aimed 
to investigate: 
 
1) The impact of GM-CSF neutralisation during Mtb infection upon the control of 
bacterial load in Mtb resistant C57BL/6 and Mtb susceptible CBA/J mouse strains 
 
2) How GM-CSF neutralisation impacts the onset and magnitude of an adaptive immune 
response in both these mouse strains 
 
3) Whether GM-CSF neutralisation impacts myeloid populations upon Mtb infection 
 
4.2 Background 
4.2.1 Functions of GM-CSF 
GM-CSF is produced by multiple cell types including: T cells, macrophages, endothelial cells 
and fibroblasts (Gasson, 1991). It was originally named due to its ability to differentiate bone 
marrow progenitors to macrophages and granulocytes (Burgess and Metcalf, 1980). Given this 
role in myeloid development it was surprising when GM-CSF deficient mice did not display 
overt defects in blood myeloid populations, possibly because other cytokines can compensate 
for the absence of GM-CSF (Dranoff et al., 1994; Stanley et al., 1994). Subsequently, however, 
GM-CSF was found to be crucial for the development of alveolar macrophages from foetal 
monocytes via induction of PPARγ (Guilliams et al., 2013; Schneider et al., 2014). Thus GM-
CSF deficient mice lack mature alveolar macrophages (Becher et al., 2014; Guilliams et al., 
2013; Schneider et al., 2014). GM-CSF stimulated induction of the transcription factor PU.1 is 
suggested to be required for maturation of alveolar macrophages and forced expression of PU.1 
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in GM-CSF deficient alveolar macrophages can rescue defects in cytokine production, 
surfactant metabolism and bacterial killing (Shibata et al., 2001).  
 
GM-CSF deficient mice develop a lung disease resembling the human disease pulmonary 
alveolar proteinosis (PAP) (Dranoff et al., 1994; Stanley et al., 1994). In humans PAP can either 
be caused by acquired or genetic factors (Seymour and Presneill, 2002). Those with genetic 
causes of PAP account for less than 10% or all PAP cases, and can result from mutations in the 
genes encoding either subunit of the GM-CSF receptor: CSFRA or CSFRB (Seymour and 
Presneill, 2002; Whitsett et al., 2015). Mutations in the genes encoding surfactant protein B, C 
or the transporter ABCA3 can also result in PAP (Seymour and Presneill, 2002; Whitsett et al., 
2015). More than 90% of PAP cases are acquired and the majority of these patients have 
autoantibodies against GM-CSF, although PAP can also occur following exposure to various 
environmental agents (Seymour and Presneill, 2002). PAP is characterised by accumulation of 
surfactant and proteinaceous material within the alveolar space, resulting in dyspnoea and 
compromised gas exchange (Trapnell and Whitsett, 2002). This build up of surfactant is due to 
the inadequate clearance of surfactant by alveolar macrophages (Dranoff et al., 1994; Trapnell 
and Whitsett, 2002). PAP patients are more susceptible to infections with opportunistic 
pathogens including Nocardia, Pneumocystis, Acinetobacter, Aspergillus, Cladosporium, Mtb 
and atypical mycobacteria, with reports of systemic infections, rather than localised containment 
(Borie et al., 2011; Seymour and Presneill, 2002). Neutrophils from patients with PAP, as well 
as GM-CSF deficient mice, display basal functional defects, as well as defects in bacterial 
killing, which could contribute to the increased susceptibility to infections (Uchida et al., 2007).  
 
In addition to its role in the development of alveolar macrophages, GM-CSF has also been 
implicated in the development of other cell subsets. In vitro GM-CSF can induce the 
differentiation of DCs, in addition to macrophages and granulocytes, from bone marrow 
precursors (Inaba et al., 1992). In vivo GM-CSF is suggested to be required for the development 
of CD103+ DCs in non-lymphoid tissue such as skin and lamina propria, although there are 
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some conflicting reports (Bogunovic et al., 2009; Hamilton, 2015; King et al., 2010). The role 
for GM-CSF in the differentiation of inflammatory DCs is controversial, with several 
conflicting reports (Hamilton, 2015). NKT cells have also been shown to be dependent upon 
GM-CSF for their functional development, with NKT cells from GM-CSF deficient mice 
exhibiting defects in cytokine secretion in response to αGalCer (Bezbradica et al., 2006).  
 
GM-CSF can also act as a pro-inflammatory cytokine to activate myeloid populations 
(Hamilton, 2008). GM-CSF is suggested to prime macrophages to enhance pro-inflammatory 
cytokine production in response to LPS (Hamilton, 2002). Indeed, stimulation of GM-CSF 
derived bone marrow macrophages with LPS induces production of pro-inflammatory cytokines 
such as TNFα and IL-12p70 in vitro. Pre-treatment of M-CSF derived macrophages with GM-
CSF, before LPS stimulation, increases production of pro-inflammatory cytokines compared to 
no pre-treatment (Fleetwood et al., 2007). Cross presentation by CD8+ DCs is enhanced by GM-
CSF (Zhan et al., 2012), as is antigen presentation by CD8- DCs (Min et al., 2010). GM-CSF 
treatment of DC subsets is also accompanied by upregulation of co-stimulatory molecules (Min 
et al., 2010). Therefore, in addition to the role of GM-CSF in the development of cell 
populations such as alveolar macrophages and NKT cells, GM-CSF is also crucial for 
maintenance of pulmonary homeostasis and has pro-inflammatory functions, influencing 
cytokine production by and activation status of myeloid populations. 
 
4.2.2 The role of GM-CSF in Mtb infection  
In the context of Mtb infection, studies using GM-CSF deficient mice have demonstrated a 
protective role for GM-CSF (Gonzalez-Juarrero et al., 2005; Szeliga et al., 2008). GM-CSF 
deficient mice show reduced survival, increased bacterial loads and disorganised granulomas in 
response to Mtb infection compared to wild-type controls (Gonzalez-Juarrero et al., 2005; 
Szeliga et al., 2008). However, due to the developmental defects in alveolar macrophage 
populations and the development of a PAP like disease, studies using GM-CSF deficient mice 
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are difficult to interpret. Indeed alveolar macrophages are thought to be one of the first cell 
types to become infected with Mtb following inhalation (Srivastava et al., 2014), and therefore 
changes in these populations could significantly impact the subsequent sequelae of infection. 
Furthermore, the developmental defects in other cell populations, such as NKT cells could also 
confound the interpretation of these results, as NKT cells are suggested to be involved in the 
response to Mtb infection through production of cytokines (Rothchild et al., 2014; Sada-Ovalle 
et al., 2008).  
 
GM-CSF, produced by NKT cells, can also act directly upon mouse macrophages to restrict Mtb 
growth (Rothchild et al., 2014). Although the mechanism for this growth restriction is unknown, 
it was shown to be independent of iNOS (Rothchild et al., 2014). Treatment of infected mice 
with KGF is suggested to induce GM-CSF production, leading to restriction of bacterial growth 
through increased macrophage activation and phagolysosome fusion (Pasula et al., 2015). In 
human monocyte derived macrophages, GM-CSF is capable of restricting Mtb growth and also 
other mycobacterial species (Bermudez and Young, 1990; Denis, 1991; Denis and Ghadirian, 
1990). These studies suggest a pro-inflammatory role for GM-CSF during Mtb infection.  
 
In the previous chapter we correlated increased protection in chronic infection following 
vaccination, with earlier and elevated production of GM-CSF. We then demonstrated that GM-
CSF neutralisation during Mtb infection, in the susceptible CBA/J mice, was detrimental to 
control of infection in both BCG vaccinated and unvaccinated mice. Given the difficulties in 
interpreting studies using GM-CSF deficient mice, we were interested in further investigating 
the role of GM-CSF in primary Mtb infection through GM-CSF neutralisation where 
developmental abnormalities would be avoided. In addition, as this strategy does not rely on 
genetic modification, the role of GM-CSF in both resistant and susceptible mice could be 
assessed, which is beneficial given that susceptible mouse strains are argued to better reflect 
human disease (Apt and Kramnik, 2009).  
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4.3 Assessing the importance of GM-CSF during Mtb infection  
 
4.3.1 GM-CSF is required to control bacterial load in both resistant C57BL/6 and susceptible 
CBA/J mice 
 
To assess the role of GM-CSF during primary Mtb infection, resistant C57BL/6 mice and 
susceptible CBA/J mice, were infected with the lab strain of Mtb, H37Rv, in the context of 
αGM-CSF treatment as shown in Figure 4.1A. Mice received an i.p. injection containing 1mg 
of αGM-CSF (clone MP1-22E9) or isotype control antibody (GL117) the day prior to Mtb 
infection and following infection mice received twice weekly i.p. injections of 0.3mg αGM-
CSF or isotype control antibody. Mice were sacrificed at days 21, 28, 41 (CBA/J only) and 55 
and bacterial loads in the lung were determined as described in Materials and Methods.  
 
In resistant C57BL/6 mice, we found there was no difference in Mtb bacterial load in the lung at 
day 21 post infection. At day 28 and day 55 post infection we found a significant increase in 
lung bacterial load in mice treated with αGM-CSF as compared to those treated with the isotype 
control (Figure 4.1B) (day 28 p<0.05, day 55 p<0.0001). In contrast, in susceptible CBA/J 
mice, no difference in bacterial load between isotype treated and αGM-CSF treated mice was 
evident at days 21 or 28 post infection. At days 41 and 55 post infection there was an increase in 
bacterial load in mice treated with αGM-CSF, although at day 41 this did not quite reach 
significance (Figure 4.1C) (day 41 p=0.07, day 55 p<0.001).  
 
4.3.2 GM-CSF marginally impacts recruitment of T cells to the lung upon Mtb infection in 
resistant mice but not susceptible mice 
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Having shown that GM-CSF is crucial for the control of bacterial load upon Mtb infection, we 
next investigated whether this correlated with a reduction in the presence of an adaptive 
immune response, as has been suggested at day 21 post Mtb infection in the GM-CSF deficient 
mouse (Gonzalez-Juarrero et al., 2005). We first assessed total T cell populations present in the 
lung at day 21 and 28 post infection, time points which should capture the onset of an adaptive 
immune response (reviewed in Cooper, 2009). Resistant and susceptible mice were infected and 
treated with αGM-CSF or isotype control as described above and as shown in Figure 4.1A. At 
days 21, 28 single cell suspensions generated from the lung were stained to identify CD4+, 
CD8+ and γδ T cells with the gating strategy shown in Appendix 1.  
 
We found that αGM-CSF mAb treatment of resistant mice during Mtb infection had a small 
impact on T cell populations present early following infection. At day 21 and day 28 post 
infection, in resistant C57BL/6 mice we found no difference in the percentage of CD4+ or CD8+ 
T cells present in the lung but found significantly lower numbers of these T cells, between mice 
treated with αGM-CSF or isotype control (Figure 4.2A and Figure 4.2B). Numbers of CD4+ 
and CD8+ T cells were equivalent between the two groups at day 28 post infection (Figure 4.2A 
and Figure 4.2B). At day 21 post infection the percentage and number of γδ T cells in the lung 
was lower in mice treated with αGM-CSF, while at day 28 post infection the percentage of γδ T 
cells was higher in mice treated with αGM-CSF but there was no difference in numbers (Figure 
4.2C). 
 
In contrast to resistant C57BL/6 mice, GM-CSF neutralisation during Mtb infection in 
susceptible CBA/J mice, did not impact CD4+, CD8+ or γδ T cell populations in the lung at days 
21 or 28 post infection (Figure 4.3A, Figure 4.3B and Figure 4.3C). 
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4.3.3 GM-CSF does not impact IFNγ  or IL-17 production by CD4+ T cells in resistant or 
susceptible mice 
 
Although we found only minimal or no differences in the total T cell populations when GM-
CSF was neutralised, the function of the T cells present could be impaired in the absence of 
GM-CSF. We therefore assessed the production of IFNγ and IL-17A by different T cell 
populations upon infection. Single cell suspensions were obtained from the lungs of mice 
infected and administered mAb as described in Figure 4.1. These were restimulated with PPD 
and αCD28 for 16 hours before addition of Brefeldin A for a further 4 hours, as described in 
Materials and Methods. Cells were harvested and intracellular cytokine staining was performed 
to identify cytokine producing CD4+, CD8+ and γδ T cells, with the gating strategy for 
identification shown in Appendix 2. We began by assessing cytokine production by CD4+ T 
cells due to the known importance of these cells in the immune response to Mtb infection 
(reviewed in O'Garra et al., 2013). 
 
In resistant C57BL/6 mice we found that CD4+ T cells produced IFNγ, but not IL-17A, at day 
21 post infection but neutralisation of GM-CSF did not impact this. Similarly at day 28 we 
found equivalent production of IFNγ by CD4+ T cells in mice treated with αGM-CSF or isotype 
control and could not detect IL-17A production (Figure 4.4A and Figure 4.4B). In contrast to 
resistant C57BL/6 mice, at day 21 post infection we could not detect IFNγ or IL-17 production 
by CD4+ T cells in susceptible CBA/J mice under any treatment condition. At day 28 post 
infection IFNγ production by CD4+ T cells was equivalent in isotype treated and αGM-CSF 
treated susceptible CBA/J mice (Figure 4.5A and Figure 4.5B).  
 
Our results show that GM-CSF is important in control of bacterial load during the immune 
response to Mtb infection and we were interested in defining the cellular source of GM-CSF 
upon infection. As CD4+ T cells can produce GM-CSF, we assessed whether CD4+ T cells were 
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a source of GM-CSF upon Mtb infection. Single cell suspensions were obtained from antibody 
treated, infected mice and restimulated with PPD and αCD28 as described in Materials and 
Methods and intracellular cytokine staining was performed to identify GM-CSF (and IFNγ) 
producing T cells. The gating strategy to identify CD4+ T cells producing GM-CSF is shown in 
Appendix 2. Only extremely low proportions and numbers of GM-CSF producing CD4+ T cells 
were detected at day 21 or day 28 post infection in resistant or susceptible mouse strains 
(Figure 4.6A and Figure 4.6B). GM-CSF is reported to be produced by many other cell types 
including macrophages, fibroblast and type II pneumocytes (Gasson, 1991) and it is likely that 
there are other cellular sources of GM-CSF upon Mtb infection. 
 
4.3.4 Neutralisation of GM-CSF decreases IFNγ  production by CD8+ T cells and IL-17 
production by γδ  T cells in resistant but not susceptible mice. 
 
It is established that CD8+ T cells and γδ T cells can produce cytokines upon Mtb infection, 
which could influence the outcome of infection (Behar, 2013; Bold and Ernst, 2012; Lockhart et 
al., 2006; Okamoto Yoshida et al., 2010). We therefore assessed whether cytokine production 
by these cell types was affected by GM-CSF neutralisation.  
 
In resistant C57BL/6 mice at day 21 post infection we detected very little production of IFNγ by 
CD8+ T cells in either mice treated with αGM-CSF mAb or isotype control (Figure 4.7A and 
Figure 4.7B). At day 28 we found a small percentage and number of CD8+ T cells produced 
IFNγ, and this production was decreased when GM-CSF was neutralised throughout infection 
(Figure 4.7A and Figure 4.7B). IL-17A production by CD8+ T cells was not found at either 
time point. 
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In susceptible CBA/J mice, as for resistant C57BL/6 mice, we did not detect IFNγ production 
by CD8+ T cells at day 21 post infection (Figure 4.8A and Figure 4.8B). At day 28 post 
infection, there was low IFNγ production by CD8+ T cells, with considerable variation within 
the groups. Neutralisation of GM-CSF throughout infection did not impact IFNγ production by 
CD8+ T cells at day 28 post infection. Similarly to resistant C57BL/6 mice, no IL-17A 
production by CD8+ T cells was detected at either time point (Figure 4.8A and Figure 4.8B).  
 
As shown earlier the total γδ T cell population was lower, both in percentage and in number, at 
day 21 post Mtb infection when GM-CSF was neutralised throughout infection in resistant 
C57BL/6 mice (Figure 4.2C). In addition, GM-CSF neutralisation during Mtb infection 
significantly decreased the percentage and number of IL-17A producing γδ T cells at day 21 
post Mtb challenge (Figure 4.9A and Figure 4.9B) (percentage p<0.05, number p<0.05). At 
day 28 post infection, there was a strong trend towards lower percentage of γδ T cells producing 
IL-17A in mice treated with αGM-CSF mAb, but this did not reach significance (p=0.051). 
There was no difference in the number of IL-17 producing γδ T cells at this time point (Figure 
4.9A and Figure 4.9B).  
 
In contrast to resistant C57BL/6 mice, in susceptible CBA/J mice no cytokine production by γδ 
T cells was detected at day 21 post infection (Figure 4.10A and Figure 4.10B). At day 28 post 
infection, IL-17A production was detected by γδ T cells but this was unaffected by GM-CSF 
neutralisation (Figure 4.10A and Figure 4.10B). 
 
4.3.5 GM-CSF neutralisation impacts myeloid populations in Mtb infection 
 
Thus far we have shown that GM-CSF is protective during Mtb infection in both resistant and 
susceptible mouse strains. A study using the GM-CSF deficient mouse, suggested that GM-CSF 
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is required for recruitment of IFNγ producing T cells to the lung at day 21 post Mtb infection 
(Gonzalez-Juarrero et al., 2005). Although there are small differences in the total T cell 
populations and cytokine production by other T cell populations in resistant mice, we did not 
find differences in IFNγ producing CD4+ T cells at day 21 or 28 post infection. As GM-CSF is 
required for the differentiation, proliferation and activation of myeloid populations (Hamilton, 
2008) we investigated how GM-CSF neutralisation impacts myeloid populations present during 
Mtb infection. 
 
We first assessed the impact of GM-CSF neutralisation upon myeloid populations present in the 
lung in naïve mice, as GM-CSF deficiency is known to affect these populations (Becher et al., 
2014; Gonzalez-Juarrero et al., 2005). Resistant C57BL/6 and susceptible CBA/J mice were i.p. 
injected with 1mg αGM-CSF (clone MP1-22E9) or isotype control (ISO) and subsequently 
received twice weekly i.p. injection containing 0.3mg of appropriate mAb for 3 or 4 weeks. 
Lungs were then harvested and single cell suspensions generated. These were stained to identify 
myeloid populations using the gating strategy shown in Appendix 3. We found that 3 weeks of 
αGM-CSF treatment of resistant C57BL/6 mice led to a decrease in the percentage and number 
of a CD11c+ CD11blo (MHC IIint, F4/80+) population we define as alveolar macrophages 
(Becher et al., 2014) (Figure 4.11A). However, after 4 week of αGM-CSF treatment, we found 
no significant difference in the percentage or number of alveolar macrophages, although there 
was a trend towards a decrease (Figure 4.11B). We did not find any differences in neutrophils 
(Ly6G+ CD11b+), CD11b+ CD11c+ DCs at either time point, and found an increase in the 
number (but not percentage) of monocytes (CD11b+ Ly6G- Ly6C hi) after 4 weeks of αGM-
CSF treatment (data not shown). 
 
 Similarly to resistant C57BL/6 mice we found that 3 weeks of treatment with αGM-CSF mAb 
led to a decrease in the percentage and number of CD11c+ CD11blo (MHC IIint, F4/80+) alveolar 
macrophages present in the lungs (Figure 4.12A). This decrease was not evident following 4 
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weeks of treatment, although there was a slight trend towards a decrease (Figure 4.12B). We 
did not find any differences in neutrophils (Ly6G+ CD11b+), CD11b+ CD11c+ DCs or 
monocytes (CD11b+ Ly6C hi) at either time point (data not shown). The observed decrease in 
CD11c+ CD11blo alveolar macrophages in the steady state is in keeping with the requirement of 
GM-CSF for alveolar macrophage maintenance (Hashimoto et al., 2013; Shibata et al., 2001). 
 
In order to assess the impact of GM-CSF neutralisation upon myeloid populations present in the 
lung during Mtb infection, resistant and susceptible mice were treated with αGM-CSF mAb or 
isotype control antibody and infected as described in Figure 4.1A. Lungs were harvested at 
days 21, 28 and 55 post infection and single cell suspensions stained to identify myeloid 
populations as shown in Appendix 3.  
 
In resistant C57BL/6 mice, we found small differences in neutrophil and monocyte populations 
when GM-CSF was neutralised during infection (Figure 4.13A and Figure 4.13B). GM-CSF 
neutralisation through infection led to a small increase in the percentage of neutrophils (Ly6G+ 
CD11b+) present at day 21 and day 28 post infection but this was not evident in terms of 
numbers. At day 55 post infection there was a small increase in the number of neutrophils in the 
lung when GM-CSF was neutralised (Figure 4.13A). At day 21 post infection we detected a 
small decrease in the number of monocytes present in the lung in mice treated with αGM-CSF, 
although their percentage was not affected (Figure 4.13B). There was no difference in the 
percentage or number of monocytes present at day 28 between isotype or αGM-CSF treated 
mice, and a small decrease in the percentage of monocytes present in αGM-CSF treated mice at 
day 55 post infection (Figure 4.13B).  
 
In contrast to the small impact GM-CSF neutralisation had on the presence of neutrophils and 
monocytes during Mtb infection, we found that in resistant C57BL/6 mice, neutralisation of 
GM-CSF dramatically reduced both the percentage and number of CD11c+ CD11blo (MHC IIint 
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, F4/80+) alveolar macrophages throughout infection at day 21, 28 and 55 post infection (Figure 
14.13C). Such a finding is in keeping with the importance of GM-CSF in the differentiation, 
maintenance and function of alveolar macrophages (Hashimoto et al., 2013; Shibata et al., 
2001). 
 
In resistant C57BL/6 mice, there was no effect on the percentage of CD11b+ CD11c+ DCs 
present in the lung at day 21 and 28 post infection however, the number of CD11b+ CD11c+ 
DCs was lower when GM-CSF was neutralised (Figure 4.14A). As GM-CSF can impact 
activation state and antigen presentation capacity of APCs, we assessed the levels of expression 
of MHC class II and the co-stimulatory molecule CD86 using the mean fluorescence intensity 
(MFI). We did not find any consistent impact of GM-CSF neutralisation, at any time point 
assessed, upon expression levels of MHC class II (Figure 4.14B) or CD86 (Figure 4.14C). 
 
In susceptible CBA/J mice, GM-CSF neutralisation led to a small increase in the percentage and 
number of neutrophils in the lung at day 21 post infection (Figure 4.15A). However, this 
increase was not evident at day 28 or 55 post infection (Figure 4.15A). We did not detect any 
differences in the percentage or number of monocytes present in the lung between isotype and 
αGM-CSF treated mice at any of the time points assessed (Figure 4.15B). In contrast to 
resistant C57BL/6 mice, αGM-CSF treatment did not affect the number or percentage of 
CD11c+ CD11blo (MHC IIint, F4/80+) alveolar macrophages at days 21 or 28 post infection 
(Figure 4.15C). A significant decrease in the percentage and number of CD11c+ CD11blo 
(MHC IIint F4/80+) alveolar macrophages in susceptible mice treated with αGM-CSF was only 
evident at day 55 post infection (Figure 4.15C).  
 
CD11b+ CD11c+ DC populations were unaffected by GM-CSF neutralisation in susceptible 
CBA/J mice at days 21 and 28 post Mtb infection (Figure 4.16A). However, at day 55 post 
infection there was a significant increase in the percentage and number of these cells in the lung 
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in mice treated with αGM-CSF mAb (Figure 4.16A). The impact of GM-CSF neutralisation on 
expression levels of MHC class II and CD86 on CD11b+ CD11c+ DCs was also assessed. No 
consistent impact of GM-CSF neutralisation upon the MFI of MHC class II (Figure 4.16B) or 
CD86 (Figure 4.16C) was observed.  
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4.4 Discussion 
Work in this thesis has shown that early and elevated production of GM-CSF, following BCG 
vaccination in the context of αIL-10R, correlated with increased control of bacterial load in 
chronic infection (see Chapter 3). Indeed studies using GM-CSF deficient mice have shown that 
GM-CSF is crucial for the immune response to Mtb infection (Gonzalez-Juarrero et al., 2005; 
Szeliga et al., 2008). However, GM-CSF deficient mice suffer from a lung pathology 
resembling PAP, leading to accumulation of surfactant in the lung (Dranoff et al., 1994; Stanley 
et al., 1994; Trapnell and Whitsett, 2002). These mice are also deficient in mature alveolar 
macrophages (Becher et al., 2014; Guilliams et al., 2013; Schneider et al., 2014). As a result, it 
is difficult to interpret whether GM-CSF itself is important during Mtb infection or whether the 
lack of mature alveolar macrophages and surfactant accumulation result in increased 
susceptibility to Mtb infection. Thus, in order to assess the role of GM-CSF during Mtb 
infection, without initial perturbation in the lung environment, we administered neutralising 
antibody throughout infection. As this approach does not rely on genetic manipulation we were 
also able to assess the function of GM-CSF in susceptible CBA/J mice. This is beneficial 
because susceptible mice have been proposed to better reflect human TB pathology and thus 
provide a better model of Mtb infection (Apt and Kramnik, 2009).  
 
4.4.1 GM-CSF neutralisation during Mtb infection exacerbates bacterial load in the lung 
 
Neutralisation of GM-CSF throughout Mtb infection increased Mtb bacterial loads in the lung in 
both resistant C57BL/6, and susceptible CBA/J mice. The increase in bacterial loads is in 
keeping with studies using the GM-CSF deficient mice (Gonzalez-Juarrero et al., 2005; Szeliga 
et al., 2008). However, these studies showed that GM-CSF knock mice all succumbed to 
infection by approximately 5 weeks post infection (Gonzalez-Juarrero et al., 2005; Szeliga et al., 
2008). This did not occur when GM-CSF is neutralised throughout infection and all mice 
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survived until the end of the experiment at day 55 post infection. This suggests that the 
phenotype in the GM-CSF deficient mouse is more severe than when GM-CSF is neutralised 
during infection. One possibility is that there was incomplete neutralisation of GM-CSF, 
resulting in some level of residual function. Another possibility is that the basal defects in lung 
homeostasis in GM-CSF deficient mice (Dranoff et al., 1994; Gonzalez-Juarrero et al., 2005; 
Stanley et al., 1994), lead to significant impairment of the control of Mtb bacterial load, to a 
much greater extent that in mice treated with αGM-CSF, where these basal defects are not 
present.  
 
4.4.2 GM-CSF neutralisation minimally impacts T cell recruitment and cytokine production 
in resistant C57BL/6 mice but not susceptible CBA/J mice 
 
GM-CSF deficient mice have been shown to display impaired recruitment of an adaptive 
immune response to the lung upon Mtb infection, which was suggested to contribute to its 
increased susceptibility (Gonzalez-Juarrero et al., 2005). We therefore assessed whether there 
were similar defects in mice treated with αGM-CSF throughout infection, which could 
contribute to the increased susceptibility observed. In resistant C57BL/6 mice we found small 
decreases in the number of total CD4+, CD8+ and γδ T cells present in the lung at day 21 post 
infection when GM-CSF was neutralised. A similar decrease in CD4+ T cells at day 21 post 
infection was found in GM-CSF deficient mice (Gonzalez-Juarrero et al., 2005). However, we 
found the effect on T cell recruitment was transient as by day 28 post infection there were no 
differences in CD4+ or CD8+ T cell populations in the lungs of C57BL/6 mice treated with 
αGM-CSF. One possible way in which GM-CSF could influence the adaptive response is 
through induction of lymphocyte attracting chemokines. In GM-CSF deficient mice a defect in 
expression of chemokines such as CCL5 in the lung was suggested to underlie their 
susceptibility (Gonzalez-Juarrero et al., 2005). Measurement of chemokines such as CCL5 
could provide more information on how GM-CSF influences T cell recruitment.  
 -Chapter 4: Evaluating the importance of GM-CSF during primary Mtb infection-  
 
 186 
 
Although the numbers of total CD4+ T cells were slightly decreased at day 21 post infection in 
resistant C57BL/6 mice treated with αGM-CSF, equivalent percentages and number of CD4+ T 
cells produced IFNγ at days 21 and 28 post infection in resistant mice, and no IL-17A 
production was detected under any condition. This contrasts with the GM-CSF knock mice 
which display lower numbers of IFNγ producing CD4+ T cells at day 21 post infection 
(Gonzalez-Juarrero et al., 2005). Although IFNγ is crucial for the immune response to Mtb 
infection (Cooper et al., 1993; Flynn et al., 1993), CD4+ T cells can produce other factors such 
as TNFα, which is also crucial for control of Mtb infection (Bean et al., 1999; Flynn et al., 
1995a). It is possible that GM-CSF neutralisation is impacting the production of another factor 
such as TNFα from CD4+ T cells that could impact the outcome of infection. In contrast to 
CD4+ T cells, IFNγ production by CD8+ T cells was reduced at day 28 post infection by αGM-
CSF treatment, although, very few CD8+ T cell produced IFNγ during Mtb infection in isotype 
control treated mice, and it is likely that CD4+ T cells are the major source. Thus this small 
decrease in CD8+ T cell derived IFNγ may not impact the outcome of infection. However, CD8+ 
T cells can also be cytotoxic and lyse target cells. Indeed perforin expression is required for 
their capacity to protect against Mtb infection when adoptively transferred (Woodworth et al., 
2008). A possibility is that this function of CD8+ T cells is impaired in the absence of GM-CSF 
which would require further investigation in future studies.  
 
In resistant C57BL/6 mice, in addition to lower total γδ T cell numbers in the lung, we also 
observed a decrease in γδ T cell derived IL-17 at day 21 post infection. Although the role of IL-
17 in primary Mtb infection is unclear, IL-17 is suggested to be required for the formation of 
granulomas following BCG infection and for localisation of the T cell response within the 
granulomas through CXCL13 induction following infection with hyper-virulent HN878 (Gopal 
et al., 2014). Thus it is possible that lower IL-17 production in mice treated with αGM-CSF 
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could be detrimental to early granuloma formation and/or detrimental to the localisation of T 
cells within the granuloma contributing to increased bacterial loads. Thus although GM-CSF 
does not appear to influence the functions of T cells we have assessed it may impact their ability 
to localise appropriately, impacting control of bacterial load. Appropriate localisation could be 
important given recent data showing direct recognition of infected cells by CD4+ T cells is 
required for control of bacterial growth (Srivastava and Ernst, 2013).  
 
In contrast to resistant C57BL/6 mice, we did not detect an impact of GM-CSF neutralisation on 
the presence of T cell populations in the lung in susceptible CBA/J mice. Furthermore we did 
not find any effect of αGM-CSF treatment on cytokine production by CD4+, CD8+ or γδ T cell 
populations at any time point assessed in susceptible CBA/J mice. The reasons for these 
differences are unclear. It is known that CBA/J mice have defects in the ability to upregulate 
adhesion molecules on T cells, which impacts the recruitment of lymphocytes to the lung, 
leading to a delayed response (Gruppo et al., 2002; Turner et al., 2001). Perhaps, in the context 
of a slower adaptive immune response in CBA/J mice, the transient effect of GM-CSF 
neutralisation to delay T cell recruitment observed in resistant C57BL/6 mice may not be 
evident. Alternatively, the kinetics of a delay in T cell recruitment may differ in susceptible 
mice, with an intermediate time point, between day 21 and 28, being required to identify such 
an effect. However, it is unclear whether such transient, small differences in T cell numbers in 
resistant mice will impact the outcome of infection. 
 
4.4.3 GM-CSF neutralisation impacts myeloid populations throughout Mtb infection 
 
As discussed above only small and transient defects in the adaptive immune response in 
resistant C57BL/6 mice were identified and no such defects were evident in susceptible CBA/J 
mice. These results in isolation are unlikely to explain the increased bacterial loads observed 
throughout infection in resistant mice treated with αGM-CSF and do not explain the increased 
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bacterial loads in susceptible mice treated with αGM-CSF. However, in both resistant and 
susceptible mouse strains treated with αGM-CSF, the increase in bacterial load was not evident 
until after the onset of adaptive immunity. This could suggest that there is a defect in the 
interaction between the adaptive response and myeloid populations leading to a defect in their 
activation and thus restriction of bacterial growth. Furthermore, as GM-CSF deficient mice 
displayed differences in myeloid populations during Mtb infection (Gonzalez-Juarrero et al., 
2005) we assessed how GM-CSF neutralisation during infection impacted myeloid populations 
in the lung. 
 
4.4.3.1 GM-CSF neutralisation decreases CD11c+ CD11blo alveolar macrophages during Mtb 
infection and in the steady-state 
During Mtb infection we found a dramatic and sustained decrease in the presence of alveolar 
macrophages in resistant C57BL/6 mice throughout Mtb infection when mice were treated with 
αGM-CSF. In susceptible mice, this decrease was not evident until day 55 post infection. It is 
possible that the timing of a decrease in alveolar macrophages could contribute to the kinetics of 
increased bacterial load in in mice treated with αGM-CSF. Indeed, in resistant C57BL/6 mice 
increased bacterial load in mice treated with αGM-CSF was observed earlier than in CBA/J 
mice and this was reflected in the decrease in alveolar macrophages. In resistant mice, alveolar 
macrophages decreased in αGM-CSF treated mice prior to the detection of an increase in 
bacterial load. Assessment of alveolar macrophage levels in susceptible mice after day 28 but 
prior to day 41 (when we first observe an increase in bacterial load) will provide further insight 
into the correlation between alveolar macrophages and Mtb bacterial loads. A decrease in 
alveolar macrophages could result from the requirement for GM-CSF for maintenance of 
alveolar macrophages in the steady state as indicated by our results neutralising GM-CSF in 
naïve mice and published literature (Hashimoto et al., 2013). This requirement could be 
exacerbated during infection due to death of infected cells and the need to replenish the 
population.  
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The functional consequence of a decrease in alveolar macrophages is unclear. A study depleting 
alveolar macrophages prior to Mtb infection, using clodronate containing liposomes suggested 
that alveolar macrophages were detrimental to control of infection, although granuloma 
formation was impaired (Leemans et al., 2001). However it has subsequently been shown that 
treatment with clodronate recruits DCs to the lung and thus confounds interpretation of these 
results (Srivastava et al., 2014). Alveolar macrophages were decreased in GM-CSF deficient 
mice during Mtb infection and impaired granuloma formation was observed (Gonzalez-Juarrero 
et al., 2005). Assessment of granuloma structure in mice treated with αGM-CSF may provide 
further insight into the consequence of reduced alveolar macrophages we observed in αGM-
CSF treated mice. 
 
4.4.3.2 Could GM-CSF neutralisation impact the functional capacity of macrophages leading to 
increased in Mtb bacterial loads? 
As well as influencing the differentiation and maintenance of alveolar macrophages, GM-CSF 
can impact function of macrophage populations (Fleetwood et al., 2007; Hamilton, 2008; 
Shibata et al., 2001). Such functional defects could contribute to the enhanced bacterial load 
observed when GM-CSF is neutralised throughout infection in both C57BL/6 and CBA/J mice. 
Indeed, in vitro GM-CSF is described to directly restrict mycobacterial growth in both human 
(Denis and Ghadirian, 1990) and mouse macrophages, possibly through increased 
phagolysosome fusion (Pasula et al., 2015; Rothchild et al., 2014). In addition, studies using 
GM-CSF deficient mice have shown that alveolar macrophage function is impaired in response 
to Pneumocysitis carinii (Paine et al., 2000), Pseudomonas aeruginosa (Ballinger et al., 2006) 
and group B streptococcal infection (LeVine et al., 1999), resulting in increased susceptibility to 
these infections. In vitro, alveolar macrophages isolated from GM-CSF deficient mice display 
impaired killing of E.coli and group B Streptococcus (Shibata et al., 2001). GM-CSF treatment 
of macrophages can also restrict Histoplasma capsulatum growth through sequestration of Zn2+ 
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to the Golgi and superoxide production (Subramanian Vignesh et al., 2013). Thus assessment of 
macrophage function following GM-CSF neutralisation, for example through assessing 
expression of iNOS, will provide further information regarding how GM-CSF influences 
macrophage function in vivo. 
 
In addition to influencing intracellular killing by macrophages, GM-CSF is reported to 
influence cytokine production. Indeed pre-treatment of macrophages with GM-CSF increases 
their production of TNFα in response to the TLR-4 ligand LPS, or the TLR-2 ligand Pam3CSK4 
(Fleetwood et al., 2007; Heidenreich et al., 1989; Sorgi et al., 2012). Investigation of TNFα 
levels in the lungs of mice treated with αGM-CSF as well as assessment of how GM-CSF 
affects cytokine production by macrophages in response to Mtb infection, will provide insight 
into the impact of GM-CSF upon cytokine production during Mtb infection. 
 
4.4.3.3 GM-CSF neutralisation leads to a small increase in the number of neutrophils present 
but could it impact their function? 
In both resistant and susceptible mice there was a small increase in the number of neutrophils 
present at day 21 post infection in mice treated with αGM-CSF. This increase was not sustained 
throughout infection in susceptible CBA/J mice. The role of neutrophils during Mtb infection is 
unclear (Lowe et al., 2012). Increased numbers of neutrophils have been linked with 
susceptibility to Mtb infection, as suggested by studies using susceptible mouse strains 
(Eruslanov et al., 2005; Marzo et al., 2014) or mice deficient in CARD9 or mir-223 (Dorhoi et 
al., 2010; Dorhoi et al., 2013). However, in these scenarios where neutrophils correlate with 
susceptibility, there are large increases in the numbers of neutrophils present, which is not what 
is observed when GM-CSF is neutralised. Neutrophils are reported to have the capacity to 
restrict bacterial growth (Yang et al., 2012). Thus increased numbers of neutrophils could 
reflect an attempt to control bacterial replication. However, neutrophils from GM-CSF deficient 
mice and patients with PAP display defects in their functional capacity to restrict bacterial 
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growth (Uchida et al., 2007). Dysfunction of neutrophils in the absence of GM-CSF, rather than 
a dramatic change in their abundance, could contribute to increased susceptibility to Mtb. 
 
4.4.3.4 GM-CSF neutralisation does not impact activation status of CD11b+ CD11c+ DCs 
GM-CSF can enhance antigen presenting capabilities of APCs (Min et al., 2010; Zhan et al., 
2012). Indeed recombinant BCG strains expressing GM-CSF increase APC numbers and 
activation, as measured by CD80 and CD86 expression, in draining lymph nodes. This 
increased activation was suggested to lead to increased induction of IFNγ producing T cells 
(Ryan et al., 2007). However, based on expression of MHC class II and the co-stimulatory 
molecule CD86, we did not find evidence to suggest that GM-CSF neutralisation impacted DC 
function during Mtb infection. This is in keeping with little or no change in the adaptive 
immune response that we observed in resistant and susceptible mice respectively.  
 
4.4.6 What is the source of GM-CSF during Mtb infection? 
 
An outstanding question from our investigation is what the cellular source(s) of GM-CSF are 
during Mtb infection. In primary infection we detected very low percentages and numbers of 
GM-CSF producing CD4+ T cells in susceptible or resistant mouse strains. Multiple cell types 
have been reported to have the capacity to produce GM-CSF including myeloid cells, 
pneumocytes, NK cells and other ILCs (Daussy et al., 2014; Gasson, 1991; Moro et al., 2010; 
Mortha et al., 2014; Robinette et al., 2015; Sojka et al., 2014). During Mtb infection NKT cells 
have been found to produce GM-CSF, although whether there are other sources was not 
addressed (Rothchild et al., 2014). Further investigation of the source and timing of GM-CSF in 
resistant and susceptible mouse strains during Mtb infection could provide further insights into 
when and how this cytokine is important during Mtb infection. 
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Overall we show that GM-CSF neutralisation is detrimental to control of Mtb bacterial load in 
resistant and susceptible mouse strains. Increased Mtb bacterial loads were observed after the 
onset of adaptive immunity in both resistant and susceptible mouse strains, although no major 
perturbation in the adaptive immune response was observed. GM-CSF neutralisation led to a 
substantial decrease in CD11c+ CD11blo alveolar macrophages in both resistant and susceptible 
mice, which could have important consequence for granuloma structure and control of infection. 
We suggest that GM-CSF impacts the activation of myeloid populations following the onset of 
adaptive immunity and their ability to restrict bacterial growth, potentially impacting their 
survival. Further investigation is necessary to provide insight into the mechanism by which 
GM-CSF is protective during Mtb infection. 
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Figure 4.1 GM-CSF is protective in the primary immune response to Mtb infection in 
resistant and susceptible mice 
 
Outline of experiment (A). C57BL/6 and CBA/J mice were i.p. injected with 1mg anti-
GM-CSF (αGM-CSF) or Isotype (ISO) control the day prior to infection with approx. 
100-200 CFU of the Mtb strain H37Rv, via aerosol route. Mice then received twice 
weekly i.p. injections of aGM-CSF or ISO. Mice were sacrificed at days 21, 28, 41 
(CBA/J only) and 55 post infection. Lung homogenates were serially diluted and plated 
to determine bacterial load in C57BL/6 mice (B) and CBA/J mice (C). Graphs show 
mean ± SD. p=0.07, *p<0.5, ***p<0.001, ****p<0.0001 by student’s unpaired t-test. 
Data representative of two independent experiments.  
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Figure 4.2 GM-CSF neutralisation during Mtb infection leads to lower numbers of T 
cells in the lung early post infection in resistant C57BL/6 mice 
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C57BL/6 mice were infected and treated with αGM-CSF or ISO as shown in Figure 4.1. 
Mice were sacrificed at day 21 and 28 post infection. Lungs were homogenized by 
passage through a 70µm filter. Single cell suspensions were stained with the following 
antibodies to assess percentages and calculate numbers of lymphoid populations by 
flow cytometry: γδ TCR FITC, Thy1.2 PECy7, CD4 e450, CD8 v500 and CD3 APC. 
Percentage and number of CD4+ T cells (defined as CD3+ Thy1.2+ CD4+) at day 21 and 
28 post infection (A). Percentage and number of CD8+ T cells (defined as CD3+ 
Thy1.2+ CD8+) at day 21 and 28 post infection (B). Percentage and number of γδ T cells 
(defined as CD3+ Thy1.2+ CD4- CD8- γδTCR+ at day 21 and 28 post infection (C). Data 
pooled from 2 (d28) or 3 (d21) independent experiments. 10-17 mice per group. Graphs 
show individual mice with mean ± SD. ns – not significant *p<0.05, **p<0.01 by 
unpaired student’s t-test. 
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Figure 4.3 GM-CSF neutralisation during Mtb infection does not impact T cell 
populations in the lung in susceptible CBA/J mice. 
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CBA/J mice were infected and treated with αGM-CSF or ISO as shown in Figure 4.1. 
Mice were sacrificed at day 21 and 28 post infection. Lungs were homogenized by 
passage through a 70µm filter. Single cell suspensions were stained with the following 
antibodies to assess percentages and calculate numbers of lymphoid populations by 
flow cytometry: γδ TCR FITC, Thy1.2 PECy7, CD4 e450, CD8 v500 and CD3 APC. 
Percentage and number of CD4+ T cells (defined as CD3+ Thy1.2+ CD4+) at day 21 and 
28 post infection (A). Percentage and number of CD8+ T cells (defined as CD3+ 
Thy1.2+ CD8+) at day 21 and 28 post infection (B). Percentage and number of γδ T cells 
(defined as CD3+ Thy1.2+ CD4- CD8- γδTCR+ at day 21 and 28 post infection (C). Data 
pooled from 2 independent experiments. 7-10 mice per group. Graphs show individual 
mice with mean ± SD. ns – not significant by unpaired student’s t-test. 
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Figure 4.4 GM-CSF neutralisation during Mtb infection does not impact IFNγ or IL-
17 production by CD4+ T cells in resistant C57BL/6 mice. 
 
C57BL/6 mice were infected and treated with αGM-CSF or ISO as shown in Figure 4.1. 
Mice were sacrificed at day 21 and 28 post infection. Lungs were homogenized by 
passage through a 70µm filter. 1x106 cells were restimulated with 20µg PPD and 2µg 
αCD28 mAb for 16h before the addition of BFA for a further 4h. Cells were then 
harvested and stained with the following to assess cytokine production: γδ TCR FITC, 
GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, IFNγ e450, CD4 v500, IL-17A APC, 
CD3 APCe780. CD4+ T cells were identified as CD3+ Thy1.2+ CD4+. Representative 
flow cytometry plots from individual mice at day 21 or 28 post infection are shown (A). 
Percentage and number of cytokine producing CD4+ T cells at day 21 or 28 post 
infection (B). Data pooled from 2 (d28) or 3 (d21) independent experiments. 9-15 mice 
per group. Graphs show individual mice with mean ± SD.   
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Figure 4.5 GM-CSF neutralisation during Mtb infection does not impact IFNγ or IL-
17 production by CD4+ T cells in susceptible CBA/J mice 
 
CBA/J mice were infected and treated with αGM-CSF or ISO as shown in Figure 4.1. 
Mice were sacrificed at day 21 and 28 post infection. Lungs were homogenized by 
passage through a 70µm filter. 1x106 cells were restimulated with 20µg PPD and 2µg 
αCD28 mAb for 16h before the addition of BFA for a further 4h. Cells were then 
harvested and stained with the following to assess cytokine production: γδ TCR FITC, 
GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, IFNγ e450, CD4 v500, IL-17A APC, 
CD3 APCe780. CD4+ T cells were identified as CD3+ Thy1.2+ CD4+. Representative 
flow cytometry plots from individual mice at day 21 or 28 post infection are shown (A). 
Percentage and number of cytokine producing CD4+ T cells at day 21 or 28 post 
infection (B). Graphs show individual mice with mean ± SD. Data pooled from 2 
independent experiments. 7-10 mice per group. Graphs show individual mice with mean 
± SD.   
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Figure 4.6 GM-CSF producing CD4+ T cells are barely detectable in the lung during 
primary Mtb infection in resistant C57BL/6 or susceptible CBA/J mice 
 
C57BL/6 and CBA/J mice were infected and treated with αGM-CSF or ISO as shown 
in Figure 4.1. Mice were sacrificed at day 21 and 28 post infection. Lungs were 
homogenized by passage through a 70µm filter. 1x106 cells were restimulated with 
20µg PPD and 2µg αCD28 mAb for 16h before the addition of BFA for a further 4h. 
Cells were then harvested and stained with the following to assess cytokine production: 
γδ TCR FITC, GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, IFNγ e450, CD4 v500, 
IL-17A APC, CD3 APCe780. CD4+ T cells were identified as CD3+ Thy1.2+ CD4+. 
Representative flow cytometry plots from individual mice at day 21 or 28 post infection 
are shown (A). Percentage and number of cytokine producing CD4+ T cells at day 21 or 
28 post infection (B). Data pooled from 2 (C57BL/6 d28, CBA/J d21, d28) or 3 
(C57BL/6 d21) independent experiments. 7-15 mice per group. Graphs show individual 
mice with mean ± SD.   
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Figure 4.7 GM-CSF neutralisation during Mtb infection decreases IFNγ production 
by CD8+ T cells in resistant C57BL/6 mice 
 
C57BL/6 mice were infected and treated with αGM-CSF or ISO as shown in Figure 4.1. 
Mice were sacrificed at day 21 and 28 post infection. Lungs were homogenized by 
passage through a 70µm filter. 1x106 cells were restimulated with 20µg PPD and 2µg 
αCD28 mAb for 16h before the addition of BFA for a further 4h. Cells were then 
harvested and stained with the following to assess cytokine production: γδ TCR FITC, 
GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, IFNγ e450, CD4 v500, IL-17A APC, 
CD3 APCe780. CD8+ T cells were identified as CD3+ Thy1.2+ CD8+. Representative 
flow cytometry plots from individual mice at day 21 or 28 post infection are shown (A). 
Percentage and number of cytokine producing CD8+ T cells at day 21 or 28 post 
infection (B). Data pooled from 2 (d28) or 3 (d21) independent experiments. 9-15 mice 
per group. Graphs show individual mice with mean ± SD. ns – not significant *p<0.05, 
**p<0.01 by unpaired student’s t-test.  
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Figure 4.8 GM-CSF neutralisation during Mtb infection does not impact IFNγ or IL-
17 production by CD8+ T cells in susceptible CBA/J mice 
 
CBA/J mice were infected and treated with αGM-CSF or ISO as shown in Figure 4.1. 
Mice were sacrificed at day 21 and 28 post infection. Lungs were homogenized by 
passage through a 70µm filter. 1x106 cells were restimulated with 20µg PPD and 2µg 
αCD28 mAb for 16h before the addition of BFA for a further 4h. Cells were then 
harvested and stained with the following to assess cytokine production: γδ TCR FITC, 
GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, IFNγ e450, CD4 v500, IL-17A APC, 
CD3 APCe780. CD8+ T cells were identified as CD3+ Thy1.2+ CD8+. Representative 
flow cytometry plots from individual mice at day 21 or 28 post infection are shown (A). 
Percentage and number of cytokine producing CD8+ T cells at day 21 or 28 post 
infection (B). Graphs show individual mice with mean ± SD. Data pooled from 2 
independent experiments. 7-10 mice per group. Graphs show individual mice with mean 
± SD  
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Figure 4.9 GM-CSF neutralisation during Mtb infection decreases early IL-17 
production by γδ T cells in resistant C57BL/6 mice  
 
C57BL/6 mice were infected and treated with αGM-CSF or ISO as shown in Figure 4.1. 
Mice were sacrificed at day 21 and 28 post infection. Lungs were homogenized by 
passage through a 70µm filter. 1x106 cells were restimulated with 20µg PPD and 2µg 
αCD28 mAb for 16h before the addition of BFA for a further 4h. Cells were then 
harvested and stained with the following to assess cytokine production: γδ TCR FITC, 
GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, IFNγ e450, CD4 v500, IL-17A APC, 
CD3 APCe780. γδ T cells were identified as CD3+ Thy1.2+ CD4- CD8- γδ TCR+. 
Representative flow cytometry plots from individual mice at day 21 or 28 post infection 
are shown (A). Percentage and number of cytokine producing γδ T cells at day 21 or 28 
post infection (B). Data pooled from 2 (d28) or 3 (d21) independent experiments. 9-15 
mice per group. Graphs show individual mice with mean ± SD. ns – not significant 
p=0.051, *p<0.05 by unpaired student’s t-test.  
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Figure 4.10 GM-CSF neutralisation during Mtb infection does not impact IFNγ or 
IL-17 production by γδ T cells in susceptible CBA/J mice 
 
CBA/J mice were infected and treated with αGM-CSF or ISO as shown in Figure 4.1. 
Mice were sacrificed at day 21 and 28 post infection. Lungs were homogenized by 
passage through a 70µm filter. 1x106 cells were restimulated with 20µg PPD and 2µg 
αCD28 mAb for 16h before the addition of BFA for a further 4h. Cells were then 
harvested and stained with the following to assess cytokine production: γδ TCR FITC, 
GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, IFNγ e450, CD4 v500, IL-17A APC, 
CD3 APCe780. γδ T cells were identified as CD3+ Thy1.2+ CD4- CD8- γδ TCR+. 
Representative flow cytometry plots from individual mice at day 21 or 28 post infection 
are shown (A). Percentage and number of cytokine producing γδ T cells at day 21 or 28 
post infection (B). Graphs show individual mice with mean ± SD. Data pooled from 2 
independent experiments. 7-10 mice per group. Graphs show individual mice with mean 
± SD.   
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Figure 4.11 GM-CSF is required in the steady state to maintain CD11c+ CD11b lo 
alveolar macrophage populations in resistant C57BL/6 mice 
 
C57BL/6 mice were i.p. injected with 1mg anti-GM-CSF (αGM-CSF) or Isotype (ISO). 
Mice then received twice weekly i.p. injections of aGM-CSF or ISO for 3 weeks or 4 
weeks. Mice were sacrificed after 3 or 4 weeks of antibody treatment. Lungs were 
harvested and digested with Collagenase D before being homogenized through passage 
through a 70µm filter. Cell suspensions were stained with the following to identify 
myeloid populations: Ly6G FITC, NK1.1 PE, Ly6C PerCP Cy5.5, CD11b PE Cy7, 
CD11c v450, F4/80 APC, MHC class II APCe780. Percentage and number of CD11c+ 
CD11b lo alveolar macrophages following 3 weeks (A) or 4 weeks (B) of antibody 
treatment. Data shown from one experiment, with 3 mice per group. Graphs show 
individual mice with mean ± SD. ns – not significant, *p<0.05 **p<0.01 by unpaired 
student’s t-test. 
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Figure 4.12 GM-CSF is required in the steady state to maintain CD11c+ CD11b lo 
alveolar macrophage populations in susceptible CBA/J mice 
 
CBA/J mice were i.p. injected with 1mg anti-GM-CSF (αGM-CSF) or Isotype (ISO). 
Mice then received twice weekly i.p. injections of aGM-CSF or ISO for 3 weeks or 4 
weeks. Mice were sacrificed after 3 or 4 weeks of antibody treatment. Lungs were 
harvested and digested with Collagenase D before being homogenized through passage 
through a 70µm filter. Cell suspensions were stained with the following to identify 
myeloid populations: Ly6G FITC, CD11c PE, Ly6C PerCP Cy5.5, CD11b PE Cy7, 
CD86 Brilliant Violet 421, F4/80 APC, MHC class II APCe780. Percentage and 
number of CD11c+ CD11b lo alveolar macrophages following 3 weeks (A) or 4 weeks 
(B) of antibody treatment. Data shown from one experiment, with 5 mice per group. 
Graphs show individual mice with mean ± SD. ns – not significant, *p<0.05 by 
unpaired student’s t-test. 
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Figure 4.13 Significant early decrease in CD11c+ CD11b alveolar macrophage 
populations with GM-CSF neutralisation during Mtb infection in resistant C57BL/6 
mice 
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C57BL/6 mice were infected and treated with αGM-CSF or ISO as shown in Figure 4.1. 
Mice were sacrificed at day 21, 28 and 55 post infection. Lungs were homogenized by 
passage through a 70µm filter. Single cell suspensions were stained with the following 
antibodies to assess percentages and calculate numbers of myeloid populations by flow 
cytometry: Ly6G FITC, CD11c PE, Ly6C PerCP Cy5.5, CD11b PE Cy7, CD86 
Brilliant Violet 421, CD8 v500, F4/80 APC, MHC class II APCe780. Percentage and 
number of neutrophils (defined as CD11b+ Ly6G+) at day 21, 28 and 55 post infection 
(A). Percentage and number of monocytes (defined as CD11b+ Ly6G- Ly6C hi) at day 
21, 28 and 55 post infection (B). Percentage and number of CD11c+ CD11b lo alveolar 
macrophages (defined as CD11c+ CD11b lo Ly6G-) at day 21, 28 and 55 post infection 
(C). Data pooled from 2 (d28, d55) or 3 (d21) independent experiments. 10-15 mice per 
group. Graphs show individual mice with mean ± SD. ns – not significant *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 by unpaired student’s t-test. 
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Figure 4.14 GM-CSF neutralisation leads to an early decrease numbers of CD11b+ 
CD11c+ DCs in the lung during Mtb infection in resistant C57BL/6 mice 
 
C57BL/6 mice were infected and treated with αGM-CSF or ISO as shown in Figure 4.1. 
Mice were sacrificed at day 21, 28 and 55 post infection. Lungs were homogenized by 
passage through a 70µm filter. Single cell suspensions were stained with the following 
antibodies to assess percentages and calculate numbers of myeloid populations by flow 
cytometry: Ly6G FITC, CD11c PE, Ly6C PerCP Cy5.5, CD11b PE Cy7, CD86 
Brilliant Violet 421, CD8 v500, F4/80 APC, MHC class II APCe780. Percentage and 
number of CD11b+ CD11c+ DCs (defined as Ly6G- CD11b+ CD11c+) at day 21, 28 and 
55 post infection (A). Mean Fluorescence Intensity (MFI) for MHC class II (MHC II) at 
day 21, 28 and 55 post infection (B) MFI for CD86 day 21, 28 and 55 post infection (C) 
Percentage and number graphs (A) shown data pooled from 2 (d28, d55) or 3 (d21) 
independent experiments with 10-15 mice per group. (B) and (C) graphs representative 
of 2 (d28, d55) or 3 (d21) independent experiments with 5-7 mice per group. Graphs 
show values for individual mice with mean ± SD. ns – not significant p=0.055, *p<0.05, 
by unpaired student’s t-test. 
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Figure 4.15 Significant late decrease in CD11c+ CD11b alveolar macrophage 
populations with GM-CSF neutralisation during Mtb infection in susceptible CBA/J 
mice 
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CBA/J mice were infected and treated with αGM-CSF or ISO as shown in Figure 4.1. Mice 
were sacrificed at day 21, 28 and 55 post infection. Lungs were homogenized by passage 
through a 70µm filter. Single cell suspensions were stained with the following antibodies to 
assess percentages and calculate numbers of myeloid populations by flow cytometry: Ly6G 
FITC, CD11c PE, Ly6C PerCP Cy5.5, CD11b PE Cy7, CD86 Brilliant Violet 421, CD8 v500, 
F4/80 APC, MHC class II APCe780. Percentage and number of neutrophils (defined as CD11b+ 
Ly6G+) at day 21, 28 and 55 post infection (A). Percentage and number of monocytes (defined 
as CD11b+ Ly6G- Ly6C hi) at day 21, 28 and 55 post infection (B). Percentage and number of 
CD11c+ CD11blo alveolar macrophages (defined as CD11c+ CD11blo Ly6G-) at day 21, 28 and 
55 post infection (C). Data pooled from 2 independent experiments. 9-10 mice per group. 
Graphs show individual mice with mean ± SD. ns – not significant *p<0.05 by unpaired 
student’s t-test. 
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Figure 4.16 GM-CSF neutralisation leads to a late increase in CD11b+ CD11c+ DC 
populations in susceptible CBA/J mice  
 
CBA/J mice were infected and treated with αGM-CSF or ISO as shown in Figure 4.1. Mice 
were sacrificed at day 21, 28 and 55 post infection. Lungs were homogenized by passage 
through a 70µm filter. Single cell suspensions were stained with the following antibodies to 
assess percentages and calculate numbers of myeloid populations by flow cytometry: Ly6G 
FITC, CD11c PE, Ly6C PerCP Cy5.5, CD11b PE Cy7, CD86 Brilliant Violet 421, CD8 v500, 
F4/80 APC, MHC class II APCe780. Percentage and number of CD11b+ CD11c+ DCs (defined 
as Ly6G- CD11b+ CD11c+) at day 21, 28 and 55 post infection (A). Mean Fluorescence 
Intensity (MFI) for MHC class II (MHC II) at day 21, 28 and 55 post infection (B) MFI for 
CD86 day 21, 28 and 55 post infection (C) Percentage and number graphs (A) shown data 
pooled from 2 independent experiments with 9-10 mice per group. (B) and (C) graphs 
representative of 2 independent experiments with 4-5 mice per group. Graphs show values for 
individual mice with mean ± SD. ns – not significant p=0.05, *p<0.05, by unpaired student’s t-
test. 
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5.1 Investigating the role of Innate Lymphoid Cells in the innate 
immune response to Mtb infection: aims of the investigation  
 
In order to determine whether innate lymphoid cells (ILCs) have a role in the innate response to 
Mtb infection we aimed to: 
 
1) Identify and phenotype ILCs upon infection with virulent H37Rv and hyper-virulent 
HN878 Mtb strains in Rag deficient mice and determine whether ILCs are a source of 
GM-CSF in Mtb infection  
 
2) Establish whether deficiency in ILC populations impacts the control of bacterial load 
during infection with hyper-virulent HN878 
 
3) Assess the impact of ILC deficiency upon myeloid populations during hyper-virulent 
HN878 infection 
 
4) Determine if GM-CSF is important in the innate immune response to hyper-virulent 
HN878 infection 
 
5.2 Background 
 ILCs are a recently described cell population that morphologically resemble lymphocytes and 
express cell surface molecule and cytokines classically associated T cell populations (reviewed 
in Serafini et al., 2015; Spits and Cupedo, 2012). However, in contrast to T cell populations, 
ILCs develop independently of RAG recombinase and lack rearranged antigen specific 
receptors (reviewed in Serafini et al., 2015). They are mainly localised at mucosal surfaces 
including the intestine and lung, where they are suitably placed to respond to invasion by 
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pathogens (reviewed in Artis and Spits, 2015). ILCs are activated, in an antigen independent 
fashion, by signals derived from myeloid populations and epithelial cells (reviewed in Artis and 
Spits, 2015). Several different sub-types of ILC have been defined based on the cytokines they 
produce in response to specific signals: ILC1s, including classical NK cells, which produce 
IFNγ, require the transcription factor T-bet, and respond to IL-12, IL-15 and IL-18, ILC2s 
which produce IL-5, IL-13, IL-9 and IL-4, require GATA3 for maintenance, and respond to IL-
2, IL-33, IL-25, TSLP, TL1A, and ILC3s which require RORγt, can express IL-17, IL-22 and in 
some cases IFNγ and respond to IL-23, IL-1β, TL1A and Retinoic Acid (reviewed in Artis and 
Spits, 2015; Sonnenberg and Artis, 2015; Spits et al., 2013; Walker et al., 2013). In addition to 
the cytokines described above ILC2s and ILC3s have also been found to produce GM-CSF 
(Moro et al., 2010; Mortha et al., 2014; Neill et al., 2010). Furthermore, “tissue resident” NK 
cells that express T-bet but lack Eomes expression have been described to produce GM-CSF 
(Daussy et al., 2014; Sojka et al., 2014) and an ILC1 population in the small intestine was 
recently described to express mRNA for GM-CSF (Robinette et al., 2015).  
 
All ILC subsets have been described to have roles during a variety of infections. In the lung 
ILC2s have been described to induce airway hypersensitivity following influenza infection 
(Chang et al., 2011). A beneficial role for ILC2s during influenza infection has also been 
described with ILC2-derived amphiregulin being required to restore epithelial integrity 
following infection (Monticelli et al., 2011). IL-13 production by ILC2s is required for 
immunity during Nippostrongylus brasiliensis infection (Moro et al., 2010; Neill et al., 2010; 
Price et al., 2010; Spits and Cupedo, 2012). Furthermore, ILC2s have been described to interact 
with T cells in the response to N. brasiliensis infection (Oliphant et al., 2014). This interaction 
was required for an optimal Th2 response and also the ability of ILCs to reduce worm burden 
when transferred into IL-13 deficient mice (Oliphant et al., 2014). ILC2s are also described to 
promote tissue repair in the lung stages of N. brasiliensis infection in an IL-9 dependent manner 
(Mohapatra et al., 2015; Turner et al., 2013). IL-22 producing ILC3s have been described in the 
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lung in response to Streptococcus pneumonia (Van Maele et al., 2014). In the gut, ILC3-derived 
IL-22 is also important in the response to Citrobacter rodentium (Qiu et al., 2012; Satoh-
Takayama et al., 2008; Sonnenberg et al., 2011). ILC3-derived IL-22 has also been shown to 
synergise with IFNλ (a type III IFN, also known as IL-28) for control of rotavirus infection 
(Hernandez et al., 2015). An IFNγ producing ILC subset derived from ILC3s has been shown to 
be important for mucus production upon Salmonella typhimurium infection but also to 
contribute to entercolitis (Klose et al., 2013). ILC1s (that are not conventional NK cells) have 
been described as source of IFNγ in response to Toxoplasma gondii infection (Klose et al., 
2014). NK cells have a long established role in the response to various viral infections and 
intracellular pathogens (Bancroft, 1993; Biron et al., 1999) and their potential role in Mtb 
infection will be discussed below.  
 
ILC2s are the main subset of ILCs present in the lung, although a small population of lung 
resident RORγt+ ILCs have been described (Van Maele et al., 2014), as have ILCs that are 
negative for the ILC2 marker T1/ST2 (Yagi et al., 2014). As ILCs are present in the lung, they 
are ideally placed to respond to Mtb infection. Furthermore, they possess the capacity to 
produce cytokines important in the immune response to Mtb including IFNγ (Cooper et al., 
1993; Flynn et al., 1993), IL-17 (Freches et al., 2013; Gopal et al., 2014; Umemura et al., 2007) 
and GM-CSF (Gonzalez-Juarrero et al., 2005; Szeliga et al., 2008).  
 
Currently, reports of ILCs in the mouse model of Mtb infection concern NK cells or “innate like 
lymphocytes” that could include NK cells and other ILCs. The O’Garra lab has previously 
shown in a vaccination model that “innate like lymphocytes” (expressing Thy1.2 but lacking 
expression of CD3, CD4, CD8 and the γδ TCR) produced IFNγ and IL-17 following Mtb 
challenge but these were not characterised further (Pitt et al., 2012b). In Rag deficient mice 
(Rag KO), which lack the RAG recombinase required for rearrangement of the antigen specific 
T and B lymphocytes, NK cell-derived IFNγ was suggested to be important to prevent 
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accumulation of granulocytes upon Mtb infection (Feng et al., 2006). The importance of NK 
cells was inferred through comparison of the Rag KO strain with the Rag KO common γ chain 
double knock out (Rag KO Il2rg KO) strain. The common γ chain forms part of the receptor for 
several cytokines including IL-2, IL-7 and IL-15 and is required for the development and 
maintenance of NK cells and other ILCs (reviewed in Serafini et al., 2015; Spits et al., 2013). 
As a result, Rag KO Il2rg KO mice lack not only NK cells, but all ILC populations, leaving the 
possibility that other ILC populations may also contribute to the increased susceptibility of Rag 
KO Il2rg KO mice to Mtb infection when compared to Rag KO mice.  
 
In wild-type mice (with a complete immune system) NK cells were identified to produce IFNγ 
and perforin upon Mtb infection (Junqueira-Kipnis et al., 2003). However, this study found NK 
cell depletion did not impact outcome of the infection, although, only early time points were 
assessed (Junqueira-Kipnis et al., 2003). Mice overexpressing IL-15 have been shown to display 
decreased bacterial loads during BCG infection, accompanied by expanded NK cell populations 
and increased IFNγ production by CD8+ T cells (Umemura et al., 2001). This increased 
resistance to infection was not seen when NK cells or CD8+ T cells were depleted, suggesting 
NK cells can contribute to immunity to BCG infection (Umemura et al., 2001). In addition, IL-
15 deficient mice, which lack NK cells and have defects in CD8+ T cell memory populations, 
show slightly higher bacterial loads in chronic infection and defects in cell recruitment to the 
lung (Lazarevic et al., 2005). Although not assessed, it is possible that a lack of NK cells 
contributed to the higher bacterial loads in chronic infection observed in these mice. Thus 
further investigation is needed to determine the role of ILCs during Mtb infection. 
 
Different strains of Mtb have different virulence and are described to induce different immune 
responses. Indeed, HN878 is a clinical isolate which belongs to the W-Beijing family 
(Sreevatsan et al., 1997) and is described to be more virulent than the lab adapted Mtb strain 
H37Rv, with mice displaying shorter survival times upon infection with HN878 compared to 
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H37Rv (Manca et al., 2001). HN878 is described to contain glycolipids that lead to low 
production of inflammatory cytokines by both human and mouse macrophages when compared 
to the lab-adapted Mtb strain H37Rv (Portevin et al., 2011; Reed et al., 2004). In addition, in the 
rabbit model of TB, HN878 induced an early inflammatory response with increased recruitment 
of innate cells in the lung in comparison to another clinical isolate CDC1551 (Subbian et al., 
2013). This was suggested to impact the outcome of infection (Subbian et al., 2013). Studies 
using multiple strains of Mtb have aided elucidation of factors involved in the response to Mtb 
infection. In the mouse model, HN878 infection failed to induce a lasting Th1 response and 
induced high levels of type I IFNs in comparison to other Mtb strains (Manca et al., 2001; 
Manca et al., 2005; Ordway et al., 2007). Subsequently, type I IFN induction was shown to 
contribute to the increased virulence of this Mtb strain (Manca et al., 2005), clarifying a 
detrimental role of type I IFNs in Mtb infection. These studies highlight the differences in the 
immune response between different strains of Mtb. Although use of H37Rv in immunological 
studies is beneficial to allow inter-lab comparison, certain factors in the immune response may 
be more evident upon infection with more virulent strains, as exemplified by type I IFNs in 
HN878 infection. Therefore assessment of the response of ILCs to both H37Rv and HN878 will 
aid our investigation and understanding of their role in Mtb infection. 
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5.3 Determining whether ILCs respond to Mtb infection 
In order to identify whether ILCs respond to Mtb infection we used two models of infection: 
infection with the hyper-virulent Mtb strain HN878 and infection with the virulent lab-adapted 
strain H37Rv both in Rag KO mice. Use of H37Rv allows us to assess the response of ILCs to a 
well established and commonly used strain of Mtb but use of HN878, a recent clinical isolate, is 
arguably a more clinically relevant isolate and may reveal aspects of the immune response not 
apparent during H37Rv infection. Rag KO mice lack the RAG recombinase required for 
rearrangement of the antigen specific T and B lymphocytes, resulting in absence of adaptive 
lymphocytes include T, B, NKT and γδ T cells. However, as ILCs do not require recombination 
of antigen specific receptors these populations are maintained in Rag KO mice. Use of the Rag 
KO mouse allowed us to assess the role of ILCs in T cell independent immunity to Mtb 
infection, which could be relevant in patients with defective T cells response such as in HIV 
infection (Feng et al., 2006) or in individuals suggested to clear or control infection without 
mounting an adaptive immune response (Young et al., 2009). Furthermore, as many of the 
factors required for ILC development are also required for T cell development, use of Rag KO 
mice allowed us to take a genetic approach to assess their function, which would not be possible 
in a wild-type model.  
 
5.3.1 Increase in T-bet positive ILCs upon H37Rv infection 
 
Rag KO mice were infected via the aerosol route with approximately 100 CFU of the lab-
adapted strain H37Rv. Lungs were then isolated at days 14, 21 and 25 post infection and 
digested with Collagenase D, as described in Materials and Methods. Flow cytometry was 
performed to identify ILC populations, with the gating strategy shown in Figure 5.1. The 
lineage cocktail (to exclude non ILCs) included CD49b (DX5), CD3, CD5, CD27, CD11b, 
CD11c, NK1.1, B220 and TCRβ and gates for CD127 (IL-7 receptor α), CD25 (IL-2 receptor α 
chain), T1/ST2 and T-bet were set using fluorescence minus one (FMO) or isotype controls 
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(Monticelli et al., 2011). ILCs (excluding NK cells) were defined as Lineage (Lin)- Thy1.2+ 
CD127+ CD25+ based on previous publications (Monticelli et al., 2011).  
 
We first determined how the percentage and number of the total ILC population, defined as Lin- 
Thy1.2+ CD127+ CD25+ changed over the course of infection (Figure 5.2). We found that there 
was no change in the total ILC population at d14 post infection. By day 21 post infection there 
was a small decrease in the percentage of ILCs as a percentage of total live cells (p<0.05 
compared to uninfected controls) but a small increase in their total number (p<0.05 compared to 
uninfected controls). This small increase in their number was also evident at day 25 post 
infection (p<0.05 compared to uninfected controls), although infection had no impact on the 
proportion of ILCs as a percentage of total live cells. 
 
We next phenotyped the ILCs further upon H37Rv infection. In the lung ILC2s are described to 
be the predominant ILC population, although a small population of T1/ST2 negative ILCs have 
also been described in the lung (Yagi et al., 2014), as have a small population of RORγt+ ILCs 
(Van Maele et al., 2014). We defined ILC2s as T1/ST2hi (as shown in gating strategy Figure 
5.1) based on previous publications (Monticelli et al., 2011; Spits et al., 2013).  
 
In addition to T1/ST2hi ILC2s, we identified a population of T1/ST2lo ILCs in the lung and 
assessed expression of RORγt and T-bet within this population. We could not detect RORγt 
expression in ILCs upon H37Rv infection (data not shown). We identified a population of T-bet 
expressing T1/ST2lo ILCs at day 21 post H37Rv infection (Figure 5.3, gates were set using a 
FMO control), with an increase in the percentage (p<0.01 compared to uninfected controls) and 
number (p<0.05 compared to uninfected controls) of T-bet+ ILCs. This increase in percentage 
and number T-bet expressing ILCs was also evident at day 25 post infection (Figure 5.3) 
(percentage p<0.05, number p<0.05 compared to uninfected controls).  
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5.3.2 ILCs produce IFNγ  but not GM-CSF in response to virulent H37Rv infection 
 
Having established that there is a change in the population of ILCs present in the lung upon Mtb 
infection we next assessed the ability of ILCs to produce cytokines in response to H37Rv 
infection. Intracellular cytokine staining was performed upon lung cell cultures from infected or 
uninfected mice, stimulated for 2 hours with PMA and Ionomycin in the presence of brefeldin 
A.  
 
ILCs were identified (defined as Lin- Thy1.2+ CD127+ CD25+) and the gates for cytokine 
production were again set using isotype controls (data not shown). Upon H37Rv infection 
cytokine production was undetectable at day 15 post infection (data not shown). We found that 
ILCs produced IFNγ at day 25 post infection but not at day 21 post infection (Figure 5.4). We 
observed increases in the percentage (d25 p<0.001 compared to uninfected controls) and 
number (d25 p<0.05 compared to uninfected controls) of IFNγ producing ILCs at day 25 post 
H37Rv infection. There was evidence of a trend towards GM-CSF production by ILCs at day 21 
and day 25 post infection, but this did not reach significance. We also assessed IL-17 
production by ILCs following H37Rv infection. IL-17 producing ILCs were undetectable at 
days 14, 21 and 25 post H37Rv infection (data not shown). 
 
As conventional NK cells could also be a source of both of IFNγ and GM-CSF (Biron et al., 
1999) and are present in the Rag KO mouse, we assessed whether these cells produced cytokine 
upon H37Rv infection. Lung cell cultures from infected or uninfected mice were stimulated for 
2h with PMA and Ionomycin in the presence of brefeldin A, as above and then intracellular 
cytokine staining was performed. We found that NK cells (defined as NK1.1+ DX5+) produce 
IFNγ but not GM-CSF upon H37Rv infection at day 21 and day 25 post H37Rv infection 
(Figure 5.5). Both the percentage of IFNγ producing NK cells (d21 p<0.01, d25 p<0.01 
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compared to uninfected controls) and the number (d21 p<0.05, d25 p<0.05 compared to 
uninfected controls) increased upon H37Rv infection.  
 
5.3.3 Increase in T-bet positive ILCs upon hyper-virulent HN878 infection  
 
We observed activation of ILCs upon H37Rv infection. However, as HN878 is a clinical isolate, 
it may better reflect the response to Mtb in a clinical setting. We were therefore interested in 
how ILCs respond to this Mtb strain and investigated whether ILCs responded to HN878 
infection in the same way as in H37Rv infection. 
 
Rag KO mice were infected via the aerosol route with approximately 100 CFU of hyper-virulent 
HN878, via the aerosol route. Lungs were then isolated at days 15, 21 and 25 post infection and 
digested with Collagenase D, as described above and in the materials and methods. Flow 
cytometry was performed to identify ILC populations, with the gating strategy shown in Figure 
5.1, and analysed as for H37Rv infection described above.  
 
We first assessed the impact of infection on the total ILC population (Figure 5.6). Upon hyper-
virulent HN878 infection the percentage of ILCs (as defined above), as a percentage of total live 
cells, in the lung remained the same at day 15 post infection but decreased from d21 post 
infection (p<0.001 compared to uninfected controls) and this decrease was maintained to day 25 
post infection (p<0.001 compared to uninfected controls). However, the overall number of ILCs 
did not change over the time points assessed, which may reflect changes in other cell 
populations. 
 
As for H37Rv infection, we next phenotyped the ILCs further upon HN878 infection. We 
defined ILC2s as T1/ST2hi (as discussed above and shown in gating strategy Figure 5.1). We 
identified a population of T1/ST2lo ILCs in the lung and assessed expression of T-bet and 
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RORγt in the T1/ST2lo population upon HN878 infection. We could not detect RORγt 
expression in ILCs upon HN878 infection as for H37Rv (data not shown). We did observe an 
increase in T-bet+ ILCs beginning at d15 post HN878 infection both in percentage (p< 0.01 
compared to uninfected controls) and number (p< 0.0001 compared to uninfected controls) 
(Figure 5.7, gates set using an FMO control,). The increase in T-bet+ ILCs was most evident at 
day 21 and day 25 post infection where there was a larger increase in the percentage (day 21 
p<0.0001, day 25 p<0.001 compared to uninfected controls) and number (day 21 p<0.0001, day 
25 p<0.001 compared to uninfected controls) of these ILCs in HN878 infected mice compared 
to uninfected controls.  
 
5.3.4 ILCs produce IFNγ  and GM-CSF in response to hyper-virulent HN878 infection 
 
Having identified a change in ILC populations present in the lung upon HN878 infection, we 
next assessed the ability of ILCs to produce cytokines in response to HN878 infection, as 
described above for H37Rv infection. Intracellular cytokine staining was performed on lung cell 
cultures from infected or uninfected mice, stimulated for 2 hours with PMA and Ionomycin in 
the presence of brefeldin A.  
 
Upon HN878 infection we found that ILCs (defined as Lin- Thy1.2+ CD127+ CD25+) produced 
IFNγ and GM-CSF at day 21 and day 25 post infection (Figure 5.8), whereas no cytokine 
production was detectable at day 15 post infection (data not shown). The gates for cytokine 
production were set using isotype controls (data not shown). We observed increases in the 
percentage (IFNγ d21 p<0.01, d25 p<0.001; GM-CSF d21 p<0.01, d25 p<0.01 compared to 
uninfected controls) and number (IFNγ d21 p<0.001, d25 p<0.01; GM-CSF d21 p<0.01, d25 
p<0.05 compared to uninfected controls) of cytokine producing ILCs upon HN878 infection. 
We also assessed IL-17 and IL-22 production by ILCs at day 21 and day 25 post infection. We 
did not observe IL-22 production at either time point (data not shown). Low levels of IL-17 
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producing ILCs were inconsistently observed at both day 21 and day 25 post HN878 infection 
(data not shown). 
 
Cytokine production by NK cells was also assessed upon HN878 infection as described for 
H37Rv infection. Following stimulation with PMA and Ionomycin for 2h in the presence of 
brefeldin A, intracellular cytokine staining was carried out. We found that NK cells (defined as 
NK1.1+ DX5+) produce IFNγ upon Mtb infection at day 21 (percentage p<0.01, number 
p<0.001) and also at day 25 post infection (percentage p<0.05, number p<0.05) (Figure 5.9). 
We did not observe production of GM-CSF at either time point by NK cells. However, GM-
CSF producing “tissue resident” NK cells that are NK1.1+ DX5- have been described in the liver 
(Daussy et al., 2014; Sojka et al., 2014). However, preliminary data suggests that NK1.1+ DX5- 
cells are not a source of GM-CSF (or IFNγ) during HN878 infection (data not shown) although 
this requires confirmation.  
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5.4 Assessing the functional significance of ILCs in the outcome of Mtb 
infection 
 
We found that ILCs respond to H37Rv and HN878 infection; however, the response of ILCs 
differed between the two Mtb strains. ILCs responded earlier and to a greater extent to HN878 
infection than to H37Rv infection. Furthermore, HN878 is a more clinically relevant Mtb strain. 
We therefore decided to assess their functional significance in the outcome of infection with 
HN878. 
 
In order to determine whether ILCs were important for the outcome of Mtb infection we took a 
genetic approach, utilising the dependence of ILCs on cytokines that signal via receptors 
containing the common γ chain (Il2rg). NK cells and some ILC1s are dependent upon IL-15 for 
development (Kennedy et al., 2000; Klose et al., 2014; Ranson et al., 2003; Vosshenrich et al., 
2005). Deficiency in response to this cytokine will lead to deficiency in NK cells and some 
ILC1s, whilst other ILC subsets are preserved, as they depend upon IL-7 for their development 
and/or maintenance (Fuchs et al., 2013; Moro et al., 2010; Satoh-Takayama et al., 2010; 
Serafini et al., 2015; Spits et al., 2013). We utilised the differential requirement of NK cells and 
other ILCs for IL-7 and IL-15 in order to assess the importance of IL-15 dependent and/or IL-7 
dependent ILCs in the response to HN878 infection. 
 
The ILC populations present in Rag KO, Rag KO IL-15 Receptor knock out (Rag KO Il-15r 
KO), Rag KO IL-7 knock out (Rag KO Il7 KO) and Rag KO Il2rg KO mice were assessed in 
the lungs of uninfected mice by flow cytometry and are shown in Figure 5.10 and summarised 
in Table 5.1. As expected Rag KO Il7 KO and Rag KO Il2rg KO retained a small population of 
Lin- Thy1.2+ cells but these were CD127 negative (Figure 5.10A). In contrast Rag KO Il15r 
KO mice retained an equivalent ILC population to that seen in the Rag KO mice (Figure 
5.10A). Rag KO Il-15r KO mice, along with Rag KO Il2rg KO mice lacked NK1.1+ cells, 
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which were retained in the Rag KO Il7 KO mice (Figure 5.10B). Although there appeared to be 
a decrease in the percentage of NK1.1+ NK cells in Rag KO Il7 KO mice (Figure 5.10B), this 
was inconsistent and their numbers were equivalent. 
 
Table 5.1 Summary of cell populations present and absent in mice used to determine a 
functional role for ILCs in Mtb infection 
 
 In order to assess whether IL-15 dependent ILCs and other ILCs had a role in Mtb infection, 
Rag KO mice were infected with HN878 alongside Rag KO Il15r KO and Rag KO Il2rg KO. 
Weight loss was assessed over the course of infection and the bacterial load in the lung was 
assessed at day 21 post infection. Bacterial loads in the lung at day 21 post infection were 
determined by serial dilutions as described in Materials and Methods and are shown in Figure 
5.11A. We found an increase in bacterial load at day 21 post infection in the Rag KO Il15r KO 
compared to the Rag KO (p<0.0001). The bacterial load was increased further in the Rag KO 
Il2rg KO compared to the Rag KO Il15r KO (p<0.01). This increase in bacterial load in the Rag 
KO Il15r KO and Rag KO Il2rg KO was accompanied by weight loss in both strains beginning 
after day 18 of infection (Figure 5.11B). However, such a pattern of weight loss was not 
observed in the Rag KO mouse (Figure 5.11B). 
 
Rag KO Il2rg KO mice are deficient for NK cells and all other ILCs (Figure 5.10, Table 5.1). 
In order to determine whether IL-7 dependent ILCs have a role in Mtb infection in the presence 
 Cell types present 
Strain T/B cells NK cells (NK1.1+) ILCs 
Rag KO No Yes Yes 
Rag KO Il7 KO No Yes No 
Rag KO Il15r KO No No Yes 
Rag KO Il2rg KO No No Yes 
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of NK cells and IL-15 dependent ILCs, we compared HN878 infection in the Rag KO and the 
Rag KO Il7 KO. At day 21 post infection we found a small decrease in the bacterial load in the 
lung in Rag KO Il7 KO compared to Rag KO mice (p<0.01) (Figure 5.12A). We reasoned that 
because disruption in early events in infection can potentially impact bacterial loads at later time 
points, the impact of ILC deficiency upon bacterial load may only be evident at a later time 
point. We therefore infected Rag KO and Rag KO Il7 KO mice with HN878 and assessed 
bacterial load at day 25 post infection. We found that on average over 5 independent 
experiments there was an increase in bacterial loads in the Rag KO Il7 KO compared to Rag KO 
mice at day 25 post-infection (p<0.01) (Figure 5.12A). However, this increased bacterial load 
data did show some variation between experiments as can be seen in the spread of bacterial load 
in the Rag KO Il7 KO mice in Figure 5.12A. We observed minimal differences in the pattern of 
weight loss over the course of infection (Figure 5.12B).  
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5.5 Deficiency in ILCs leads to increased recruitment of neutrophils to 
the lung upon hyper-virulent HN878 infection 
 
NK cells and ILCs produce IFNγ and/or GM-CSF in response to Mtb infection and we show 
that deficiency in IL-15 dependent and/or IL-7 dependent ILCs is detrimental to the outcome of 
infection. IFNγ and GM-CSF both activate macrophages to control bacterial growth (North and 
Jung, 2004; Pasula et al., 2015; Rothchild et al., 2014). Furthermore, IFNγ is also important for 
control of neutrophilia and the prevention of immunopathology (Desvignes et al., 2012; Feng et 
al., 2006; Nandi and Behar, 2011). Given that IFNγ and GM-CSF can influence myeloid 
populations, we next investigated the impact of IL-15 dependent and/or IL-7 dependent ILCs on 
the myeloid populations present upon HN878 infection.  
 
Rag KO, Rag KO Il15r KO and Rag KO Il2rg KO mice were infected with HN878 and myeloid 
populations were assessed at day 21 post infection by flow cytometry. At day 21 post HN878 
infection the percentage and number of neutrophils (defined as Ly6G+ CD11b+) present in the 
lung was increased in Rag KO Il15r KO compared to the Rag KO (percentage p<0.05, number 
p<0.05) and also in the Rag KO Il2rg KO compared to the Rag KO (percentage p<0.01, number 
p<0.001) as shown in Figure 5.13A. Also at day 21 post HN878 infection the percentage and 
number of CD11c+ CD11blo alveolar macrophages was lower in Rag KO Il15r KO compared to 
Rag KO (percentage p<0.01, number p<0.05) and also in the Rag KO Il2rg KO compared to 
Rag KO (percentage p<0.0001, number p<0.01) as shown in Figure 5.13B. In addition the 
percentage and number of CD11c+ CD11blo alveolar macrophages was lower in Rag KO Il2rg 
KO compared to Rag KO Il15r KO (percentage p<0.01, number p<0.01) as shown in Figure 
5.13B. 
  
Myeloid populations were also assessed by flow cytometry in the Rag KO and Rag KO Il7 KO 
25 days following HN878 infection. We found there was a very slight trend towards an increase 
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in the percentage of neutrophils (defined as above as Ly6G+ CD11b+) (Figure 5.14A) present in 
the lung in the Rag KO Il7 KO compared to the Rag KO but this was not significant. However, 
the number of neutrophils present in the lung in Rag KO Il7 KO was significantly increased 
compared to Rag KO (Figure 5.14A) (p<0.05). No significant differences in populations of 
CD11c+ CD11blo alveolar macrophages were observed (Figure 5.14B).  
 
Neutrophils have been linked to susceptibility to Mtb infection (Eruslanov et al., 2005; Keller et 
al., 2006; Marzo et al., 2014) and accumulation of neutrophils can contribute to 
immunopathology (Feng et al., 2006; Nandi and Behar, 2011). Given that we observed an 
increase in neutrophils upon HN878 infection in the Rag KO Il15r KO and Rag KO Il2rg KO, 
we investigated whether this was detrimental to control of infection and contributing to 
susceptibility of these strains of mice to Mtb infection. To address this we infected Rag KO, 
Rag KO Il15r KO and Rag KO Il2rg KO mice with HN878 and depleted neutrophils from day 
10 post infection using a monoclonal antibody against Ly6G (clone 1A8, isotype GL117). An 
outline of the experiment is shown in Figure 5.15A. Depletion of neutrophils increased the 
amount of weight loss following infection in all strains but most notably in Rag KO Il15r KO 
mice (Figure 5.15B). The weight loss was so pronounced in one Rag KO Il2rg KO treated with 
αLy6G, it was sacrificed before the end of the experiment.  
 
The bacterial load in the lungs was determined as described in Materials and Methods. 
Neutrophil depletion did not impact the bacterial load in the Rag KO mice (Figure 5.15C). In 
the Rag KO Il15r KO mice neutrophil depletion led to a decrease in bacterial load by 
approximately 0.65log10. In contrast, and somewhat surprisingly, in the Rag KO Il2rg KO mice 
neutrophil depletion did not impact the control of bacterial load.   
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5.6 GM-CSF is crucial to the immune response to HN878 infection 
5.6.1 GM-CSF is important to the innate immune response to HN878  
 
We identified ILCs as a source of GM-CSF upon HN878 infection. We therefore hypothesised 
that GM-CSF production by ILCs was important for their protective contribution to the immune 
response to HN878 infection. In order to test this we treated mice with a monoclonal antibody 
against GM-CSF (clone MP1-22E9) or an isotype control antibody (clone GL117) throughout 
infection in Rag KO and Rag KO Il7 KO mice (outline of experiment shown in Figure 5.16A).  
 
We found that GM-CSF had a protective role in the innate immune response to HN878 
infection as there was a dramatic increase in bacterial load at day 25 post infection in Rag KO 
mice treated with anti-GM-CSF mAb compared to isotype controls (Figure 5.16B, p<0.05). 
This increase in bacterial load surpassed that seen in the Rag KO Il7 KO. In Rag KO Il7 KO 
mice treated with anti-GM-CSF mAb we also observed an increase in bacterial load compared 
to isotype controls (Figure 5.16B p<0.05), suggesting additional cellular sources of GM-CSF.  
 
5.6.2 GM-CSF is crucial to the immune response to HN878 infection in a wild-type mouse 
 
In Chapter 4 we assessed the impact of GM-CSF neutralisation upon the outcome of H37Rv 
infection, however we did not assess GM-CSF neutralisation during hyper-virulent HN878 
infection. Given the dramatic increase in HN878 bacterial load in Rag KO mice treated with 
αGM-CSF mAb, we were interested to investigate the impact of GM-CSF neutralisation upon 
the outcome of HN878 infection in wild-type mice. In order to investigate this GM-CSF was 
neutralised throughout HN878 infection in intact Mtb resistant C57BL/6 mice. An outline of the 
experiment is shown in Figure 5.17A. The bacterial loads in the lung were increased 
dramatically when GM-CSF was neutralised from day 21 post infection onwards (Figure 
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5.17B). We assessed the populations of lymphocytes present in the lung upon infection using 
flow cytometry. At day 21 post infection there was a strong trend towards a decrease in the 
percentage and number of CD4+ T cells (defined as CD3+ Thy1.2+ CD4+) in those mice where 
GM-CSF had been neutralised (Figure 5.17C). At day 21 post infection the percentage and 
number of CD8+ T cells (define as CD3+ Thy1.2+ CD8+) was significantly lower in mice where 
GM-CSF had been neutralised (data not shown) but there was no effect on the presence of γδ T 
cells (defined as CD3+ Thy1.2+ CD4- CD8- γδ TCR+) (data not shown).  
 
Having found that GM-CSF was required for T cell recruitment to the lung upon HN878 
infection, we assessed the ability of CD4+ T cells to produce cytokines. At day 21 post 
infection, lung homogenates were stimulated with PPD for 16 hours before the addition of 
brefeldin A for a final 4 hours. Cells were then harvested and intracellular cytokine staining was 
performed to identify CD4+ T cell populations producing IFNγ and IL-17 (CD4+ T cells defined 
as above). Although there was a trend towards a lower CD4+ T cell population in the absence of 
GM-CSF there did not appear to be a defect in the ability of CD4+ T cells to produce IFNγ 
following restimulation as the percentage and number of IFNγ producing T cells were similar 
between those mice treated with anti-GM-CSF and the isotype controls (Figure 5.17D). 
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5.7 Discussion 
It is well established that a protective immune response to Mtb is dependent upon CD4+ T cells 
(Mogues et al., 2001; Saunders et al., 2002). However, the contribution of subsets of innate 
lymphocytes such as NK cells to the immune response is less well understood with conflicting 
reports of their importance in different immunological settings (Feng et al., 2006; Junqueira-
Kipnis et al., 2003). This, coupled with the recent description of other ILCs underlines the 
requirement for further study of these subsets. As the predominant ILC population in the lung 
are ILC2s it is also possible these cells could be detrimental to control of Mtb infection through 
promotion of a type 2 response. Alternatively ILCs could provide early sources of cytokines 
important in control of Mtb and also provide T cell independent protection.  
 
5.7.1 Differential response of ILCs to HN878 and H37Rv infection 
 
We have shown that ILCs respond to both hyper-virulent HN878 and also virulent H37Rv 
infection in Rag KO mice with a population of T-bet positive ILCs present in the lung upon Mtb 
infection. A T-bet positive ILC subset has not been previously described in the lung. However, 
a small population of RORγt+ ILCs have been described in the lung using RORγt reporter mice 
(Van Maele et al., 2014). In addition, a population of ILCs negative for T1/ST2 (an ILC2 
marker) were identified in the lung (Yagi et al., 2014). The T-bet+ ILCs we identified upon Mtb 
infection could derive from these previously described non-ILC2 (potentially RORγt+) 
populations in the lung. Indeed, a transition from an ILC3 phenotype (RORγt+) to an ILC1-like 
phenotype has been described in both mice and humans, where there is downregulation of 
RORγt and upregulation of T-bet (Bernink et al., 2015; Klose et al., 2013; Serafini et al., 2015; 
Vonarbourg et al., 2010). However, we were unable to detect RORγt expression in any ILC 
population in the lung in naïve or infected mice. Use of a RORγt reporter mouse would facilitate 
identification of ILCs expressing RORγt in the lung. It is possible that we were unable to detect 
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RORγt expression is that these cells are “ex ILC3s” and have downregulated RORγt such that 
they are RORγt lo/negative, and have upregulated T-bet allowing IFNγ expression, as has been 
described for NKp46+ CCR6- ILC3s in the gut (Klose et al., 2013; Vonarbourg et al., 2010). 
Assessment of the expression of NKp46 and CCR6 on the T-bet expressing cells as well as use 
of a RORγt fate reporter mouse would enable us to determine if the T-bet expressing ILCs 
observed originate from RORγt dependent ILC3s as has been previously described. 
Alternatively the T-bet expressing ILCs could represent ILC1s that have not derived from 
ILC3s (Klose et al., 2014). However, these cells are described to be CD27+ and NK1.1+, 
markers not expressed by the T-bet+ ILCs we identified (Klose et al., 2014; Serafini et al., 
2015).  
 
We found IFNγ and GM-CSF production by ILCs in response to HN878 infection from day 21 
post infection but only IFNγ in response to H37Rv at day 25 post infection. Both IFNγ and GM-
CSF are important for control of Mtb infection (Cooper et al., 1993; Flynn et al., 1993; 
Gonzalez-Juarrero et al., 2005; Szeliga et al., 2008), thus production of these cytokines by ILCs 
could contribute to protection against Mtb infection.  
 
The response of ILCs to Mtb infection differed depending on the infecting strain. The 
expression of T-bet was more pronounced in response to hyper-virulent HN878 infection than 
during virulent H37Rv infection and ILCs producing GM-CSF were only evident during HN878 
infection. Differences in the immune response to Mtb strains have been established (Subbian et 
al., 2013; Portevin et al., 2011; Reed et al., 2004; Manca et al., 2001; Manca et al., 2005; 
Ordway et al., 2007). In rabbits HN878 has been seen to induce an early granulocyte response 
when compared to another clinical isolate CDC1551, which was suggested to impact the 
subsequent outcome of infection (Subbian et al., 2013). Furthermore, HN878 induces higher 
levels of type I IFNs than other clinical isolates (Manca et al., 2001). It is possible that the 
differences in the immune responses induced between the two strains could explain the 
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differences in the level of T-bet expression, kinetics of IFNγ expression and also GM-CSF 
expression in ILCs that we report here. As ILCs can be activated by factors produced by 
myeloid populations (reviewed in Artis and Spits, 2015), the early increased granulocyte 
response in HN878 infection could contribute to the kinetics of cytokine production and the 
level of T-bet expression. Furthermore, the bacterial loads at the time points assessed are higher 
in HN878 infection compared to H37Rv infection (data not shown). Thus it is possible that the 
differences we observe in cytokine production between H37Rv and HN878 at the time points 
assessed, result from differences in bacterial loads at that time point. Assessment of the ILC 
response at a later time point in H37Rv infection may be more similar to that observed 
following HN878 infection but this remains to be assessed.  
 
5.7.2 NK cells and other ILCs are important for the innate response to Mtb infection 
 
Having identified that ILCs respond to Mtb infection in Rag KO mice we used a genetic 
approach to assess whether ILCs have a functional role in Mtb infection. Such an approach 
would not have been possible in the context of an adaptive response. We utilised the 
requirement of ILCs for cytokines that signal via the common γ chain. NK cells and NK1.1+ 
ILC1s are dependent upon IL-15 (Klose et al., 2014; Ranson et al., 2003) whereas other ILC 
subsets are dependent upon IL-7 (Moro et al., 2010; Satoh-Takayama et al., 2010; Serafini et 
al., 2015; Vonarbourg and Diefenbach, 2012). 
 
We show that Rag KO Il15r KO mice (lacking T, B and IL-15 dependent ILCs) are more 
susceptible to HN878 infection than Rag KO mice at day 21 post infection. Furthermore, we 
show that Rag KO Il2rg KO mice (lacking T, B, NK cells and all other ILCs) are more 
susceptible than Rag KO Il15r KO mice at day 21 post infection. Therefore we show that IL-15 
dependent ILCs are important for the innate control of Mtb infection, and can infer that other 
ILC populations also contribute to control which leads to the difference in susceptibility 
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between the Rag KO Il15r KO and Rag KO Il2rg KO. This result demonstrates a role for IL-15 
dependent ILCs in Mtb infection in Rag KO mice, along with IFNγ production by NK cells, and 
is in keeping with previous literature (Feng et al., 2006). However, our data also suggests an 
additional role for other ILC populations. However, in the context of an adaptive response, it 
has been shown that depletion of NK cells during Mtb infection does not impact the control of 
infection at day 21 post infection (Junqueira-Kipnis et al., 2003). A consideration is that the 
immune setting may influence the importance of NK cells in response to Mtb infection. For 
example, dramatic immunomodulation can occur in humans during HIV infection at least partly 
through depletion of CD4+ T cells, increasing susceptibility to Mtb infection and reactivation 
(Geldmacher et al., 2012). In this situation, in the absence of an effective CD4+ T cell response, 
it is possible NK cells have a more pronounced role in the immune response to Mtb infection. 
 
Rag KO Il7 KO mice were not more susceptible to HN878 infection than Rag KO mice at day 
21 post infection. However, at day 25 post infection Rag KO Il7 KO displayed higher bacterial 
loads. This finding, taken together with findings in the Rag KO Il15r KO, suggests that IL-15 
dependent ILCs are more important than IL-7 dependent ILCs to the innate immune response to 
Mtb infection, as the effect of deficiency in IL-15 dependent ILCs is evident earlier and is more 
severe. However, collectively our data shows both are involved. 
 
The predominant population of ILCs in the naïve lung are ILC2s, which promote type 2 
immune response producing cytokines such as IL-5 and IL-13 (Artis and Spits, 2015; Monticelli 
et al., 2011; Yagi et al., 2014). Type 2 responses are suggested to be detrimental to control of 
Mtb infection potentially through suppression of protective Th1 responses (reviewed in O'Garra 
et al., 2013). As mentioned earlier, it was possible that ILC2s could have been detrimental to 
control of Mtb infection potentially through promotion of type 2 responses. However, Rag KO 
Il7 KO mice, which lack ILC2 populations, do not show increased control of bacterial infection 
suggesting this scenario does not occur. It is possible that cytokines that expand and activate 
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ILC2s such as IL-33 and IL-25 (reviewed in Artis and Spits, 2015) are not induced upon Mtb 
infection, meaning ILC2s are not activated to promote a type 2 response. However, further work 
will be required to confirm expression of such cytokines and the activation of ILC2s for 
example through assessment of their production of IL-5 and IL-13. Additionally, it has recently 
been suggested that IFNγ limits the expansion of ILC2s, their induction of eosinophilia and IL-5 
expression upon N. brasiliensis infection (Molofsky et al., 2015). In line with this, production of 
IFNγ upon Mtb infection may act to suppress the response of ILC2s. 
 
In order to assess the function of IL-7 dependent ILCs during Mtb infection we utilised the Rag 
KO Il7 KO mouse. However, although ILCs are dependent on IL-7 for their development and/or 
maintenance (reviewed in Serafini et al., 2015; Vonarbourg and Diefenbach, 2012), it has been 
suggested that deficiency in IL-7 only reduces ILC numbers and does not lead to complete 
deficiency due to the ability of TSLP, another cytokine that signals via the α subunit of the IL-7 
receptor (IL-7Rα), to compensate for loss of IL-7 (Hoyler et al., 2012; Vonarbourg et al., 2010). 
Although we found that there was loss of a Lin- Thy1.2+ CD127+ population in the Rag KO Il7 
KO, use of an Il7rα deficient mouse strain may provide a more complete deficiency in ILCs and 
confirm our results. 
 
Taken together, we show a protective role for ILCs, including NK cells, in the immune response 
to Mtb infection in the absence of an adaptive immune system in Rag KO mice. Further work 
assessing the response of ILCs in a wild type mouse would be beneficial to our understanding of 
the their response upon Mtb infection. Indeed, it has been reported that NK cells and other ILCs 
from Rag deficient mice are hyper-responsive (Karo et al., 2014), which could influence their 
response to Mtb infection. It is also important to consider potential additional roles of ILCs in 
the initiation and regulation of the adaptive immune response. Indeed ILCs have been described 
to interact with T cells to influence outcome of infection, initiate allergic responses and regulate 
T cell response to commensal bacteria (Gold et al., 2014; Halim et al., 2014; Hepworth et al., 
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2015; Hepworth et al., 2013; Mortha et al., 2014; Oliphant et al., 2014) and thus ILCs could 
have additional roles in Mtb infection, which requires further investigation. However, use of the 
Rag deficient mouse has allowed us to take a genetic approach to determine the relative 
importance of different ILCs during Mtb infection, which would not have been possible in the 
presence of an adaptive immune system.  
 
5.7.3 Deficiency in NK cells and/or other ILCs leads to neutrophilia upon Mtb infection 
 
We observed that the increased bacterial loads observed in the absence of NK cells and/or other 
ILCs correlated with accumulation of neutrophils upon Mtb infection. IFNγ has been described 
to regulate neutrophils in Mtb infection through suppressing their recruitment and survival 
(Desvignes et al., 2012; Nandi and Behar, 2011). We would hypothesise that in the absence of 
NK cells and/or other ILCs there is impairment in IFNγ production in infection. Therefore the 
absence of IFNγ leads to higher numbers of neutrophils in the lung, which could contribute to 
immunopathology or provide a permissive environment for bacterial growth (Eruslanov et al., 
2005; Nandi and Behar, 2011). 
 
In order to determine whether neutrophil accumulation was detrimental to control of infection 
and contributing to susceptibility to Mtb infection in ILC deficient animals, we depleted 
neutrophils using an αLy6G mAb. In all strains depletion of neutrophils led to more weight loss 
over the course of infection, although this was most pronounced in Rag KO Il15r KO mice. 
This could suggest that neutrophils are contributing to control of the immune response and thus, 
in their absence, the increased level of weight loss reflects a more exaggerated immune 
response. Alternatively, this could suggest neutrophils are contributing to control of infection 
and in their absence disease is exacerbated.  
 
 -Chapter 5: The role of Innate Lymphoid Cells in the immune response to Mtb infection-  
 
 238 
In contrast to the weight loss observed, depletion of neutrophils had different effects on the 
control of bacterial load in the different mouse strains. Neutrophil depletion led to lower 
bacterial loads in Rag KO Il15r KO mice, suggesting that neutrophils in Rag KO Il15r KO mice 
are detrimental to control of infection. The lower bacterial load in the context of increased 
weight loss when neutrophils are depleted suggests that neutrophils may be functioning to 
suppress the immune response to Mtb. Indeed neutrophils have been described to be a source of 
the immunosuppressive cytokine IL-10 during Mtb infection (Dorhoi et al., 2010; Dorhoi et al., 
2013; Zhang et al., 2009), although further investigation will be required to confirm this 
hypothesis. The lower bacterial load in the absence of neutrophils could also suggest that 
neutrophils provide a permissive environment for Mtb growth as has been previously suggested 
(Eruslanov et al., 2005). 
 
However, in contrast to Rag KO Il15r KO, in Rag KO and Rag KO Il2rg KO neutrophil 
depletion did not impact control of bacterial load. A possible explanation for the different 
impact of neutrophil depletion in Rag KO Il15r KO and Rag KO Il2rg KO is that lower 
proportions and numbers of CD11c+ CD11blo macrophages were present in the lung in Rag KO 
Il2rg KO compared to Rag KO Il15r KO. If neutrophils are suppressing the anti-mycobacterial 
response in alveolar macrophages to facilitate bacterial growth in Rag KO Il15r KO, this may 
not be evident in Rag KO Il2rg KO as the population is lacking. Furthermore, Rag KO Il2rg 
KO mice will have deficiencies in populations producing macrophage activating cytokines such 
as IFNγ and GM-CSF (Flynn and Chan, 2001; Pasula et al., 2015; Rothchild et al., 2014). 
Therefore, even in the absence of neutrophils, macrophages may still not be sufficiently 
activated to control bacterial growth. Further work will be required to determine if the state of 
macrophage activation differs between Rag KO Il15r KO and Rag KO Il2rg KO and how 
neutrophil depletion affects this. 
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 5.7.4 GM-CSF is crucial to the innate and adaptive response to Mtb infection 
 
We found that ILCs, but not conventional NK cells, were a source of GM-CSF upon Mtb 
infection. We therefore hypothesised that GM-CSF production by ILCs may be an important 
factor for their protective role in Mtb infection. Neutralisation of GM-CSF in the Rag KO and 
Rag KO Il7 KO mice revealed that GM-CSF was an important factor for the innate control of 
Mtb infection, with an increase in bacterial load in Rag KO mice treated with αGM-CSF 
compared to isotype controls. This increase in bacterial load upon αGM-CSF treatment was also 
evident in the Rag KO Il7 KO mice. This suggests that, although ILCs are a source of GM-CSF, 
there are other sources of GM-CSF that contribute to protection upon Mtb infection. GM-CSF 
producing “tissue resident” NK cells that are DX5- have been described in the liver (Daussy et 
al., 2014; Sojka et al., 2014). It is possible that there is a population of NK cells, distinct from 
conventional NK cells, present in Mtb infection that produce GM-CSF. Although, very few 
tissue resident NK cells, expressing the same markers as the GM-CSF producing liver tissue 
resident NK cells, were found in the lung (Sojka et al., 2014). In keeping with this, our 
preliminary results suggest that NK1.1+ DX5- cells are not a source of GM-CSF during Mtb 
infection, although confirmation of these results is required. Production of GM-CSF by various 
other cell types present in the lung including fibroblasts, type II pneumocytes and macrophages 
has also been reported (Gasson, 1991; Trapnell and Whitsett, 2002). These populations could 
also contribute to GM-CSF production during Mtb infection and this will require further 
investigation. 
 
We were surprised to see such a dramatic phenotype in the Rag KO mice when GM-CSF was 
neutralised during HN878 infection, as previous work in mice lacking GM-CSF suggested a 
defect in antigen presenting function, lymphocyte recruitment and IFNγ production by CD4+ T 
cells in the lung was responsible for their enhanced susceptibility to less virulent Mtb infection 
(Gonzalez-Juarrero et al., 2005). However, GM-CSF has been described to restrict 
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mycobacterial growth in macrophages in vitro (Denis and Ghadirian, 1990; Pasula et al., 2015; 
Rothchild et al., 2014). In the Rag KO GM-CSF neutralisation could impair macrophage 
activation and control of mycobacterial growth, leading to increased bacterial loads.  
 
In Chapter 4 we investigated the role of GM-CSF during H37Rv infection in Mtb resistant and 
Mtb susceptible mouse strains. Given the dramatic phenotype in Rag KO mice when GM-CSF 
was neutralised during HN878 infection, we investigated the role of GM-CSF in wild type mice 
infected with the hyper-virulent HN878 Mtb strain. There was an increase in bacterial load in 
mice treated with αGM-CSF from day 21 post infection. We observed a strong trend towards a 
decrease in proportion and number of CD4+ T cells in the lung at day 21 post infection. 
However, there did not appear to be a defect in their ability to produce IFNγ. This suggests that, 
in keeping with the literature, GM-CSF is important for the recruitment of CD4+ T cells to the 
lung (Gonzalez-Juarrero et al., 2005). However, as we did not observe a defect in their IFNγ 
production this suggests those present are functional. CD4+ T cells could be impaired for 
production of another factor (e.g. TNFα) that we are not measuring, resulting in impaired 
control of Mtb infection. Another likely possibility is that GM-CSF is affecting the function of 
myeloid populations due to the ability of GM-CSF to activate macrophages to restrict 
mycobacterial growth (Denis and Ghadirian, 1990; Flynn and Chan, 2001; Pasula et al., 2015; 
Rothchild et al., 2014). Therefore, the absence of GM-CSF may affect macrophage ability to 
control bacterial load. It is likely that both the impact of GM-CSF upon the recruitment of T 
cells and its effect upon macrophage activation will contribute to the increased susceptibility of 
wild-type mice to HN878 infection when GM-CSF is neutralised. 
 
Overall we show that a population of T-bet+ ILCs are present upon infection with either the lab-
adapted Mtb strain H37Rv or the hyper-virulent strain HN878. Furthermore, ILCs are a source 
of cytokines following infection with either strain of Mtb. Deficiency in NK cells and/or other 
ILCs increases susceptibility to HN878 infection and leads to accumulation of neutrophils in the 
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lung, which in the absence of NK cells, are detrimental to control of bacterial load. Furthermore, 
we show that GM-CSF is crucial to control bacterial loads in HN878 infection in both Rag KO 
and wild-type mice. Further work is required to determine the mechanisms by which ILCs are 
protective and also response of ILCs to Mtb infection in the context of an adaptive immune 
system. 
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Figure 5.1 Identification of Innate Lymphoid cells - gating strategy and definition of 
ILCs 
 
Rag KO mice were infected with approximately 100 CFU of the hyper-virulent Mtb strain 
HN878 via the aerosol route. At day 21 post infection lungs were harvested and digested by 
incubation with collagenase D, as described in the materials and methods. Single cell 
suspensions from the lung were obtained by passage through a 70µm filter. Single cell 
suspensions were stained with the following antibodies: T1/ST2 FITC, CD127 PE, RORγt 
PerCP e710, Thy1.2 PE Cy7, T-bet Pacific Blue, Sca-1 v500, CD25 APC e780 and Lineage 
markers: CD49b (DX5) APC, CD3 APC, CD5 APC, CD27 APC, CD11b APC, CD11c APC, 
NK1.1 APC, B220 APC, TCRβ APC. ILCs were identified as Lin- Thy1.2+ CD127+ CD25+ and 
further phenotyped based on expression of T1/ST2, T-bet and RORγt. Flow cytometery plots 
shown are from one mouse representative of infected mice at day 21 post infection. The same 
gating strategy was used to identify ILCs in uninfected mice and also in H37Rv infected mice. 
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Figure 5.2 H37Rv infection induces a small increase in total numbers of Lin- Thy1.2+ 
CD127+ CD25+ ILCs in the lung 
 
Rag KO mice were left uninfected or infected with approximately 100 CFU of the lab-adapted 
Mtb strain H37Rv via the aerosol route. At days 14, 21 and 25 post infection mice were 
sacrificed. Lungs were harvested and digested with collagenase D as described in the materials 
and methods. Single cell suspensions from the lung were obtained by passage through a 70µm 
filter. Single cell suspensions were stained with the following antibodies: T1/ST2 FITC, CD127 
PE, RORγt PerCP e710, Thy1.2 PE Cy7, T-bet Pacific Blue, Sca-1 v500, CD25 APC e780 and 
Lineage markers (Lin): CD49b (DX5) APC, CD3 APC, CD5 APC, CD27 APC, CD11b APC, 
CD11c APC, NK1.1 APC, B220 APC, TCRβ APC. Percentage and number of ILCs defined as 
Lin- Thy1.2+ CD127+ CD25+ at day 14, 21 and 25 post infection are shown. Graphs show 
individual mice with mean ± SD. Individual time points are from independent experiments. 
Data representative of 1(d14), 2 (d25) or 3 (d21) independent experiments. 5 mice per group. ns 
– not significant, * p<0.05 by unpaired student’s t-test.  
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Figure 5.3 H37Rv infection in Rag KO mice leads to an increase in T-bet+ ILCs in 
the lung 
 
Rag KO mice were left uninfected or infected with approximately 100 CFU of the lab-adapted 
Mtb strain H37Rv via the aerosol route. At days 14, 21 and 25 post infection mice were 
sacrificed. Lungs were harvested and digested with collagenase D as described in the materials 
and methods. Single cell suspensions from the lung were obtained by passage through a 70µm 
filter. Single cell suspensions were stained with the following antibodies: T1/ST2 FITC, CD127 
PE, RORγt PerCP e710, Thy1.2 PE Cy7, T-bet Pacific Blue, Sca-1 v500, CD25 APC e780 and 
Lineage markers (Lin): CD49b (DX5) APC, CD3 APC, CD5 APC, CD27 APC, CD11b APC, 
CD11c APC, NK1.1 APC, B220 APC, TCRβ APC. Histograms showing T-bet expression in 
Lin- Thy1.2+ CD127+ CD25+ T1/ST2loILCs at day 14, 21 and 25 post infection are shown (A). 
Histograms are concatenated from all individuals in the group. Percentage and number of T-bet+ 
Lin- Thy1.2+ CD127+ CD25+ T1/ST2lo ILCs (B) Graphs show individual mice with mean ± SD. 
Individual time points are from independent experiments. Data representative of 1(d14) or 2 
(d21 and d25) independent experiments. 5 mice per group. ns – not significant, * p<0.05 by 
unpaired student’s t-test.   
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Figure 5.4 Innate Lymphoid cells are a source of IFNγ following H37Rv infection of 
Rag KO mice 
 
Rag KO mice were left uninfected or infected with approximately 100 CFU of the lab-adapted 
Mtb strain H37Rv via the aerosol route. At days 21 and 25 post infection mice were sacrificed. 
Lungs were harvested and digested with collagenase D as described in the materials and 
methods. Single cell suspensions from the lung were obtained by passage through a 70µm filter. 
5x105 cells were restimulated with 50ng/ml PMA and 500ng/ml ionomycin in the presence of 
Brefeldin A for 2 hours. Cells were then harvested and stained with the following to identify 
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IFNγ and GM-CSF production by ILCs: GM-CSF FITC, CD127 PE, Lineage markers (Lin): 
CD49b (DX5) PerCP e710, CD3 PerCP Cy5.5, CD5 PerCP Cy5.5, CD27 PerCP Cy5.5, CD11b 
PerCP Cy5.5, CD11c PerCP Cy5.5, NK1.1 PerCP Cy5.5, B220 PerCP Cy5.5, TCRβ PerCP 
Cy5.5, Thy1.2 PE Cy7, IFNγ e450 and CD25 APC e780. ILCs were identified as Lin- Thy1.2+ 
CD127+ CD25+. Representative flow cytometry plots from individual mice at day 21 or 25 post 
infection are shown. Graphs of percentage and number of IFNγ or GM-CSF producing ILCs are 
shown at day 21 and 25 post infection. Graphs show individual mice with mean ± SD. 
Individual time points are from independent experiments. Data representative of 1 (GM-CSF 
d21 and 25) or 2 (IFNγ d21 and 25) independent experiments. 4-5 mice per group. ns – not 
significant, p=0.06, p=0.08, p=0.01, * p<0.05, *** p<0.001 by unpaired student’s t-test.  
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Figure 5.5 Conventional NK cells produce IFNγ not GM-CSF upon H37Rv Infection 
 
Rag KO mice were left uninfected or infected with approximately 100 CFU of the lab-adapted 
Mtb strain H37Rv via the aerosol route. At days 21 and 25 post infection mice were sacrificed. 
Lungs were harvested and digested with collagenase D as described in the materials and 
methods. Single cell suspensions from the lung were obtained by passage through a 70µm filter. 
5x105 cells were restimulated with 50ng/ml PMA and 500ng/ml ionomycin in the presence of 
Brefeldin A for 2 hours. Cells were then harvested and stained with the following to identify 
IFNγ and GM-CSF production by conventional NK cells: GM-CSF FITC, NK1.1 PE, CD27 
PerCP Cy5.5, CD11b PE Cy7, IFNγ e450 and CD49b (DX5) APC. NK cells were identified as 
NK1.1+ DX5+ (CD11blo-hi). Representative flow cytometry plots from individual mice at day 21 
or 25 post infection are shown. Graphs of percentage and number of IFNγ NK cells are shown at 
day 21 and 25 post infection. Graphs show individual mice with mean ± SD. Data representative 
of 1 independent experiment. 3-5 mice per group. * p<0.05, *** p<0.001 by unpaired student’s 
t-test.   
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Figure 5.6 HN878 infection does not impact total numbers of Lin- Thy1.2+ CD127+ 
CD25+ ILCs in the lung 
 
Rag KO mice were left uninfected or infected with approximately 100 CFU of the hyper-
virulent Mtb strain HN878 via the aerosol route. At days 15, 21 and 25 post infection mice were 
sacrificed. Lungs were harvested and digested with collagenase D as described in the materials 
and methods. Single cell suspensions from the lung were obtained by passage through a 70µm 
filter. Single cell suspensions were stained with the following antibodies: T1/ST2 FITC, CD127 
PE, RORγt PerCP e710, Thy1.2 PE Cy7, T-bet Pacific Blue, Sca-1 v500, CD25 APC e780 and 
Lineage markers (Lin): CD49b (DX5) APC, CD3 APC, CD5 APC, CD27 APC, CD11b APC, 
CD11c APC, NK1.1 APC, B220 APC, TCRβ AP. Percentage and number of ILCs defined as 
Lin- Thy1.2+ CD127+ CD25+ at day 15, 21 and 25 post infection are shown. Graphs show 
individual mice with mean ± SD. Individual time points are from independent experiments. 
Data representative of 3 (d14), 5 (d21) or 4 (d25) independent experiments. 3-5 mice per group. 
ns – not significant, *** p<0.001 by unpaired student’s t-test.  
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Figure 5.7 HN878 infection in Rag deficient mice leads to an increase in  
T-bet+ ILCs in the lung 
 
Rag KO mice were left uninfected or infected with approximately 100 CFU of the hyper-
virulent Mtb strain HN878 via the aerosol route. At days 14, 21 and 25 post infection mice were 
sacrificed. Lungs were harvested and digested with collagenase D as described in the materials 
and methods. Single cell suspensions from the lung were obtained by passage through a 70µm 
filter. Single cell suspensions were stained with the following antibodies: T1/ST2 FITC, CD127 
PE, RORγt PerCP e710, Thy1.2 PE Cy7, T-bet Pacific Blue, Sca-1 v500, CD25 APC e780 and 
Lineage markers (Lin): CD49b (DX5) APC, CD3 APC, CD5 APC, CD27 APC, CD11b APC, 
CD11c APC, NK1.1 APC, B220 APC, TCRβ APC. Histograms showing T-bet expression in 
Lin- Thy1.2+ CD127+ CD25+ T1/ST2lo ILCs at day 14, 21 and 25 post infection are shown (A). 
Histograms are concatenated from all individuals in the group. Percentage and number of T-bet+ 
Lin- Thy1.2+ CD127+ CD25+ T1/ST2lo ILCs (B) Graphs show individual mice with mean ± SD. 
Individual time points are from independent experiments. Data representative of 2 (d14) or 5 
(d21) or 4 (d25) independent experiments. 3-5 mice per group. ns – not significant, * p<0.05 by 
unpaired student’s t-test.   
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Figure 5.8 Innate Lymphoid cells are a source of IFNγ and GM-CSF upon  
HN878 infection in Rag KO mice 
 
Rag KO mice were left uninfected or infected with approximately 100 CFU of the hyper-
virulent Mtb strain HN878 via the aerosol route. At days 21 and 25 post infection mice were 
sacrificed. Lungs were harvested and digested with collagenase D as described in the materials 
and methods. Single cell suspensions from the lung were obtained by passage through a 70µm 
filter. 5x105 cells were restimulated with 50ng/ml PMA and 500ng/ml ionomycin in the 
presence of Brefeldin A for 2 hours. Cells were then harvested and stained with the following to 
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identify IFNγ and GM-CSF production by ILCs: GM-CSF FITC, CD127 PE, Lineage markers 
(Lin): CD49b (DX5) PerCP e710, CD3 PerCP Cy5.5, CD5 PerCP Cy5.5, CD27 PerCP Cy5.5, 
CD11b PerCP Cy5.5, CD11c PerCP Cy5.5, NK1.1 PerCP Cy5.5, B220 PerCP Cy5.5, TCRβ 
PerCP Cy5.5, Thy1.2 PE Cy7, IFNγ e450 and CD25 APC e780. ILCs were identified as Lin- 
Thy1.2+ CD127+ CD25+. Representative flow cytometry plots from individual mice at day 21 or 
25 post infection are shown. Graphs of percentage and number of IFNγ or GM-CSF producing 
ILCs are shown at day 21 and 25 post infection. Graphs show individual mice with mean ± SD. 
Individual time points are from independent experiments. Data representative of 3 (GM-CSF 
d21 and 25, IFNγ d25) or 4 (IFNγ d21) independent experiments. 4-5 mice per group. ns – not 
significant, * p<0.05, **p<0.01, *** p<0.001 by unpaired student’s t-test.   
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Figure 5.9 Conventional NK cells produce IFNγ not GM-CSF upon HN878 infection 
 
Rag KO mice were left uninfected or infected with approximately 100 CFU of the hyper-
virulent Mtb strain HN878 via the aerosol route. At days 21 and 25 post infection mice were 
sacrificed. Lungs were harvested and digested with collagenase D as described in the materials 
and methods. Single cell suspensions from the lung were obtained by passage through a 70µm 
filter. 5x105 cells were restimulated with 50ng/ml PMA and 500ng/ml ionomycin in the 
presence of Brefeldin A for 2 hours. Cells were then harvested and stained with the following to 
identify IFNγ and GM-CSF production by conventional NK cells: GM-CSF FITC, NK1.1 PE, 
CD27 PerCP Cy5.5, CD11b PE Cy7, IFNγ e450 and CD49b (DX5) APC. NK cells were 
identified as NK1.1+ DX5+ (CD11blo-hi). Representative flow cytometry plots from individual 
mice at day 21 or 25 post infection are shown. Graphs of percentage and number of IFNγ NK 
cells are shown at day 21 and 25 post infection. Graphs show individual mice with mean ± SD. 
Data representative of 2 (d21) or 3 (d25) independent experiments. 2-5 mice per group. * 
p<0.05, ** p<0.01, *** p<0.001 by unpaired student’s t-test.   
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Figure 5.10 Phenotyping deficiencies of ILC populations in Rag KO Il7 KO,  
Rag KO Il15r KO and Rag KO Il2rg KO mice 
 
Lungs were harvested from naïve Rag KO, Rag KO Il7 KO, Rag KO Il15r KO and Rag KO 
Il2rg KO mice. Single cell suspensions were obtained following digestion with collagenase D 
and passage through a 70µm filter. Flow cytometry plots and graphs of percentage and number 
of ILCs in the 4 different mouse strains (A). ILCs were defined as Lin- Thy1.2+ CD127+ 
following staining with the following antibody cocktail: T1/ST2 FITC, CD127 PE, RORγt 
PerCP e710, Thy1.2 PE Cy7, T-bet Pacific Blue, Sca-1 v500, CD25 APC e780 and Lineage 
markers (Lin): CD49b (DX5) APC, CD3 APC, CD5 APC, CD27 APC, CD11b APC, CD11c 
APC, NK1.1 APC, B220 APC, TCRβ APC. Graphs of percentage and number of NK cells in 
the 4 different mouse strains (B). NK cells were defined as NK1.1+ following staining with the 
following antibodies: Ly6G FITC, PE NK1.1, PerCP Cy5.5 Ly6C, F4/80 PE Cy7, CD11c v450, 
CD11b v500, CD115 APC, MHC II APC e780. Representative flow cytometry plots from 
individual mice are shown. Graphs show individual mice with mean ± SD. 2-3 mice per group. 
Comparisons of ILCs and NK cells in all four strains was performed twice. Comparison of only 
Rag KO, Rag KO Il15r KO, Rag KO Il2rg KO was performed twice and comparison of Rag 
KO and Rag KO Il7 KO four times.   
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Figure 5.11 IL-15 dependent ILCs have a protective role in the innate immune 
response to HN878 infection 
 
Rag KO, Rag KO Il15r KO and Rag KO Il2rg KO mice were infected with approximately 100 
CFU of the hyper-virulent Mtb strain HN878 via the aerosol route. At day 21 post infection 
lungs were harvested and digested in collagenase D. Single cell suspensions were obtained and 
serially diluted and plated to determine bacterial loads in the lung. Graph show individual mice 
with mean ± SD (A). Weight loss was monitored over the course of infection. Graph shows 
mean ± SD (B). 4-5 mice per group. Data representative of 3 independent experiments. ** 
p<0.01, *** p<0.001, **** p<0.0001 by unpaired student’s t-test.  
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Figure 5.12 IL-7 dependent ILCs are required in the innate immune response to 
HN878 infection. 
 
Rag KO and Rag KO Il7 KO mice were infected with approximately 100 CFU of the hyper-
virulent Mtb strain HN878 via the aerosol route. At day 21 or 25 post infection lungs were 
harvested and digested in collagenase D. Single cell suspensions were obtained and serially 
diluted and plated to determine bacterial loads in the lung. Graph show individual mice with 
mean ± SD (A). Bacterial loads at day 21 representative of 1 independent experiment. Bacterial 
loads at day 25 show data pooled from 5 independent experiments. Weight loss was monitored 
over the course of infection. Graph shows mean ± SD (B). Weight loss representative of 4 
independent experiments. 5-25 mice per group. ** p<0.01 by unpaired student’s t-test.  
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Figure 5.13 The absence of IL-15 and/or IL-7 dependent ILCs during HN878 
infection leads to neutrophil accumulation and a decrease in alveolar macrophages  
 
Rag KO, Rag KO Il15r KO and Rag KO Il2rg KO mice were infected with approximately 100 
CFU of the hyper-virulent Mtb strain HN878 via the aerosol route. At day 21 post infection 
lungs were harvested and digested in collagenase D. Single cell suspensions were obtained and 
stained with the following to identify myeloid populations: Ly6G FITC, PE NK1.1, PerCP 
Cy5.5 Ly6C, F4/80 PE Cy7, CD11c v450, CD11b v500, CD115 APC, MHC II APC e780. 
Percentage and number of neutrophils (defined as Ly6G+ CD11b+) at day 21 post infection (A). 
Percentage and number of CD11c+ CD11blo alveolar macrophages (defined as Ly6G- CD11c+ 
CD11blo) at day 21 post infection (B). Graphs show individual mice with mean ± SD. 3-5 mice 
per group. Data representative of 3 independent experiments. * p<0.05, ** p<0.01, *** p<0.001 
**** p<0.0001 by unpaired student’s t-test.  
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Figure 5.14 Neutrophils accumulate in response to HN878 infection in the absence of 
IL-7 dependent ILCs  
 
Rag KO and Rag KO Il7 KO mice were infected with approximately 100 CFU the hyper-
virulent Mtb strain HN878 via the aerosol route. At day 25 post infection lungs were harvested 
and digested in collagenase D. Single cell suspensions were obtained and stained with the 
following to identify myeloid populations: Ly6G FITC, PE NK1.1, PerCP Cy5.5 Ly6C, F4/80 
PE Cy7, CD11c v450, CD11b v500, CD115 APC, MHC II APC e780. Percentage and number 
of neutrophils (defined as Ly6G+ CD11b+) at day 25 post infection (A). Percentage and number 
of CD11c+ CD11blo alveolar macrophages (defined as Ly6G- CD11c+ CD11blo) at day 25 post 
infection (B). Graphs show individual mice with mean ± SD. 3-5 mice per group. Data 
representative of 4 independent experiments. p=0.18, * p<0.05 by unpaired student’s t-test.  
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Figure 5.15 Depletion of neutrophils during HN878 infection increased weight loss of 
the course of infection and lowers Mtb bacterial load in Rag KO Il15r KO mice 
 
Rag KO, Rag KO Il15r KO and Rag KO Il2rg KO mice were infected with approximately 100 
CFU the hyper-virulent Mtb strain HN878 via the aerosol route. Mice received i.p. injections on 
days 10, 12, 14, 16 and 18 containing 0.2mg αLy6G (clone 1A8) or isotype (GL117). At day 21 
post infection mice were sacrificed and lungs were harvested (A). Weight loss was monitored 
over the course of infection. Graph shows mean ± SD. 7-8 mice per group (B). Single cell 
suspensions from the lungs were obtained following digestion with collagenase D, as described 
in materials and methods. These were serially diluted and plated to determine bacterial loads in 
the lung at day 21 post infection. Graph shows individual mice with mean ± SD. 4-5 mice per 
group (C). Data representative of 1 experiment. ns- not significant, p=0.08. *p<0.05, **p<0.01 
by unpaired student’s t-test.   
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Figure 5.16 GM-CSF is crucial to the innate immune response to HN878 infection  
 
Outline of experiment (A). Rag KO and Rag KO Il7 KO mice were i.p. injected with 1mg anti-
GM-CSF (αGM-CSF, clone MP1-22E9) or Isotype (ISO, clone GL117) control the day prior to 
infection with approx. 100-200 CFU the hyper-virulent Mtb strain HN878, via aerosol route. 
Mice then received twice weekly i.p. injections of aGM-CSF or ISO. Mice were sacrificed at 
day 25 post infection. Single cell suspensions from the lungs were obtained following digestion 
with collagenase D, as described in materials and methods. These were serially diluted and 
plated to determine bacterial loads in the lung at day 25 post infection (B). Graph shows 
individual mice with mean ± SD. 4-5 mice per group. Data representative of 1 experiment. 
p=0.066. *p<0.05 unpaired student’s t-test.   
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Figure 5.17 GM-CSF is crucial to the immune response to HN878 infection in wild 
type mice 
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Outline of experiment (A). C57BL/6 mice were i.p. injected with 1mg anti-GM-CSF (αGM-
CSF, clone MP1-22E9) or Isotype (ISO, GL117) control the day prior to infection with approx. 
100-200 CFU the hyper-virulent Mtb strain HN878, via aerosol route. Mice then received twice 
weekly i.p. injections of αGM-CSF or ISO. Mice were sacrificed at day 14, 21 or 25 post 
infection. Single cell suspensions from the lungs were obtained following digestion with 
collagenase D, as described in materials and methods. These were serially diluted and plated to 
determine bacterial loads in the lung at days 14, 21 and 28 post infection. Graph shows mean ± 
SD. 5 mice per group (B). Single cell suspensions were stained with the following antibodies to 
identify CD4+ T cells: γδ TCR FITC, Thy1.2 PECy7, CD4 e450, CD8 v500 and CD3 APC. 
Percentage and number of CD4+ T cells (defined as Thy1.2+ CD3+ CD4+) at day 21 post 
infection (C). Graphs show individual mice with mean ± SD. 3-5 mice per group. 1x106 cells 
were restimulated with 20µg PPD and 2µg αCD28 mAb for 16h before the addition of BFA for 
a further 4h. Cells were then harvested and stained with the following to assess cytokine 
production: γδ TCR FITC, GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, IFNγ e450, CD4 
v500, IL-17A APC, CD3 APCe780. Percentage and number of cytokine producing CD4+ T 
cells (defined as CD3+ Thy1.2+ CD4+) at day 21 post infection (D). Graphs show individual 
mice with mean ± SD. 5 mice per group. Data representative of 1 experiment. p=0.075, p=0.076 
by unpaired student’s t-test. 
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TB is the second leading cause of death from infectious disease, with an estimated 1.5 million 
deaths in 2013 (WHO, 2014b). Currently the only licensed vaccine, BCG, affords variable 
protection against TB disease (Fine, 1995). Novel vaccine regimes are under development but 
an incomplete understanding of a protective response to Mtb hinders the rational design of 
vaccines. There is a significant delay in the onset of an immune response capable of controlling 
Mtb bacterial growth (reviewed in Cooper, 2009). It is argued that the delay in the control of 
bacterial growth allows Mtb to manipulate its environment, such that when a potentially 
protective response is expressed, it can be ineffective (reviewed in Cooper, 2009; Orme et al., 
2015). Therefore, a possible avenue to improve vaccination is to manipulate the speed at which 
the T cell response is expressed (reviewed in Cooper, 2009). Furthermore a more detailed 
understanding of how innate lymphocytes such as NK cells, NKT cells, MAIT cells and ILCs 
respond to Mtb infection and influence the early response to infection will further our 
understanding of a protective response to Mtb. If possible, augmenting the response of such 
rapidly responding innate lymphocyte populations may provide another way in which 
vaccination can be improved (Zufferey et al., 2013).  
 
6.1 IL-10R blockade improves the protective effect of BCG 
vaccination, influencing early immune events following Mtb challenge 
 
6.1.1 Influence of IL-10R blockade during BCG vaccination on the adaptive response 
following Mtb challenge in Mtb susceptible mice 
 
IL-10 is detrimental to control of Mtb infection, and increased IL-10 levels during Mtb infection 
have been linked with increased susceptibility (Beamer et al., 2008; Redford et al., 2010; Turner 
et al., 2002). Previous work from the O’Garra lab has shown that IL-10 also suppresses the 
response to BCG vaccination and the protection it affords against Mtb challenge in both Mtb 
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resistant and Mtb susceptible mouse models (Pitt et al., 2012b). In resistant mice, increased 
control of Mtb bacterial load when BCG vaccination was administered in the context of αIL-
10R mAb correlated with an accelerated arrival of and enhanced IFNγ producing CD4+ T cells 
(Pitt et al., 2012b). However, the early immune response in Mtb susceptible mice was not 
assessed. Acceleration in the onset of an adaptive immune response is one way in which 
vaccination can be improved, given the expression of an adaptive immune response is 
considerably delayed in response to Mtb infection (reviewed in Cooper, 2009). Chapter 3 of this 
thesis investigated whether BCG vaccination in the context of αIL-10R mAb, accelerated the 
arrival of the adaptive response in susceptible CBA/J mice. In contrast to resistant C57BL/6 
mice, the increased protection in chronic infection afforded by this vaccine regime was not 
accompanied by significantly accelerated recruitment of IFNγ producing CD4+ T cells in 
susceptible CBA/J mice, although increased levels of IFNγ were observed at later time points 
(Pitt et al., 2012b). The differences identified between resistant and susceptible mouse strains 
highlight the importance of selecting appropriate models to investigate vaccine candidates.  
 
Although BCG vaccination in the context of αIL-10R did not lead to accelerated recruitment of 
IFNγ producing CD4+ T cells, increased protection in chronic infection did correlate with 
accelerated and increased production of IL-17 by γδ T cells and CD8+ T cells and GM-CSF by 
CD4+ T cells. This result supports the idea that modulation of the early events following Mtb 
infection can positively impact the subsequent course of infection and that IFNγ may not be the 
sole determinant of protection, as has been previously reported (Abebe, 2012; Kagina et al., 
2010; Mittrucker et al., 2007). 
 
In addition to the speed of the onset of a T cell response, its appropriate localisation within the 
lung could be an important factor in increasing protection against Mtb infection. Indeed, T cells 
localised in the lung parenchyma were able to confer superior levels of protection against Mtb 
upon transfer than those localised in the vasculature (Sakai et al., 2014). IL-17 is described to be 
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important to induce chemokines to recruit (CXCL9, CXCL10, CXCL11) and localise 
(CXCL13) T cells in the recall response following vaccination (Gopal et al., 2013; Khader et 
al., 2007). The functional significance of the increased levels of IL-17 and GM-CSF upon Mtb 
challenge identified in the lungs of mice vaccinated with BCG in the context of αIL-10R is 
unclear. However, as IL-17 has been described to be involved in the localisation of T cells 
within the lung, further investigation into chemokine induction and histological analysis will 
allow assessment of localisation of T cells in granulomas, providing insight into how increased 
protection is achieved.  
 
In contrast to the role of IL-17 in the recall response following vaccination, the role of GM-CSF 
has not been investigated and is not regularly measured in animal studies assessing vaccine 
efficacy. However, increased GM-CSF production was observed in the lung following Mtb 
challenge in mice vaccinated with the recombinant BCG VPM1002 compared to parental BCG 
(Desel et al., 2011) and increased GM-CSF expression in PBMCs of previously BCG 
vaccinated individuals upon BCG challenge has been observed (Matsumiya et al., 2015). Taken 
together with our results correlating increased production of GM-CSF with protection, could 
suggest that vaccine regimes that increase GM-CSF production could be beneficial.  
 
6.1.2 Potential to improve vaccination against Mtb infection by modulating the innate 
immune response 
 
In addition to accelerating the onset of adaptive immunity, BCG vaccination could also increase 
protection against Mtb challenge through modulation of the innate immune response. Indeed, 
“trained immunity” has been described, where innate cells display increased response to 
secondary and/or heterologous infection, and this is suggested to contribute to the 
epidemiological observation that BCG vaccination provides protection against heterologous 
infection (Freyne et al., 2015; Quintin et al., 2014). BCG induced trained immunity has been 
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demonstrated in humans where BCG vaccination led to NOD2 dependent epigenetic 
reprogramming of monocytes resulting in increased production of pro-inflammatory cytokines 
by PBMCs when stimulated ex vivo with Mtb, or the heterologous infections Candida albicans 
or Staphylococcus aureus (Kleinnijenhuis et al., 2012). Furthermore, BCG vaccination of SCID 
mice afforded protection against lethal Candia albicans infection, demonstrating a T and B cell 
independent mechanism (Kleinnijenhuis et al., 2012). The protection afforded by BCG against 
Candida albincans infection was subsequently shown to be at least partially dependent upon 
NK cells (Kleinnijenhuis et al., 2014).  
 
 An avenue through which vaccination against Mtb could potentially be improved is in 
harnessing and augmenting the response of innate lymphocytes such as NK cells. In humans 
NK cells have also been demonstrated to produce IFNγ following BCG vaccination (Zufferey et 
al., 2013). Furthermore, MHC class II expressing NK cells have been demonstrated to expand 
following BCG stimulation and have increased cytotoxic capacity in comparison to MHC class 
II negative cells (Evans et al., 2011). Such cells were found to expand in response to IL-2 
(Evans et al., 2011). Therefore one way in which NK cell responses could be augmented is to 
increase IL-2 production upon Mtb challenge. Indeed a positive correlation between IL-2 
production by T cells and NK cell activation was found in Tanzanian children vaccinated with 
the malaria vaccine candidate RTS,S/AS01 (Horowitz et al., 2012). Furthermore therapeutic 
vaccination of chronically infected HIV patients led to IL-2 production by CD4+ T cells, which 
was suggested to lead to an increased IFNγ production by NK cells (Jost et al., 2014). Both 
these studies suggest that innate lymphocyte responses can be augmented through increasing IL-
2 production by T cells.  
 
As well as augmenting the NK cell response through increased cytokine production by T cells, 
it has been suggested that NK cells can themselves develop immune memory, where antigen 
specific NK cells persist and can mount enhanced responses upon challenge (Paust and von 
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Andrian, 2011). For example, hapten induced contact hypersensitivity can be elicited in T and B 
cell deficient mice (O'Leary et al., 2006). Hapten specific NK cells were found to persist for at 
least 4 weeks, reside in the liver and have the capacity to transfer sensitivity to naïve mice 
(O'Leary et al., 2006). Subsequently it was shown that NK memory could also be induced 
following viral infection (Paust et al., 2010; Sun et al., 2009). In addition to these findings in 
mice, recently it has been reported that antigen specific NK cell memory is also induced in NHP 
following Simian Immunodeficiency Virus infection or following vaccination (Reeves et al., 
2015). These results suggest that as NK cells can display features of immune memory there is 
potential for vaccine strategies to harness this to improve protection.  
 
In Chapter 3 of this thesis we identified increased IFNγ levels at day 21 post Mtb challenge in 
PPD restimulated lung cultures from mice vaccinated with BCG in the context of αIL-10R 
mAb. It is possible that NK cells and/or other ILCs provide this early IFNγ and therefore 
assessment of the cytokine response of innate lymphocytes to Mtb infection following BCG 
vaccination in the context of αIL-10R treatment is required.  
 
6.1.3 Could IL-10 suppress the immune response to other vaccines? 
 
Although it is unlikely that IL-10R blockade using mAb will be clinically viable, given the 
expense and practicalities of receiving multiple injections, our results do highlight the potential 
of IL-10 to suppress protective responses to BCG vaccination. This raises the question whether 
IL-10 is also suppressive in other candidate vaccine regimes. IL-10 can be induced by type I 
IFNs in various settings, including Mtb infection (Mayer-Barber et al., 2011; McNab et al., 
2014; Teles et al., 2013). Several of the vaccine candidates currently in clinical trials will induce 
type I IFNs for example, MVA (the vector used for MVA85A) is described to induce type I 
IFNs (Waibler et al., 2007) and the adjuvant IC31 (which is used for the vaccine candidates H1, 
H4 and H56) contains TLR9 agonists which will induce type I IFN (Akira and Takeda, 2004). 
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Thus this induction of type I IFNs could be accompanied by IL-10 expression and decreased 
induction of key cytokines such as IL-12 and IL-1, leading to suboptimal induction of a 
protective response. Investigation of whether novel vaccine candidates induce IL-10 and 
whether this suppresses the induction of an optimal response to novel vaccine candidates could 
aid our understanding of how to improve them. 
 
Understanding other mechanisms of immunosuppression, in addition to IL-10, will also increase 
our ability to improve vaccination. Indeed increased Treg frequency following vaccination with 
MVA85A in volunteers correlated with a low response to the vaccine as defined by IFNγ 
release in response to antigen 85A peptides (Matsumiya et al., 2013). Furthermore, increased 
basal levels of Indoleamine 2,3-dioxygenase activity (which suppresses T cell function), prior to 
vaccination, in South African adults compared to UK adults correlated with a lower response to 
MVA85A vaccination, as defined by IFNγ release in response to antigen 85A peptides (Tanner 
et al., 2014). By understanding factors that negatively impact the immunogenicity of a vaccine, 
there is potential to improve vaccination and identify individuals in which vaccination may be 
less effective. 
 
6.1.4 Could IL-10R blockade during BCG vaccination also increase protection upon 
challenge with clinical isolates of Mtb? 
 
Assessment of the ability of a vaccine to protect against clinically relevant isolates could further 
our understanding of protective responses and enable better prediction of those vaccine regimes 
with the potential to be protective in a clinical setting (McShane and Williams, 2014). Although 
αIL-10R blockade during BCG enhances the protection against challenge with the lab strain of 
Mtb H37Rv, assessment of its ability to protect against clinical isolates of Mtb would also be 
important. It is known that different strains of Mtb induce different responses in several animal 
models (Manca et al., 2001; Ordway et al., 2007; Reed et al., 2004; Subbian et al., 2013) and 
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also in human monocytes (Newton et al., 2006; Portevin et al., 2011). Furthermore, BCG 
vaccinated mice challenged with clinical isolates of Mtb display lower bacterial load in the lung 
compared to controls for a shorter time than those challenged with the lab-adapted strain H37Rv 
(Grode et al., 2005; Ordway et al., 2011). Assessment of whether increased IL-17 and GM-CSF 
correlates with increased control of bacterial load in mice vaccinated with BCG in the context of 
αIL-10R blockade challenged with a clinical isolate of Mtb, will provide further support that 
vaccine regimes that aim to achieve this could be beneficial. 
 
6.2 GM-CSF is required for the protective response following primary 
Mtb infection 
 
GM-CSF is known to be required for the immune response to Mtb infection following studies of 
GM-CSF deficient mice (Gonzalez-Juarrero et al., 2005). However, GM-CSF deficient mice 
develop a lung disease that resembles pulmonary alveolar proteinosis (Dranoff et al., 1994; 
Stanley et al., 1994; Trapnell and Whitsett, 2002), which leads to basal defects that can 
confound interpretation of these results. Using antibody neutralisation of GM-CSF, we were 
able to assess the role of GM-CSF during Mtb infection in both resistant and susceptible mice, 
without basal defects that could impact the immune response to Mtb infection. Results in this 
thesis show that in both resistant and susceptible mice, GM-CSF is protective in the immune 
response to infection with the lab Mtb strain H37Rv. Furthermore, GM-CSF neutralisation 
dramatically increases susceptibility of Mtb resistant mice and Rag deficient mice to infection 
with the hyper-virulent Mtb strain HN878. Our results showing that GM-CSF neutralisation 
during Mtb infection can increase susceptibility to Mtb could be clinically relevant. Several 
clinical trials are underway to assess the use of antibodies targeting the GM-CSFRα or GM-
CSF in treatment of rheumatoid arthritis and/or multiple sclerosis (Hamilton, 2015). Patients 
receiving treatment targeting GM-CSF may be at increased risk of tuberculosis infection or 
reactivation as has been described in patients treated with anti-TNF mAbs (Keane et al., 2001) 
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and thus patients should be closely monitored. Assessment of the impact of GM-CSF 
neutralisation in latently infected NHP would provide valuable information regarding how 
treatments targeting GM-CSF could impact the outcome of Mtb infection in human patients.  
 
6.3 Innate lymphoid cells in the immune response to Mtb 
 
Previous work from the O’Garra lab demonstrated that an “innate-like lymphocyte” population, 
lacking CD3, CD4, CD8 and γδ TCR but expressing Thy1.2, was a source of IFNγ and IL-17 
upon Mtb challenge in mice vaccinated with BCG in the context of αIL-10R blockade but these 
were not characterised further (Pitt et al., 2012b). NK cells and the recently described ILCs 
could be contained within this population. Although NK cells respond to Mtb infection (Feng et 
al., 2006; Junqueira-Kipnis et al., 2003), the role of other ILCs has not been addressed. The 
rapidity with which these cells respond during infection could mean they influence the early 
immune response to Mtb infection, but this is still an outstanding question (Orme et al., 2015). 
Chapter 5 of this thesis investigated the response and role of NK cells and ILCs in the innate 
immune response to Mtb infection. Using Rag KO mice our results demonstrated that ILCs 
respond to infection with both the lab-adapted strain H37Rv and hyper virulent HN878, with a 
subset of ILCs expressing T-bet upon infection. ILCs were a source of cytokines during Mtb 
infection, producing IFNγ upon H37Rv infection, and IFNγ and GM-CSF upon HN878 
infection. Furthermore work in this thesis demonstrated that IL-15 and IL-7 dependent ILCs are 
important in the control of HN878 bacterial loads, although our data shows that IL-15 
dependent ILCs are more important in the protective response against HN878 infection. 
Furthermore, subsequent experiments employing histology to assess lung pathology have 
demonstrated increased lung pathology in the absence of IL-15 dependent ILCs alone and 
further increased pathology in the absence of IL-15 and IL-7 dependent ILCs. It is possible that 
ILCs, along with NK cells and other innate lymphocytes will contribute to immunity in 
individuals suggested to be capable of clearing Mtb infection without mounting an adaptive 
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response (Barry et al., 2009; Young et al., 2009). More investigation is required to determine 
the mechanisms for this innate clearance, which is hindered by the difficulties in identifying 
such individuals.  
 
In addition to an increase in bacterial loads, we observed an accumulation of neutrophils in the 
lung during Mtb infection in the absence of IL-15 dependent ILCs and/or IL-7 dependent ILCs. 
Given that IFNγ has been described to regulate neutrophil accumulation and survival during 
Mtb infection (Desvignes et al., 2012; Feng et al., 2006; Nandi and Behar, 2011), we 
hypothesise that the accumulation of neutrophils we observe is a result of decreased levels of 
IFNγ in the lung. We aim to assess the protein levels of IFNγ, as well as other cytokines (such 
as GM-CSF, IL-17, G-CSF), in the lungs of Mtb infected mice lacking IL-15 dependent and/or 
IL-7 dependent ILCs, to identify potential candidates that could contribute to the observed 
neutrophilia. Indeed mRNA has been collected from the lungs of the three different mouse 
strains as well as supernatants from restimulation of lung cell suspensions, analysis of which 
will provide such information. 
 
The role of neutrophils during Mtb infection is debated, with some reports suggesting they 
provide a niche for bacterial growth and others suggesting they are capable of restricting 
bacterial growth (Eruslanov et al., 2005; Lowe et al., 2012; Yang et al., 2012). In Chapter 5 of 
this thesis we show that the accumulation of neutrophils in the absence of IL-15 dependent ILCs 
was detrimental to control of bacterial load but not in the absence of both IL-15 and IL-7 
dependent ILCs (Rag KO Il2rg KO). This result reinforces the complex role for neutrophils 
during Mtb infection and suggests that it is context dependent. Further work will attempt to 
address why neutrophils appear to have different roles in Rag KO Il15r KO and Rag KO Il2rg 
KO. Insight will be provided by assessing differences in neutrophil function between Rag KO 
Il15r KO and Rag KO Il2rg KO mice through assessment of their bacterial loads and expression 
of cytokines. Furthermore, assessment of how (or if) macrophage activation differs between the 
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two mouse strains, and how neutrophils impacts this, could provide an explanation for the 
apparent differences in the contribution of neutrophils to control of bacterial load.  
 
6.4 Future Perspectives 
6.4.1 The affect of IL-10 receptor blockade during BCG vaccination upon the response of 
ILCs to Mtb challenge 
 
A future experiment to assess how the early response of ILCs upon Mtb challenge is impacted 
by IL-10R blockade during BCG vaccination will further understanding of both ILC responses 
upon Mtb infection and potential avenues by which IL-10R blockade enhances the protective 
affect of BCG vaccination. This could be achieved through analysing the cytokine responses of 
ILCs (as described in Chapter 5) at day 14, 21 and 28 post Mtb challenge. Furthermore, given 
the studies discussed above that suggest IL-2 production by CD4+ T cells can increase NK cell 
responses, assessment of how IL-10R blockade during BCG vaccination impacts IL-2 
production by CD4+ T cells could provide insight into the mechanism by which ILC responses 
could be modulated by this vaccine regime. 
 
6.4.2 What are the sources of GM-CSF during Mtb infection? 
 
Many cell types have the capacity to produce GM-CSF including ILCs, NK cells, NKT cells, T 
cells, myeloid cells such as macrophages as well as fibroblasts and endothelial cells (Daussy et 
al., 2014; Gasson, 1991; Moro et al., 2010; Mortha et al., 2014; Robinette et al., 2015; Sojka et 
al., 2014). Although we identify ILCs as a source of GM-CSF, results neutralising GM-CSF in 
Rag KO mice suggest there are other sources. Experiments to assess the other cellular sources 
of GM-CSF, in addition to ILCs, are required. This could be achieved partly through 
performing intracellular cytokine staining on myeloid populations.  Use of a GM-CSF reporter 
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mouse, where GM-CSF expression is accompanied by expression of a fluorescent protein such 
as GFP, would be beneficial to identifying cellular sources of GM-CSF both in the naïve and 
infected state, especially given the technical difficulties of performing intracellular cytokine 
staining on myeloid populations. However, to our knowledge, such a mouse is currently 
unavailable.  
 
6.4.3 The mechanism for the protective role of GM-CSF during Mtb infection 
 
The mechanism for the protective role of GM-CSF during Mtb infection remains unclear. In 
order to try to determine this, experiments utilising histology would be important. Lung 
histology could be used to assess the impact of GM-CSF neutralisation upon granuloma 
structure. In addition, immunohistochemistry could be utilised to assess the location of T cells 
within the lung and individual granulomas, which could be important given the recent data 
suggesting the location of T cells influence their protective capacity (Sakai et al., 2014; 
Srivastava and Ernst, 2013). Furthermore immunohistochemistry staining for iNOS within the 
infected lung could be used to assess the influence of GM-CSF upon macrophage activation, 
which could contribute to the protective role of GM-CSF in both wild-type and Rag deficient 
mice. Additionally, staining infected lung sections to identify mycobacteria (e.g. using a Ziehl 
Neelsen stain) may provide information regarding how GM-CSF influences bacterial loads 
within myeloid cells as well as within the granuloma. The work to assess the influence of GM-
CSF upon activation of myeloid subsets could be supported by in vitro work assessing the 
influence of GM-CSF upon restriction of bacterial growth and expression of pro-inflammatory 
molecules.  
 
6.4.4 The role of ILCs and their importance as a source of GM-CSF during Mtb infection 
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The results presented in this thesis provide evidence that ILCs are capable of responding to Mtb 
infection, however an outstanding question remains: what is their role in the context of an 
adaptive immune response? Use of flowcytometry to identify ILCs and their cytokine 
production in a wild-type mouse is required. In order to assess the functional importance of 
ILCs in the context of an adaptive immune response anti-Thy1 antibody mediated depletion of 
ILCs could be utilised with concomitant transfer of congenically marked T cells. Such an 
experimental design will lead to a T cell response (as these would be congenically marked and 
therefore not recognised by the depleting antibody) in the absence of ILCs. As well as the 
potential to identify the importance of ILCs as an early source of cytokines, this experiment 
would enable assessment of the influence of ILCs upon the T cell response. This could be 
important, especially given recent data highlighting the ability of ILCs to influence the adaptive 
response (Gold et al., 2014; Halim et al., 2014; Hepworth et al., 2015; Hepworth et al., 2013; 
Mortha et al., 2014; Oliphant et al., 2014).  
 
In order to further investigate the importance of ILCs as a source of GM-CSF during Mtb 
infection a similar experiment utilising depletion of ILCs using anti-Thy1 antibody mediated 
depletion with concomitant transfer of congenically marked T cells and GM-CSF sufficient or 
deficient ILCs could be conducted. This would allow assessment of the outcome of infection in 
the context of absence of ILC derived GM-CSF. Such an experimental design would show 
whether GM-CSF deficiency specifically in ILCs is important for the outcome of Mtb infection 
in the context of an adaptive immune response.  
 
6.5 Concluding remarks 
 
An incomplete understanding of the protective immune response to Mtb hinders development of 
successful vaccines against Mtb. Improved vaccine strategies are required if the aim of a TB 
free world by 2050 is to be achieved (WHO, 2006). Work in this thesis has aimed to further our 
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understanding of factors that contribute to a protective response. It demonstrates early and 
increased levels of GM-CSF and IL-17 correlate with increased control of bacterial load in 
chronic infection. Furthermore, GM-CSF is important for optimal protection in the recall 
response. These results taken together suggest augmenting production of GM-CSF could be 
beneficial to improve vaccination. GM-CSF is also important in primary Mtb infection, which is 
of clinical relevance given on-going clinical trials assessing use of monoclonal antibodies 
against GM-CSF or its receptor in treatment of rheumatoid arthritis or multiple sclerosis 
(Hamilton, 2015).  
 
This thesis also aimed to further our understanding of the role of NK cells and ILCs in the early, 
innate response to Mtb infection. ILCs are a source of GM-CSF upon Mtb infection and 
contribute to protection in the innate immune response to Mtb infection. Innate lymphocytes 
(including ILCs, NK cells and MAIT cells) could provide an early source of cytokines, 
influencing the outcome of infection. Further investigation into these cell populations in humans 
will advance our understanding of these cell populations and their contribution to the immune 
response to Mtb. Furthermore, investigation into whether their responses can be augmented by 
vaccines could provide strategies to improve vaccination. Improving our understanding of a 
protective immune response to Mtb will facilitate development of improved vaccines and novel 
biological therapies, and potentially contribute to control of the global TB epidemic. 
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Appendix 1 
Appendix 1 Gating strategy to identify T cell populations  
CBA/J mice were BCG vaccinated and challenged with Mtb as shown in Figure 3.1. 
Lungs were homogenized by passage through a 70µm filter. Samples were stained with 
the following antibodies to assess percentages and calculate numbers of lymphoid 
populations by flow cytometry: γδ TCR FITC, Thy1.2 PECy7, CD4 e450, CD8 v500 
and CD3 APC. CD4+ T cells were identified as CD3+ Thy1.2+ CD4+, CD8+ T cells as 
CD3+ Thy1.2+ and γδ T cells as CD3+ Thy1.2+ γδ TCR+. Representative flow cytometry 
plots from the lung of a mouse BCG vaccinated in the context of αIL-10R mAb 
harvested at day 28 post infection is shown. The same gating strategy was used to 
identify T cell populations following Mtb infection and αGM-CSF treatment as shown 
in Figure 4.1A.  
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Appendix 2 
 
Appendix 2 Gating strategy to identify cytokine production by T cell populations. 
CBA/J mice were BCG vaccinated and challenged with Mtb as shown in Figure 3.1. 
Lungs were homogenized by passage through a 70µm filter. 1x106 cells were 
restimulated with 20µg PPD and 2µg αCD28 mAb for 16h before the addition of BFA 
for a further 4h. Cells were then harvested and stained with the following to assess 
cytokine production: γδ TCR FITC, GM-CSF PE, CD8 PerCP e710, Thy1.2 PE Cy7, 
IFNγ e450, CD4 v500, IL-17A APC, CD3 APCe780. CD4+ T cells were identified as 
CD3+ Thy1.2+ CD4+, CD8+ T cells as CD3+ Thy1.2+ and γδ T cells as CD3+ Thy1.2+ γδ 
TCR+. Cytokine gates set from isotype controls. Representative flow cytometry plots 
from the lung of a mouse BCG vaccinated in the context of αIL-10R mAb harvested at 
day 28 post infection is shown. The same gating strategy was used to identify cytokine 
producing T cells following Mtb infection and αGM-CSF treatment as shown in Figure 
4.1A.  
Gated on single, live cells
CD4+ T cells CD4+ T cells
CD4+ T cells CD4+ T cells
Isotype IsotypeIs
ot
yp
e
Is
ot
yp
e
CD8+ T cells CD8+ T cells
Isotype IsotypeIs
ot
yp
e
Is
ot
yp
e
CD8+ T cells CD8+ T cells
IL-17AIF
N
Š
IF
N
Š
GM-CSF
IL-17AIF
N
Š
IF
N
Š
GM-CSF
CD8
C
D
4
Thy1.2
C
D
3
IsotypeIs
ot
yp
e
IL-17A
IF
N
Š
ŠŞ T cells
ŠŞ T cells
CD4
ŠŞ
 T
C
R
 -Appendices-  
 
 309 
Appendix 3 
 
Appendix 3 Gating strategy to myeloid populations in the lung 
 
C57BL/6 or CBA/J mice were treated with αGM-CSF or isotype control mAb as shown in 
Figure 4.1A. Lungs were homogenized by passage through a 70µm filter. Samples were stained 
with the following antibodies to assess percentages and calculate numbers of myeloid 
populations by flow cytometry: Ly6G FITC, CD11c PE, Ly6C PerCP Cy5.5, CD11b PECy7, 
CD86 Brilliant Violet 421, CD8 v500, F4/80 APC and MHC class II (MHC II) APCe780. 
Neutrophils were identified as Ly6G+ CD11b+, CD11c+ CD11blo macrophages as Ly6G- 
CD11blo CD11c+, monocytes as Ly6G- CD11b+ Ly6C+, CD11b+ CD11c+ DCs as Ly6G- 
CD11b+ CD11c+. Representative flow cytometry plots from the lung of an Mtb infected 
C57BL/6 mouse treated with isotype control at day 21 post infection.  
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